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Abstract
Gene therapy is an area that is currently developing for treatment o f various 
congenital and acquired diseases. The basic concept is that a transgene is expressed in a 
target cell resulting in alleviation of disease. In general there are certain obstacles 
limiting gene therapy regardless of the target disease. These include restriction of 
transgene expression to target cells, inadequate transgene expression and ineffective in 
vivo transgene delivery.
Cancer is one of the leading diseases to cause death in the human and canine 
population. For this reason gene therapy has been studied as a potential novel treatment 
for cancer.
Two step transcriptional amplification system is a system applied to gene 
therapy in order to improve efficacy. In this system a relatively weak tissue or disease 
specific promoter initiates the transcription o f a transcriptional activator protein. This 
protein when expressed in target cells binds to binding sites upstream of a secondary 
promoter which then drives the transcription o f the transgene of interest at a high level.
By use of a two step amplification mechanism and a novel transcriptional 
activator fusion protein VP16E2, we increased transgene expression compared to the 
commonly used Gal4VP16 transcriptional activator fusion protein. By incorporating the 
human telomerase promoter hTERT as a primary promoter and the minimal 
6xE23’BpTATA promoter as a secondary promoter, transgene expression is maintained 
in telomerase positive cells representing cancer cells, but is restricted in telomerase 
negative cell lines. By inserting the tumour necrosis factor apoptosis inducing ligand 
(TRAIL) gene as a transgene in this system we have shown that apoptosis is elicited in 
telomerase positive cells although not in telomerase negative cells.
The similarities in incidence and nature of human and canine cancer forms and 
the need for a better translational model for human disease has put canines in focus for 
cancer studies and drug development. Conditionally replicative oncolytic viruses 
developed in humans are species specific and therefore can not be studied satisfactorily 
in rodent preclinical models. We have made a mutant adenovirus based on the canine 
adenovirus type 1. We have put the viral replication under control of our two step 
amplification mechanism making the viral replication dependent on telomerase activity 
of the infected cell. This virus is able to kill telomerase positive canine cells but not
XVI
telomerase negative canine cells in vitro. This virus is a potential tool for studying a 
conditionally replicative oncolytic virus in vivo in naturally occurring canine cancer 
cases. This is a good translational model for human cancer treatment and thereby 
benefits both species.
XVII
Chapter 1.
Introduction and background information.
Gene therapy is a relatively new science which has been developed as an 
approach to treat acquired and congenital disorders for which other treatment options 
are inadequate. Gene therapy is simplistically defined as the transfer of genetic material 
into cells of an organism for the purpose of curing or alleviating disease. This definition 
covers a wide range of methods depending on the application. The first approved gene 
therapy trial was carried out in 1990 and since then numerous trials have been carried 
out for treatment of various diseases (Trent & Alexander 2004). The outcome of the 
gene therapy trials to date has been disappointing due to challenges in targeting of 
transgene expression to target cells, insufficient transgene expression and inadequate in 
vivo transgene delivery. One success in gene therapy is the correction of the genetic 
defect in X-linked severe combined immune deficiency (SCID-X1) children after in 
vitro retroviral transduction of T cells.
There are major considerations to be taken into account when developing a gene 
therapy system. Targeting the cell populations of interest is an important safety issue 
since transgene expression in “off target” cells can have adverse effects. A cell 
population can be targeted by considering anatomical compartmental restrictions of 
transgene delivery or looking at target cell phenotypic characteristics which could be 
used for targeting gene expression to the cells. The blood retina barrier and the anatomy 
of the eye as an example offer an opportunity for local gene delivery to the eye with 
minimal risk of contamination to “off target” sites. The altered cellular gene expression 
patterns in specific tissues or diseases offer an opportunity to design gene expression 
systems that will function only in these cells by use o f disease or tissue specific 
promoters controlling the gene expression.
The magnitude of transgene expression in cells is a limitation and is often not 
adequate to elicit a therapeutic effect. This is particularly pronounced in conjunction 
with tissue or disease specific promoters since these are relatively weak. Therefore two 
step transcriptional amplification (TSTA) systems have been developed in order to 
increase the magnitude of gene expression elicited by the tissue or disease specific 
promoters. The concept of these systems is to be able to preserve the cellular sensitivity
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of the promoters to the target cells albeit at the same time allowing for a high level of 
transgene expression without compromising the specificity o f the system.
In vivo transgene delivery is a major challenge. This can in some 
circumstances be traversed by harvesting of cells and transducing them in vitro before 
returning them to the host as an allograft. Several gene delivery mechanisms for in vivo 
delivery are being developed of either viral or non viral origin. When considering a 
gene delivery mechanism one should take into account what sort of gene expression is 
required for a therapeutic outcome. Congenital disorders will often require life long 
transgene expression in order to antagonise clinical symptoms. This can be achieved by 
using gene vectors which allow for genomic integration and hence stable expression of 
the transgene. This can be accomplished by using integrating viruses such as 
retroviruses or adeno associated virus however these types of vectors harbour a great 
risk for insertional mutagenesis (Hacein-Bey-Abina et al. 2003). For acquired 
conditions such as cancer, fractures or tissue repair only transient transgene expression 
is required until the condition is eliminated and therefore a broader range of both viral 
and non viral non integrating transgene delivery systems can be considered.
Despite efforts in engineering highly developed systems to target gene 
expression to specific cells, to amplify the transgene transcription and to deliver the 
transgenes to cells the efficacy of current systems is low and there is a demand for 
improvement of current systems and a need for better in vivo animal models.
1.1 Gene therapy.
Gene therapy can be categorised as replacement gene therapy, immunotherapy, 
suicide gene therapy, effect gene therapy, protective gene therapy, silencing gene 
therapy and oncolytic gene therapy; each category aimed at specific diseases for which 
they are suitable.
Originally gene therapy was thought o f as a method to cure or alleviate fatal 
diseases, however recent studies also focus on non fatal diseases such as arthritis, 
fracture repair, retinal degeneration and skin diseases for which no successful treatment 
option is applicable and for which the life quality of the patient could be radically 
improved by gene therapy (Alton 2007, Alton et al. 2007, Cotrim & Baum 2008, 
Mochizuki et al. 2008).
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1.1.1 Replacement gene therapy
Replacement gene therapy is, as the name indicates, expression of a functional 
exogenous gene for which the cells are deficient. This type of gene therapy has 
therapeutic value for congenital or acquired disorders in which a gene product is faulty 
or absent either systemically or in a certain location or cell type. Examples o f diseases 
in which replacement gene therapy is a potential treatment option with the corrective 
transgene are diseases such as cystic fibrosis with the cystic fibrosis transmembrane 
regulator gene (Selkirk 2004), Duchene muscular dystrophy with the dystrophin 
transgene (Alton 2007, Selkirk 2004), lysosomal storage disease with lysosomal 
enzymes as transgenes (Alton 2007), haemophilia with factor VIII or IX as transgenes 
(Alton et al. 2007), Parkinson’s disease with dopamine expressing transgenes 
(Mochizuki et al. 2008) and cancer with the tumour suppressor gene p53 as a transgene 
(El-Aneed 2004b, Selkirk 2004). Some major obstacles exist for replacement gene 
therapy especially for congenital genetic disorders. Since these diseases are genetic 
disorders, a permanent lifelong expression of the transgene is often required to reverse 
clinical symptoms. On the other hand, since the gene used as a transgene is often not 
expressed in the diseased individual there is a significant risk o f the individual 
producing antibodies against the transgene and thereby nullifying the therapeutic effect 
(Zaldumbide & Hoeben 2007). Another problem is the restriction and regulation of the 
gene expression to certain cell types without exceeding normal concentrations resulting 
in adverse effects from overproduction. Under normal physiological conditions the cells 
are able to regulate the gene expression by various mechanisms however such 
mechanism will often not apply to exogenous expressed genes.
The only successful gene therapy trial resulting in correction of a genetic 
disorder in humans to date is the reconstitution of a long lasting immune response in 
SCID-X1 affected children (Cavazzana-Calvo et al. 2000, Hacein-Bey-Abina et al. 
2003, Trent & Alexander 2004, Alton 2007, Cavazzana-Calvo & Fischer 2007, Sokolic 
et al. 2008). In this trial bone marrow was harvested from the host and CD34+ 
lymphocytes were isolated and infected repetitively with a retroviral vector encoding 
the yc cytokine receptor gene which is absent in this disease. The treated cells were 
redelivered to the host as an allograft resulting in circulation of T-cells expressing the yc 
cytokine receptor gene and correction o f clinical symptoms (Cavazzana-Calvo et al. 
2000). To date successful reconstitution of long term immune response has been
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achieved in 17 out of 20 treated patients (Sokolic et al. 2008). A major drawback for 
this treatment was development o f leukaemia in 5 of the 17 successfully treated patients 
which lead to death in one patient (Sokolic et al. 2008). The development of leukaemia 
was due to insertional mutagenesis by integration of the viral vector in the LM 02 proto­
oncogene leading to increased expression of this gene resulting in carcinogenesis 
(Hacein-Bey-Abina et al. 2003, Bester et al. 2006). Despite the success in correcting the 
SCID-X1 genetic disorder the severe side effects in the form of leukaemia observed 
with this trial has encouraged development of safer gene therapy treatment regimes.
1.1.2 Immunotherapy
Immunotherapy is an area of gene therapy in which the immune system is 
activated to recognise the transgene. This can be done indirectly by inducing transgene 
expression in normal tissue and thereby evoking an immune response by stimulating 
antigen presenting cells or directly by in vitro transfection of antigen presenting cells 
with the antigen of interest (El-Aneed 2004b). Immuno gene therapy is currently being 
developed for treatment of different types of cancers since this procedure could offer a 
possibility of targeting distant tumour metastasis and residual cancer cells after surgery 
(Bergman et al. 2003, Barough 2006, Domcheck et al. 2007, Yamano et al. 2007, 
Wolchok et al. 2007, Bird et al. 2008, Hunder et al. 2008).
1.1.3 Suicide gene therapy
Suicide gene therapy is a form of gene therapy in which the exogenous gene is 
an enzyme which when expressed in a cell can cleave a pro-drug to its active cytotoxic 
form and thereby kill the host cell. This treatment form is being developed for treatment 
of various types o f cancer (Nathwani 2004, Selkirk 2004, Lawler 2006 Alton et al. 
2007). Suicide gene therapy in cancer has many advantages compared to conventional 
drug treatments offering higher efficacy and lower toxicity. The pro-drug commonly 
does not have an effect on normal cells and since the pro-drug will only be 
enzymatically activated in the target cells, a high concentration of the toxic drug will be 
present at the target site (Portsmouth et al. 2007). An important condition is that the 
suicide gene is a gene that is not normally expressed by the host cells. Another 
advantage with the system is the bystander effect which is often observed with suicide
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gene therapy. This is an effect in which non transfected cells surrounding a transfected 
cell will be affected by the activated pro-drug. This bystander effect can be a result of 
free diffusion of the activated pro-drug through the cell membranes to surrounding cells 
however some of the activated pro-drugs have a charge that does not allow them to 
freely diffuse across the cell membrane. These substances often exert a bystander effect 
via gap-junctions formed between closely situated cells which allow for the transfer of 
activated pro-drug between cells (Luminiczky & Safrany 2006, Portsmouth et al. 2007).
The list o f suicide gene and pro-drug combinations is long and many of these 
have already been tested in clinical trials with variable outcome. The thymidine kinase 
enzyme derived from herpes simplex virus type 1 which can convert ganciclovir to its 
phosphorylated cytotoxic counterpart is the most studied suicide gene therapy system 
(Lawler et al. 2006, Portsmouth et al. 2007). The herpes simplex virus 1 thymidine 
kinase (HSV-tk) ganciclovir suicide gene therapy system has been studied intensively in 
vitro and in vivo in preclinical animal models and has also been tested in phase I, II and 
III clinical trials for cancer therapy but has failed to show significant efficacy 
(Portsmouth et al. 2007).
1.1.4 Effect gene therapy.
Effect gene therapy is not an official categorization however a definition in 
which I have chosen to group gene therapy forms which could not be grouped under any 
of the other classifications. Effect gene therapy is a type of gene therapy where the 
transgene exerts a function which would normally not be seen in the target cell. This is a 
very broad definition and includes a broad range o f diseases and transgenes. The 
concept is not very different from replacement gene therapy except that the transgene is 
not replacing a normal cell product. Likewise the outcome o f the transgene expression is 
broad. Examples of diseases which are proposed to be treated with this form of gene 
therapy are Alzheimer’s disease where nerve growth factor is used as a transgene 
(Selkirk 2004), atherosclerosis and peripheral vascular disease with vascular endothelial 
growth factor as a transgene (Selkirk 2004), fractures with bone morphogenetic protein 
as a transgene (Carofino & Lieberman 2008) and cancer with the tumour necrosis factor 
apoptosis inducing ligand (TRAIL) as a transgene (Kim et al. 2004a, Ma et al. 2005).
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1.1.5 Protective gene therapy.
Protective gene therapy is conducted in order to protect certain cell types from 
cytotoxic therapy that may be applied to adjacent cells. A good example is gene therapy 
for radiation therapy induced toxicity on normal cells. These can be protected by 
administering super-oxide dismutase expressing plasmids in the area surrounding the 
irradiation target (Min et al. 2005, Cotrim & Baum 2008). Another example is the 
transfer o f drug resistance genes into haematopoietic stem cells in order to protect these 
from cytotoxic drugs targeting replicating cells. This sort o f therapy is often performed 
in vitro after which the stem cells are reintroduced to the bone marrow (Blaese et al. 
1995, Gunji et al. 2000). A variety o f chemoprotective genes are currently being 
developed for use in cancer therapy (Sorrentino 2002, Seth 2005).
1.1.6 Silencing gene therapy
Silencing gene therapy is a method that has evolved recently after the 
description of RNA interference in Caenorhabditis elegans in 1998 (Fire et al. 1998). 
This technique allows for silencing of gene expression at a post transcriptional level by 
targeting the RNA transcript (Fire et al. 1998, Lage 2005). RNA interference is only one 
of many ways to silence gene expression. Other methods include DNAzymes, 
ribozymes and antisense oligodeoxynucleotides each having different advantages and 
disadvantages for gene silencing (Lage 2005, Dass et al. 2008). Silencing gene therapy 
is currently being developed for various types of cancer in which various genes 
associated with apoptosis regulation and cell signalling can be silenced (Masiero et al.
2007). Other diseases in which silencing gene therapy has been taken forward are 
Huntington’s disease targeting the Huntington gene (Mochizuki et al. 2008).
1.1.7 Limitations in gene therapy
All gene therapy approaches face similar obstacles with regard to efficacy and 
patient safety when applied to an in vivo situation. In general certain elements need to 
be fulfilled for a gene therapy protocol to be successful. These are efficient delivery and 
uptake o f the transgene in cells, specific expression o f the transgene in target cells
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avoiding adverse effects in non target cells and adequate levels of transgene expression 
allowing for a therapeutic effect.
1.2 Gene delivery mechanisms
A condition that needs to be considered in gene therapy when selecting a 
possible delivery mechanism is the final mode of drug application. The mode of 
application depends on the disease treated and the effect aimed for. Topical delivery is 
useful for conditions that affect, for example the skin (Hengge 2005). Systemic 
application is useful for diseases that potentially affect multiple organ systems and 
where a systemic effect could be beneficial, which can be seen in diseases such as 
cancer. Local application can be performed either by injection directly into an organ of 
interest or by intramuscular, intracutaneous or subcutaneous injections. Local 
application can also be performed via an intravascular route in which the blood flow is 
restricted to a certain area. Direct application into a surgical site is also a potential mode 
of application. Other modes of delivery are delivery into some of the fluid filled body 
cavities such as intra peritoneal and intra cerebrospinal which is beneficial for diseases 
localised in those areas. These modes o f application are all based on in vivo application; 
however in vitro gene delivery is also a potential mode of delivery. This method is 
based on harvest of cells or tissue and then performing in vitro gene delivery before 
transplanting the cells or tissue back into the host (Ghali et al. 2008).
There are two major groups of gene delivery mechanisms in gene therapy; viral 
and non-viral. Each group compromises different advantages and disadvantages but as a 
general rule the viral gene therapy delivery mechanisms are considered more efficient 
although are regarded as less safe (Kaneda & Tabata 2006).
1.2.1 Non-viral gene delivery mechanisms
Non-viral gene delivery mechanisms are generally safer than viral methods 
though not as effective as viral gene delivery mechanisms.
7
1.2.1.1 Naked plasmid DNA
The simplest of transgene delivery forms is delivery o f naked plasmid DNA. 
This method has been widely used and data show that a great proportion of human 
clinical gene therapy trials have been done using plasmid DNA and that this proportion 
is rising (Edelstein et al. 2004, Edelstein et al. 2007). This increase is probably a 
consequence of the low risk associated with in vivo transfection of cells with plasmid 
DNA.
Delivery o f naked plasmid DNA can be done by simple injection locally or 
systemically. An advantage with using naked plasmid DNA for gene therapy in vivo is 
that it is relatively poorly immunogenic and does normally not induce an immune 
response and therefore is a minimal risk to bio-safety (Trent & Alexander 2004). 
Another advantage is that plasmid DNA is easy to work with and relatively easy to 
produce (Trent & Alexander 2004, Kawakami et al. 2008). The naked plasmid DNA is 
however subject to fast DNA degradation by blood nucleases and clearance from the 
liver when delivered systemically and in this context the half life of naked plasmid 
DNA delivered intravenously is estimated to be 5 minutes (Henshaw & Yuan 2008). 
Once the DNA has traversed the cell membrane the half life in the cell cytoplasm is 
approximately 90 minutes (Henshaw & Yuan 2008). The physical state of DNA 
influences the cellular DNA uptake and in this context supercoiled DNA shows a higher 
level of uptake compared to linear and circular DNA (Henshaw & Yuan 2008). In order 
to improve the cellular uptake of naked plasmid DNA various physical delivery 
mechanisms have been developed (Ferber 2001).
1.2.1.2 Electroporation.
Electroporation is a simple way to enhance cellular uptake o f plasmid DNA in 
vivo. This method is based on the concept that cells in an electric field will form 
temporary hydrophilic pores in the cell membrane which will allow for uptake o f the 
DNA molecules by passive diffusion (Escoffre et al. 2007, Henshaw & Yuan 2008). 
The plasmid DNA can be applied either locally or systemically and the electric field is 
then applied to the location of interest. The electric field can be created by use o f either 
parallel-plate electrodes or needle electrodes of which the first is limited to surface 
application (Henshaw & Yuan 2008). The electric field also improves the spread of 
plasmid DNA by electrophoresis o f the negatively charged DNA molecules in the tissue
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(Escoffre et al. 2007, Henshaw & Yuan 2008). Electroporation has been shown to 
increase DNA uptake 80 times compared to naked DNA (Ferber 2001). A limitation of 
the method is that it is mostly applicable to superficial structures such as skin and that 
only relatively weak currents can be used to avoid cellular damage (Yamashita et al. 
2002, Henshaw & Yuan 2008). Electroporation is not only used for gene therapy but is 
also used for chemotherapy to improve uptake of chemotherapy drugs into tumour cells 
(Tijink et al. 2006).
1.2.1.3 Sonoporation.
Ultrasound is another physical method used to increase the uptake of plasmid 
DNA in cells. This method, also named sonoporation works in a similar fashion as 
electroporation however using sound waves instead o f electric current to permeabilise 
the cell membrane (De Carvelho et al. 2007). A combination o f electroporation and 
sonoporation called electrosonoporation has also shown to enhance the uptake o f naked 
plasmid DNA into cells. This method allows for a higher level of DNA uptake and 
fewer side effects compared to either electroporation or sonoporation alone (Yamashita 
et al. 2002, Yamashita et al. 2004).
1.2.1.4 Hydrodynamics.
Another physical method which has been used to increase the uptake of naked 
DNA in vivo is hydrodynamics. This method also known as hydroporation, uses 
hydrostatic pressure to force the DNA into the cells. This can be done by either rapid 
systemic injection o f large volumes of plasmid DNA in a physiologic solution or by 
clamping the vein in the location of interest and thereby increasing the pressure by 
stagnation o f blood. The increased pressure generates pores in the plasma membrane by 
which the DNA can be taken up (Ferber 2001, Neal et al. 2007, Suda & Liu 2007). In 
rodent cancer models hydrodynamic vein delivery has shown to be a successful method 
to deliver naked plasmid DNA to hepatocytes and this method also had an antitumour 
effect (Yonenaga et al. 2007). This method is however not applicable to humans since 
the volumes used in the mouse studies are equivalent to 8-10 % of the animals body 
weight which would be equivalent to infusing around 8 litres o f fluid intravenously into 
an adult human, a procedure which could lead to heart failure (Ferber 2001, Suda & Liu
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2007, Yonenaga et al. 2007). Percutaneous ethanol injection is a widely used treatment 
for hepatocellular carcinoma and therefore one should consider if  the effect seen in the 
hydrodynamic vein delivery studies is due to the effect of the plasmid DNA or from the 
fluid pressure (Schwartz et al. 2007). Surgical clamping of a vein and subsequent 
plasmid DNA injection might be a more suitable way of performing hydroporation for 
gene delivery in larger animals and humans (Feber 2001).
1.2.1.5 Gene gun.
Another physical method of improving cellular uptake of naked plasmid DNA is 
by tissue bombardment with DNA coated gold particles using a device called a gene 
gun (Kawakami et al. 2008). The gene gun accelerates the DNA coated gold particles to 
a high velocity at which they can penetrate the cell membrane. This method can be 
applied in vivo on superficial structures such as skin or on internal organs under surgery 
or it can be applied in vitro for transplanted cells (Cambell et al. 2007, Chang et al.
2008).
1.2.1.6 Chemical methods.
Cellular plasmid DNA uptake can also be enhanced by chemical methods. 
Cationic polymers which can be o f either natural or synthetic origin, or cationic lipids 
also know as liposomes, can be used to form a complex with the negatively charged 
plasmid DNA (Haider et al. 2005, Kaneda & Tabata 2006). This will result in an overall 
positive surface charge of the complex which allows the complex to interact and be 
taken up through the negatively charged cell membrane (El-Aneed 2004a). Modification 
of these complexes can be done in order to make them more stable or to allow for cell 
specific uptake (Haider et al. 2005, Kawakami et al. 2008).
1.2.2 Viral gene delivery mechanisms
Viruses have evolved to infect host cells by evading the naturally occurring host 
defence barriers. They can therefore be considered optimised vehicles for in vivo and ex 
vivo gene delivery to cells. The ability of viruses to cause disease and interact with the 
host genome is though a concern for the safety of viral gene therapy.
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Many viruses are pathogenic and even though they do not all induce direct cell 
death to the infected cell they often have other adverse effects in the host (Verma & 
Weitzman 2005). In order to use viruses as vectors the viral components responsible for 
the pathogenic effect are removed and replaced with the transgene of interest. There are 
many different viruses that have been studied for their potential use as a gene delivery 
vectors. Each type offers different advantages and disadvantages and many conditions 
need to be considered before choosing a viral vector. The size of the transgene is of 
importance since viruses have different capacities for carrying foreign DNA. The target 
cell type should be considered since some viruses transduce specific cell types more 
efficiently than others such as herpes simplex virus which has been shown to transduce 
cells in the central nervous system efficiently (Lawler et al. 2006). The mode and effect 
of the required transgene expression should also be considered. If it is the aim to correct 
a genetic disorder then a permanent expression of the corrective transgene is often 
required in order to achieve a clinical effect. Viruses that integrate into the host DNA 
will result in continuous expression of the transgene whilst non integrative viruses that 
stay episomal often have a transient effect that will wane after cell division and time.
The most commonly used viral vectors for gene therapy are based on 
retroviruses, adenoviruses, vaccinia viruses, poxviruses, adeno-associated viruses and 
herpes simplex viruses (Edelstein et al. 2004, Edelstein et al. 2007).
1.2.2.1 Retroviruses.
Retroviruses were previously the most commonly used vectors for human 
clinical gene therapy trials (Edelstein et al. 2004). Newer figures however show a 
decrease in the overall use o f retroviral vectors for gene therapy (Edelstein et al. 2007). 
Retroviruses are single stranded enveloped diploid RNA viruses (Verma & Weitzman
2005). The viruses code for an integrase protein which facilitates the integration of 
proviral DNA, generated by reverse transcription, into the host genome and thereby 
establishing stable viral gene expression by use of host transcriptional machinery 
(Verma & Weitzman 2005).
The prototypic retroviruses such as oncoretroviruses are characterised by their 
ability to only infect replicating cells. The murine leukaemia virus (MLV) was 
successfully used as a viral vector for gene therapy treatment o f SCID-X1 in children 
(Cavazzana-Calvo et al. 2000) as described in chapter 1.1.1. As described the
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development of leukaemia in several patients was a major drawback for this trial. It has 
been shown that the MLV virus does not insert randomly in the host genome but selects 
certain regions above others. The insertion of the virus is therefore not completely 
random and the risk of integration induced oncogenesis is therefore increased which is 
why major focus has been on using other retrovirus vectors (Pfeifer 2004, Sokolic et al. 
2008).
Lentiviruses belong to a subgroup of retroviruses that have been well studied 
for use in gene therapy and also for easy generation o f transgenic animals (Pfeifer
2004). Conventional retroviruses can only infect dividing cells and an advantage with 
lentiviruses is their ability to infect both dividing and non dividing cells. Lentiviruses 
are in general more complex than other retroviruses in that they code for additional 
genes in their genome which facilitate their more complex lifecycle and their ability to 
infect non dividing cells and evade host immune responses (Quinonex & Sutton 2002). 
The human immuno deficiency virus type 1 (HIV-1) is the most well studied lentivirus 
for use in gene therapy but other viruses such as feline immuno deficiency virus (FIV) 
and simian immuno deficiency virus (SIV) have been studied for use as vectors due to 
the risk associated with the pathogenesis of the HIV-1 virus (Pfeifer 2004, Saenz & 
Poeschla 2004, Verma & Weitzman 2005). In order to make the viral vectors safe, most 
of the viral genome is removed except for a few essential sequences and the packaging 
sequences (Pfeifer 2004). The modified lentiviral based vectors have a packaging 
capacity of approximately 8.5 kb foreign DNA and the vector inserts randomly in the 
host genome (Pfeifer 2004). A great safety issue when using retrovirus based vectors is 
the risk of insertion of the virus at a site where it could activate an oncogene and 
thereby induce a carcinogenic phenotype. The modified lentivirus vectors have however 
been shown to insert randomly into the host genome and the risk of oncogene activation 
upon insertion is estimated to be 1/100000 (Pfeifer 2004). HIV-1 virus has a 
predilection for CD4 expressing cells and therefore further modifications have been 
done on HIV-1 to increase its tropism to a wider range of cells. Other modifications 
include construction of self inactivating lentiviruses in which viral enhancers and 
promoters have been removed (Quinonex & Sutton 2002, Pfeifer 2004).
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1.1.2.2 Herpesviruses.
Herpesviruses have been studied for their use as viral vectors in gene therapy but 
their use is minor compared to retroviruses (Edelstein et al. 2007). Herpes viruses are a 
group of linear double stranded enveloped DNA viruses which have an advantage over 
other viruses in that the virus vector has a large gene carrying capacity o f up to 30kb, 
allowing the insertion of large complex genes (Verma & Weitzman 2005). The human 
herpes virus type 1 has been studied for use in gene therapy. The virus has a tropism for 
neuronal tissue as reflected by the pathogenesis of the virus and therefore it is 
commonly studied for gene therapy in neuronal diseases (Hoffmann & Wildner 2007). 
The virus can infect both dividing and non dividing cells and the virus does not 
integrate in the host genome which allows for only transient transgene expression when 
used as a transgene vector (Verma & Weitzman 2005, Witlox et al. 2007). Wild type 
herpes viruses induce cell lysis in the host cell upon replication and therefore it is 
important that the virus is replication incompetent when used as a viral vector (Verma 
& Weitzman 2005). A disadvantage of using herpesviruses for gene therapy is their 
strong immunogenicity and potential cytotoxic effect (Edelstein et al. 2004, Verma & 
Weitzman 2005, Witlox et al. 2007). The human herpes virus type 1 has not only been 
studied for its use as a gene delivery vector but has also been studied for use as an 
oncolytic virus for cancers of neuronal origin in particular, due to its ability to induce 
cell lysis upon viral replication (Kuruppu et al. 2007, Liu et al. 2007).
1.1.2.3 Adeno-associated viruses.
Adeno-associated viruses (AAV) are single stranded DNA parvoviruses (Verma 
& Weitzman 2005, Witlox et al. 2005). This virus type is increasingly being used for 
human gene therapy trials (Edelstein et al. 2004, Edelstein et al. 2007). AAV has been 
in particular focus for gene therapy because it is a non-pathogenic virus which can 
infect a wide range of cells and only replicate productively in association with a helper 
virus, such as adenovirus (Verma & Weitzman 2005). AAV has also been shown to 
integrate at specific locations in the host genome making it a useful tool for long term 
gene therapy for genetic disorders. It has also been shown that it is possible to direct 
AAV integration to a site specific position using homologous recombination although 
most of the vims will integrate randomly. In general only a small proportion of vims 
integrates into the host genome whilst most persist as episomal DNA (Schultz &
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Chamberlain 2008). The AAV is approximately 4.7kb however the viral packaging 
signals are located in the inverted terminal repeats sequences flanking the viral genome 
and the whole viral genome can therefore be replaced by a maximum of 5 kb foreign 
DNA (El-Aneed 2004a, Schultz & Chamberlain 2008). The AAV is in great focus for 
gene therapy but the risk and consequences of random insertion o f the transgene in the 
host genome and the high immunogenicity o f the virus are disadvantageous. 
Furthermore the virus is difficult to culture due to its dependence on other viruses for 
replication (Verma & Weitzman 2005, Witlox et al. 2007, Schultz & Chamberlain 
2008).
1.2.3 Adenoviruses for gene therapy.
Adenoviruses are some of the most commonly used vectors in human gene 
therapy trials (Edelstein et al. 2007). As this virus is of particular interest for this project 
a more detailed description of this virus will follow.
Adenoviruses were discovered and isolated in the early 1950’s (Ginsberg
1999). The Adenoviridae family comprises the genera mastadenovirus, aviadenovirus, 
atadenovirus, siadenovirus and a possible 5th genus which is uncertain. The 
aviadenoviruses are restricted to infections in birds and the mastadenoviruses are 
restricted to infection in mammals. The atadenovirus and siadenovirus have less 
restricted host spectrum (Davison et al. 2003). Adenoviruses are widely prevalent and 
often associated with only mild disease which reflects the viruses’ ability to infect a 
host and delay the host’s early and innate immune response allowing for an initial large 
production of viral progeny which can infect other individuals before the host immune 
response eradicates the virus (Russell 2000).
1.2.3.1 Adenovirus characteristics
Adenoviruses replicate in the cell nucleus (Goncalves 2006) which makes these 
viruses suitable for use as gene therapy vectors since transgenes are delivered to the cell 
nucleus.
Adenoviruses are double stranded linear DNA viruses, encapsidated by an 
icosahedral protein capsid. The size of the viral DNA varies from 26 to 45 kbp and the 
genome is characterised by an inverted terminal repeat and the binding of a terminal 
protein to the 5’ ends o f the linear DNA (Davison et al. 2003). The mastadeno virus
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genus is the major focus group for gene therapy vectors as this group comprises the 
human adenoviruses. There are many well characterised mammalian adenoviruses but 
most studies have been done on the human adenovirus type 2 and 5 (Shenk 1996). The 
following description of adenoviruses will therefore be mostly based on studies done in 
human adenovirus type 2 and 5, however many characteristics are shared between these 
and other mammalian adenoviruses (Davison et al. 2003). The atadenovirus, 
aviadenovirus and siadenovirus differ from the mastadenovirus group in that some of 
the early gene regions are not present in these genera and the following description will 
therefore not be applicable for these genera (Davison et al. 2003).
The adenovirus icosahedral capsid is characterised by 20 facets formed by a 
trimeric hexon protein and 12 vertices formed by the penton base protein as illustrated 
in figure 1.1. From each vertice a knobbed trimeric fibre projects externally. The penton 
base and the fibre-knob are important for the interaction and entry of the virus to the 
host cell (Shenk 1996, Seiradake et al. 2006). Upon infection the viral fiber knob binds 
to the coxsackie adenovirus receptor (CAR) on the cell surface. The fiber-knob 
interaction with the receptor is followed by binding of an arginine-glycine-asparagine 
(RGD) motif in the penton base to integrins in the cell membrane (Shenk 1996). This 
leads to clathrin mediated endocytosis of the viral particle (Russell 2000). Some 
adenoviruses lack the RGD motif and enter the cell using a different mechanism and 
some viruses have also been shown to infect cells independently of the CAR (Soudais et 
al. 2000, Stoff-Khalili 2005, Seiradake et al. 2006).
Once inside the cell the viral capsid is partly degraded by virus encoded 
proteases and the virus is trafficked to the cell nucleus by interaction between the virus 
and cellular structures (Russell 2000). Experimentally virus has been detected in the 
cytoplasm and the cell nucleus 1 and 2 hours respectively after infection (Russell 2000). 
Once the virus enters the cell nucleus viral transcription is initiated by use of the RNA 
polymerase type II (Goncalves & Vries 2006).
1.2.3.2 Adenovirus genome
The adenovirus genome contains several overlapping reading frames for genes 
that can be divided into early and late transcription units according to their expression 
relative to the virus’ replicative life cycle. The early genes are transcribed prior to the 
virus DNA replication whilst the late gene transcription is initiated after the initiation o f 
DNA replication (Russell 2000). Splicing is a common method by which each of the
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viral genes gives rise to multiple mRNAs by use of different splice sites (Shenk 1996). 
A schematic presentation of the adenovirus genome is shown in figure 1.2.
The early genes comprise the E l, E2, E3 and E4 gene regions (Shenk 1996). The 
E l gene can be divided into the El a and Elb. The main function o f the E la  gene is to 
alter the cellular metabolism to favour viral replication (Russell 2000). The E lb  gene is 
responsible for prolonging the survival of the infected cell by reducing the transcription 
of the p53 gene which is induced as a cellular defence by the expression of the E la  gene 
(Russell 2000). The E lb  gene also plays a role in transcription of late viral genes. The 
viral E2 gene can also be devided into two regions E2a and E2b. This gene is 
responsible for the machinery for viral DNA replication and also plays a role in 
transcription of late viral genes. At an early stage it was shown that the E3 gene is non 
essential for viral replication but plays a role for the pathogenesis o f the virus (Ginsberg
1999). The basic function o f the E3 gene is to protect the virus from the host cell 
defence mechanisms by means of suppressing the expression of the major 
histocompatibility complex class 1 molecule on the cell surface and by inhibition of 
pro-apoptotic pathways (Russell 2000, Horwitz 2004). An important E3 gene product is 
the adenovirus death protein since this protein promotes cytolysis o f the host cell and 
release o f viral progeny after completion of viral replication (Horwitz 2004). Removal 
of the E3 gene reduces the ability o f the virus to evade the host immune response and 
also reduces its cytopathic effect (Muruve 2004).
The genes encoded in the E4 region are responsible for arresting the host protein 
synthesis and also initiation of viral DNA replication (Goncalves & Vries 2006).
After the early adenovirus genes have been expressed the viral DNA replication 
is initiated, starting in the inverted repeat sequence (Shenk 1996). The newly replicated 
DNA can act as a template for further DNA replication or be a template for late viral 
gene transcription (Goncalves & Vries 2006). The late adenoviral genes comprise the 
LI, L2, L3, L4 and L5 genes. These encode the structural proteins o f the virus (Russell
2000). Once expressed these proteins are transported back into the nucleus where the 
viral progeny is assembled in an immature form. This immature state is related to some 
of the structural proteins being formed as precursor proteins which need to be cleaved 
by viral encoded proteases in order to function (Shenk 1996, Russell 2000). Following 
viral maturation by protein cleavage the nuclear membrane is permeabilised and the 
viral progeny are released from the cell by cell lysis (Rao et al. 1996, Tollefson et al. 
1996).
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Figure 1.1
Fiber knob
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Penton base, Vertex
Figure 1.1 Adenovirus model.
Figure showing simplistic model o f  the three dimensional structure o f  the adenovirus 
capsid (Figure by Jamie McClement).
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Figure 1.2
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Figure 1.2 Model of the adenovirus genome.
L4 E3 L5
E4
Model showing schematic presentation o f  the adenovirus genome and location o f  early 
E la ,  E lb ,  E2a, E2b, E3, E4 and late L I ,  L2, L3, L4, L5 genes. ITR : inverted terminal 
repeat..
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1.2.3.3 Adenovirus vectors
The adenovirus has been widely used as a vector in gene therapy. This is mainly 
based on the ability of the virus to infect a broad range of different dividing and non­
dividing cell types and the low morbidity of the virus in vivo (Cao et al. 2004, El-Aneed 
2004a). The clear disadvantages of adenovirus vectors in gene therapy are the high 
antigenicity of the virus and the high prevalence o f the virus in the human population. 
As a result o f this antibodies against adenovirus can be detected in 90% of the human 
population which antagonises the use of adenovirus especially for long term gene 
expression (Russell 2000, Muruve 2004).
The most commonly used adenoviruses for gene therapy vectors are the human 
type 5 and less commonly type 2 adenoviruses (Cao et al. 2004, Cotrim & Baum 2008). 
The wild type adenovirus has a gene carrying capacity of approximately 2 kbp foreign 
DNA (Russell 2000). Adenovirus replication results in lysis of the infected cell and 
therefore for use as a gene therapy vector the adenovirus must be made replication 
incompetent (Verma & Weitzman 2007). This can be achieved by removing some of the 
genes essential for viral replication which in turn results in a higher gene carrying 
capacity of the virus. This capacity can also be further increased by deletion of some of 
the viral non essential genes (Alba et al. 2005). The development of adenoviral vectors 
has gone from being very simple single gene deletion viruses to optimised hybrid 
systems.
1.2.3.4 First and second generation adenoviral vectors
The first generation virus vectors were depleted in the E l gene region 
increasing the gene carrying capacity to approximately 4kbp (Cao et al. 2004). The 
removal of the E l genes result in a replication incompetent virus and the virus is 
therefore propagated by use of complementary cells expressing the E l genes in trans 
(Alba et al. 2005, Zhang & Godbey 2006). Further increase in the gene carrying 
capacity was achieved by removing the non essential E3 gene region increasing the 
carrying capacity by further 4kb (Cao et al. 2004). The second generation adenoviral 
vectors would in addition to having El and E3 deleted also have the E2 or E4 genes 
deleted which could increase the gene carrying capacity to around 10-13 kbp (Russell 
2000, Cao et al. 2004, Flotte 2007).
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The use of adenovirus vectors for gene therapy is limited by the virus vector 
capsid proteins which elicit a strong inflammatory response including induction of 
inflammatory cytokines and chemokines, when virus vectors are administered 
systemically to humans in vivo at a high dose (Cao et al. 2004, Muruve 2004). This 
effect which is dose dependent leads to a risk of cytotoxic shock in the host. Lower 
doses and also doses administered locally are better tolerated. The acute shock reaction 
is part o f the host’s innate immune response which is activated prior to viral gene 
expression. The E3 and E l gene products have been shown to mediate the host immune 
response however these genes are commonly lacking in the first and second generation 
adenoviral vectors leading to increased inflammation (Muruve 2004). The innate 
immune response recruits macrophages, natural killer cells and neutrophils and it has 
been observed that this can lead to rapid clearance of first generation adenovirus vectors 
from the liver with only 10-20% left 24 hours after systemic injection (Muruve 2004, 
Alba et al. 2005).
Host immune response is a major obstacle for use of adenoviral vectors. As 
previously mentioned most people carry antibodies against adenovirus. These 
antibodies are mostly directed against the virus capsid proteins and are effective in 
eliminating infective particles in the host. To combat the fast clearance of the virus, 
methods have been developed to shield the virus from the host immune response and 
thereby increase the virus vector half life. This has been done by administering immune 
suppressant drugs or by binding the adenovirus capsid proteins to polyethylene glycol 
compounds which are immunologically inert and thereby protect the virus from being 
recognised by the host (Russell 2000, Cao et al. 2004).
1.2.3.5 Helper dependent adenoviruses
Helper dependent adenoviruses, also known as third generation adenoviruses, 
are viral vectors in which only the inverted repeat sequences and the viral packaging 
signal are present while the remainder of the viral genome is excised (Alba et al. 2005, 
Zhang & Godbey 2006). These viral vectors do not express any viral proteins and 
therefore they must be generated in the presence of a helper adenovirus expressing all 
the viral genes in trans (Alba et al. 2005). This introduces a risk of contaminating the 
viral vector stock with replication competent helper virus and introducing a high safety 
threat for in vivo use. Several methods have been developed to overcome this obstacle
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and produce large amounts of virus vectors with minimal contamination (Cao et al. 
2004, Alba et al. 2005, Goncalves & Vries 2006).
Firstly, using helper viruses with defective packaging signals was originally 
thought to be the solution, however the high risk of recombination between the viruses 
and thereby introduction of a functional packaging signal lead to a high level of 
contamination from the helper virus (Alba et al. 2005). Specific removal of the helper 
virus packaging signal by use of the cyclization recombination protein (Cre) in 
conjunction with the locus o f X-over PI (loxP) site also known as the Cre/Lox system is 
a way to overcome this problem (Cao et al. 2004, Alba et al. 2005, Goncalves & Vries
2006). This system allows for the specific excision of unwanted DNA sequences. In this 
system the viral packaging signal in the helper adenovirus is flanked by lox P sites. To 
propagate the viral vector both the helper virus and the helper dependent virus are 
infected or transfected into Cre expressing cells. The Cre protein then binds to the LoxP 
site resulting in site specific cleavage and religation and thereby excision o f the 
packaging signal from the helper virus. This method reduced the helper virus 
contamination to a range between 0.1-10% (Alba et al. 2005). The residual 
contamination is most likely to be a result of inadequate activity of the Cre protein and 
therefore other recombinases have been investigated for use (Goncalves & Vries 2006). 
Thirdly, another improvement was insertion of the packaging signal in the helper virus 
in reverse which could limit recombination events and reduced the contamination levels 
of helper virus to 0.02-0.1 % (Alba et al. 2005).
The helper dependent adenoviruses allow for the insertion of large cDNA 
sequences, regulatory sequences and promoters required for tissue specific gene 
expression at a regulated physiological level (Goncalves & Vries 2006). For the viral 
particle to be packaged efficiently the insert DNA must be similar in size to the wild 
type virus which is around 36kb; this can be achieved by using stuffer DNA if the 
inserted gene is too small (Cao et al. 2004, Alba et al. 2005). Due to the lack of viral 
protein expression the helper dependent adenoviral vectors are advantageous to use 
since they are less immunogenic and result in a reduced adaptive cellular immune 
response when delivered systemically compared to first and second generation vectors 
(Cao et al. 2004, Alba et al. 2005). The innate immune response which is triggered 
independently of adenoviral gene expression is still a concern for the stability and 
toxicity o f these vectors when administered in vivo (Alba et al. 2005, Flotte 2007).
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1.2.3.6 Animal adenoviruses
Animal adenoviruses are being exploited as alternatives to human adenoviruses 
for use in human gene therapy, for use in gene therapy in large animal models and to 
create hybrid viruses between human and animal viruses to improve infectious potential 
and evade the host pre-existing immune response (Kremer et al. 2000, Hemminki et al. 
2003, Lucas et al. 2003, Kremer 2004, Perreau et al. 2007, Zheng et al. 2007) Another 
risk that can be eliminated by using animal adenoviruses for human gene therapy is 
replication o f adenovirus vectors in the presence of wild type adenoviruses in the host 
with accompanying risk of recombination (Rasmussen et al. 1999).
Studies have shown that the bovine adenovirus type 3 can infect human cells 
without cytotoxicity, as it does not replicate and does not recombine with co-infected 
human adenoviruses (Rasmussen et al. 1999). This study also showed that the E l and 
E3 regions in the virus could be excised allowing for the insertion of exogenous DNA 
opening a window for the use o f this virus as an alternative vector for human 
adenoviruses in gene therapy.
1.2.3.7 Canine adenoviruses
The canine adenoviruses type 1 (CAV-1) and type 2 (CAV-2) have been studied 
for use as gene therapy vectors both in humans and canines (Rasmussen et al. 1999, 
Kremer et al. 2000, Hay 2003, Hemminki et al. 2003, Kremer 2004, Stoff-Khalili et al. 
2005). These two viruses share many similarities in sequence but differ significantly in 
pathogenicity (Linne 1992). The two viruses can routinely be distinguished by PCR 
(Morrison et al. 1997, Decaro et al. 2007). The canine adenoviruses share many features 
with the human adenovirus however diverge on several aspects. Genetically it has been 
shown that the CAV-1 and CAV-2 are depleted in the CG nucleotide showing a basic 
evolutionary difference from the human adenoviruses (Davison et al. 2003).
1.2.3.8 CAV-1
The CAV-1 is a highly morbid virus in the canine population and is not 
associated with disease in any other species. The virus has a predilection for infecting 
vascular endothelial cells and hepatocytes most commonly causing the disease known 
as canine infectious hepatitis although the virus can be found in various organs
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throughout the body upon infection (Cullan & MacLachlan 2001). Infection with CAV- 
1 can be fatal especially in young dogs however it can also result in asymptomatic or 
mild disease. The clinical signs associated with clinical disease are fever, inappetance, 
abdominal pain, vomiting, diarrhea and dyspnea (Cullan & MacLachlan 2001, Decaro et 
al. 2007). Prolonged infection with CAV-1 can result in immune-mediated 
glomerulonephritis which is a result o f soluble immune complexes being deposited in 
the kidneys, followed by complement stimulation and recruitment of neutrophils 
(Confer & Panciera 2001, Cullan & MacLachlan 2001). Uveitis, also known as blue- 
eye, is another secondary effect from prolonged CAV-1 infection as a result o f a type III 
hypersensitivity reaction. Disease as a result o f CAV-1 infection is uncommon in the 
developed world due to vaccination practice often using freeze dried attenuated CAV-2 
virus (Cullan & MacLachlan 2001, Decaro et al. 2007). The CAV-2 virus is used for 
vaccination because this virus is associated with only mild disease and provides cross­
reactivity for the CAV-1 virus and vaccination is therefore less hazardous. Previous 
vaccination protocols with attenuated CAV-1 virus showed profound side effects 
(Decaro et al. 2007).
The complete DNA sequence of the CAV-1 virus field strain RI261 has been 
published and the virus genome contained the same gene arrangements and features as 
the human adenoviruses type 2, 5, 12 and 40 and the CAV-2 virus to which it was 
compared (Morrison et al. 1997). The E3 region of CAV-1 containing only 2 open 
reading frames, differs significantly from the human adenovirus E3 region in which 5 
and 8 open reading frames are identified for the hAd 40 and hAd 2 respectively. The 
complete CAV-1 genome is 30536 base pairs and is therefore smaller than the human 
adenoviruses 2, 5, 12 and 40 which are 35937, 35935, 34125 and 34214 base pairs 
respectively. Similar to the human viruses the genome is flanked by 161 base pair long 
inverted repeat sequences (Morrison et al. 1997, Davisons et al. 2003).
1.2.3.9 CAV-2
Infection with CAV-2 is often involved in the multifactorial infectious 
tracheobronchitis seen in dogs also commonly known as kennel cough (Lopez 2001). 
This disease as the name indicates has been implicated with dogs housed in close 
proximity such as in boarding kennels. The clinical symptoms of the disease are
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generally mild causing rhinitis, pharyngitis, tonsillitis, conjunctivitis and in more severe 
cases pneumonia (Lopez 2001).
The complete genome of CAV-2 has been sequenced showing that this virus 
shares many sequence similarities with CAV-1 which was already demonstrated early 
by hybridisation analysis that estimated 75% nucleotide identity between the two strains 
(Linne 1992, Morrison et al. 1997, Davison et al. 2003). The full length CAV-2 genome 
is 31323 base pairs in size and therefore in a similar size range to the CAV-1 virus 
(Davisons et al. 2003). One of the major differences found between the CAV-1 and 
CAV-2 virus is the E3 coding region. A comparison in this region between the two 
strains has shown that the CAV-2 encodes for a 40.7 kDa polypeptide whilst the CAV-1 
only encoded a 22 kDa polypeptide. Further differences between the E3 regions were 
found suggesting that the E3 region is functionally different in these two strains (Linne 
1992). It is hypothesised that the E3 region can account for the major difference in 
pathogenity observed between the two CAV strains (Linne 1992). The CAV-2 virus 
lacks the RGF motif which is used for interaction o f the virus with integrins on the cell 
surface in order to enter the cell by endocytosis (Davison et al. 2003). This suggests that 
the virus enters the cell by a different mechanism (Soudais et al. 2000).
Both the CAV-1 and CAV-2 have been studied for use as gene therapy vectors. 
Most research has been focused on the use of the CAV-2 due to the mild disease 
associated with this virus (Rasmussen et al. 1999).
1.2.3.10 CAV vectors for gene therapy.
The CAV virus structure has been studied in regard to broadening the tropism of 
already existing human adenovirus gene therapy systems for use in cancer therapy in 
particular. The commonly used human adenoviral vectors depend primarily on CAR 
expression on the cell surface in order to gain entry to the cell however this receptor is 
down regulated in some cancer types (Stoff-Khalili et al. 2005). It was shown that 
hybrid hAd 5 virus vectors containing chimeric fiber knobs derived from the CAV-1 or 
CAV-2 demonstrated a major infectivity enhancement and consequently transgene 
expression in CAR deficient cells and that this effect was especially pronounced when 
the CAV-1 fiber knob protein was used (Stoff-Khalili et al. 2005).
Other studies have examined the use of CAV-2 as an alternative vector for 
delivery o f transgenes to human cells and by using this approach circumventing some of
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the problems with regard to pre-existing immune responses against adenoviruses in 
humans (Kremer 2004). The CAV-2 virus’s ability to transduce different human and 
non human cell types has been evaluated. The CAV-2 shows a slightly different tropism 
than the hAd 5 when used as a vector. It has been shown that any cell that can be 
transduced with CAV-2 can be transduced by hAd 5 but that the reverse situation is not 
so (Kremer 2004). Experiments show that the transduction of certain cell lines and 
transgene expression is lower with the CAV-2 than the hAd5 derived vectors however 
this disadvantage may be outbalanced by the potentially poorer immune response 
against CAV-2 in humans (Kremer et al. 2000, Keriel et al. 2006). This offers a 
potential for long term transgene therapy in humans with a CAV-2 based vector since 
the virus will not be eradicated as quickly by the humoral immune response.
The CAV-2 also represents an opportunity for specific targeting of certain cell 
types and in this context it has been shown that the CAV-2 vectors have a preference for 
transducing neuronal tissue and it could therefore be useful in treatment o f neuronal 
disorders (Kremer et al. 2000, Kremer 2004). The CAV-2 vector could also be used for 
research purposes as a neuronal tracer (Kremer 2004).
The CAV-1 has not been studied as extensively as the CAV-2 for use in gene 
therapy. This could be due to the pathogenesis o f this virus which can lead to fatal 
disease especially in neonates and immunosuppressed dogs (Cullan & MacLachlan 
2001, Decaro et al. 2007). The ability of this virus to infect a broad range of cells in 
vivo could suggest that this virus would be an improvement especially for cell types 
which are difficult to transduce.
1.2.3.11 Adenoviral immune response
The pre-existing host immune response against adenoviruses is the major 
concern in adenovirus based gene therapy. Long term gene expression from adenoviral 
vectors is limited by the immune response, likewise systemically administered virus 
particles can be rapidly cleared from the blood stream. The mode of application could 
have a great impact on the efficacy of the treatment. Local gene therapy such as 
intratumoural injection is not initially affected by circulating neutralizing antibodies 
however the innate immune response is still a concern (Hay 2003). A clinical trial 
using an adenovirus gene therapy vector which had a severe outcome was the fatal 
systemic inflammatory response in an 18 year old boy who received an intravenous
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injection in the hepatic vein with an E l and E4 deleted human adenovirus type 5 vector 
expressing human ornithine transcarbamylase (Raper et al. 2003). The patient in this 
trial suffered clinically from ornithine transcarbamylase deficiency due to a gene 
mutation. This is a disease that though severe can be managed by dietary restrictions. 
However in some severe cases the patients succumb to hyperammonemic coma (Raper 
et al. 2003). The result from this trial shows one o f the problems with the immunogenity 
of adenoviruses and the trial has had a great impact on the planning o f future clinical 
trials not least because the disease for which the patient was treated was not fatal itself.
1.3 Targeting gene therapy to specific cells.
It is important in gene therapy to restrict transgene expression to target cells. 
Expression of a transgene in non target cells can have adverse effects on the patient. 
One way to restrict transgene expression to certain cell types has been by harvesting 
target cells and infecting them in vitro and returning them to the patient. This method is 
however restricted to a few diseases and cell types. Another way to restrict transgene 
expression to target cells which has shown great potential is the use of tissue or disease 
specific promoters. Using tissue or disease specific promoters to drive the transcription 
o f a transgene can restrict the expression of this gene to target cells were the promoters 
are active.
There are many promoters that have been applied to gene therapy for cancer in 
particular in order to restrict gene expression to target cells. These include the survivin 
promoter which has shown to be active in cancer cells (Zhu et al. 2004, Uchide et al. 
2005), the prostate specific antigen promoter which has been shown to be active in 
prostate cells and in particular prostate cancer cells (Diamandis 1998, Zhang et al. 
2002), the cholecystokinin type A receptor promoter which is up-regulated in pancreatic 
cancer (Li et al. 2006) and the carcino embryonic antigen promoter which is active in 
cancer cells in particular colon cancer cells (Ueda 2003).
1.3.1 Telomerase targeted gene therapy.
The promoters associated with transcription of the telomerase enzyme complex 
have been studied thoroughly for their use to specifically target cancer cells. Since these
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promoters are of particular interest for this thesis a more detailed description o f the 
telomerase associated genes and their promoters will follow.
1.3.1.1 Telomerase and the end replication problem.
The telomerase enzyme complex is active in cells in order to overcome the DNA 
end replication problem at cell division (Meyerson2000, Chan & Blackburn 2003). The 
inability of the DNA polymerase to replicate the 3’ end of the lagging strand results in 
loss o f 50-200 nucleotides under each cell cycle as seen in figure 1.3 (Blackburn 1991, 
Kim et al. 1994, Chan & Blackburn 2003). This would be detrimental to the 
chromosomes and therefore ends of the chromosomes are capped by telomeres. 
Telomeres consist of multiple repeats of the non coding TTAGGG nucleotide sequence 
(Blackburn 1991). This sequence is conserved amongst most eukaryotes however the 
number of repeats present varies between species (Kelland 2005). The 3’ end o f the 
telomeres contain a G-rich overhang which together with the repeat sequence interacts 
with a protein complex called shelterin which consists of several telomere binding 
proteins. The function of the shelterin complex is to protect the chromosome ends and 
control telomere lengthening (Blasco 2007). The G-rich overhang is particularly 
important since this structure can fold back onto the double stranded DNA and thereby 
form a structure known as the T-loop. This conformation protects the 3’ end of the 
chromosome from DNA repair mechanisms. In this manner the telomeres prevent the 
chromosomal ends against being treated as double stranded DNA breaks (Blasco 2007). 
Under each cell cycle telomeric DNA is lost resulting in continuously shortening of the 
telomeres. Normal somatic cells are not able to compensate for telomeric loss resulting 
in critical short telomeres after multiple cell divisions. Once the telomeres have reached 
a critical short length the cell is no longer able to replicate and the cell goes into a state 
of senescence. The telomeres can therefore be referred to as a cellular mitotic clock 
(Meyerson 2000, Harley 2008). The average telomere length in adult human somatic 
cells is 7-12 kb. In comparison the length in the dog is 12-23kb and the length in the 
mouse and rat are 40-100 and 20-100 kb respectively (Kelland 2005).
Stem cells, activated lymphocytes, keratinocytes and male germ cells have a 
greater replication potential than other cells and in order to circumvent the cellular 
senescence set by the attrition of telomeres, they maintain the length of their telomeres 
by activation of the telomerase enzyme (Meyerson 2000, Keith et al. 2002). Many
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cancer cells which are continuously replicating wili likewise activate the telomerase 
enzyme in order to expand their replicative potential and therefore the telomerase 
associated promoters are of particular interest in caicer directed gene therapy 
(Blackburn 2005, Harley 2008, Shay & Keith 2008).
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1.3.1.2 Telomerase components
The telomerase enzyme consists of two major components, a Telomerase reverse 
transcriptase (TERT) and a Telomerase RNA template (TR) (Blackburn 2000). These 
two components are adequate to execute telomerase activity in vitro although in vivo 
there are many other associated components that play an important role for function and 
regulation of telomerase activity (Blasco 2007). Of particular interest is the dyskerin 
protein (DKC1) which is mutated in the disease dyskeratosis congenita. Dyskerin 
stabilises the telomerase complex and mutations lead to short telomeres resulting in 
disease (Mitchell et al. 1999, Keith et al. 2002, Blasco 2007). Novel work has shown 
that the telomerase enzyme consists of two TERT molecules and two TR molecules 
together with one dyskerin molecule which acts as a stabiliser (Blasco 2007).
The TERT component of the telomerase enzyme functions as a reverse 
transcriptase to elongate the telomeres and uses the TR component as an RNA template 
for the telomeric repeats (Blackburn 1991, Blackburn 2000). The remaining 
components in the complex participate in stabilising and regulating the telomerase 
complex (Blasco 2007).
1.3.1.3 Telomerase’s role in aging and disease
In humans telomerase is active during embryogenesis and in adult somatic cells 
the activity is low or absent resulting in the average telomere length being shorter in 
elderly compared to young people (Homsby 2007). There are many factors that can 
influence the telomer length in cells such as obesity (Valdes et al. 2005), smoking 
(Valdes et al. 2005, Yim et al. 2007) and socio-economic status (Cherkas et al. 2006).
Congenital disorders in which the ability to maintain telomeres is dysfunctional 
result in degenerative diseases reflecting the inability o f stem cells to renew tissues and 
also a premature death. The most commonly known human diseases associated with 
telomerase abnormalities are dyskeratosis congenita, aplastic anemia and idiopathic 
pulmonary fibrosis (Blasco 2007).
Some cancer cells have limitless replicative potential and as a consequence 
necessitate continuous telomerase activity to inhibit cells from entering cellular 
senescence. In this context telomerase activity has been detected in 90% of human 
cultured cancer cell lines (Kim et al. 1994, Kelland 2005). It is essential for a cell to
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maintain telomere length for continuous cell cycling. In the absence of telomerase 
activity this is achieved by the alternative lengthening of telomeres (ALT) mechanism 
(Reddel 2001, Lundblad 2002, Reddel 2007, Nittis et al. 2008). This is a complex not 
well understood mechanism in which the telomeres are maintained by a form of 
homologous recombination. An interesting aspect of this is that this mechanism is more 
common in tumours of mesenchymal origin than epithelium derived tumours (Nittis et 
al. 2008).
It is possible for some tumours to develop in the absence o f a telomere 
maintenance mechanism (Keith et al. 2002). These tumours are proposed to have 
telomere lengths that allow the cells to divide and the tumour to reach a certain size 
until the telomeres become critically short. These tumours will have a less aggressive 
phenotype than tumours with telomerase activity (Keith et al. 2002). It is also suggested 
that some tumour types could harbour both telomerase expressing and ALT cell types 
(Reddel et al. 2001, Yan et al. 2002, Reddel 2003). Even though telomerase expression 
leads to the ability of the cells to replicate continuously no deregulation in the cell cycle 
is observed and it is therefore not regarded as an oncogene (Harley 2002).
1.3.1.4 Targeting telomerase expressing cells.
To utilise the increased telomerase activity for cancer cell gene therapy two 
promoters have been used; the TERT and the TR promoter mainly because of their 
central role in the function of the telomerase enzyme complex. TERT and TR promoters 
have been isolated and sequenced in humans but also in some mammalian species 
including dogs (Zhao et al. 1998, Cong et al. 1999, Takakura et al. 1999, Long et al.
2005).
1.3.1.5 The human TERT promoter.
The human TERT (hTERT) promoter is GC-rich and lacks a TATA and a 
CAAT box. Several binding sites for transcription factors have been identified in the 
promoter (Cong et al. 1999, Takakura et al. 1999). The core promoter of hTERT is 181 
base pairs upstream of the ATG for the hTERT transcription start site (Takakura et al. 
1999). This promoter despite its shorter length than the full length promoter is still 
tightly regulated reflecting the telomerase activity in cells. An alternative recognition
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sequence for the RNA polymerase to identify the transcription start site in absence of a 
TATA box in the hTERT promoter has been identified as the CCTCTCC sequence 
located 3 base pairs upstream of the ATG start site (Takakura et al. 1999). Expression 
of hTERT mRNA has been shown to reflect the telomerase activity in cells and 
therefore the TERT promoter activity must be tightly regulated in the cells to 
encompass this (Cong et al. 1999).
The mouse TERT promoter is different from the human promoter and 
telomerase is expressed in many tissues in this species throughout life making this an 
unreliable model for studying telomerase activity (Horikawa et al. 2005, Nasir 2008).
1.3.1.6 The human TR promoter.
The human TR (hTR) promoter contains a CAAT site and a TATA box. The 
hTR promoter is a 867 base pair region upstream of the ATG start site (Zhao et al. 
1998). A minimal promoter was isolated as being essential for promoter activity 
consisting of the first 272 base pairs upstream of the ATG start site. Upstream positive 
and negative elements regulate the activity of the hTR promoter. The mouse hTR 
promoter has a core promoter of 94 base pairs however there are no significant sequence 
homologies between the mouse and the human TR promoter, though some regulatory 
protein binding sites were present in both (Zhao et al. 1998)
The activity of the hTR promoter in relation to telomerase activity is debatable. 
Some show that the TR promoter is very tightly regulated by several mechanisms in 
accordance to the telomerase activity in the cell whilst others show that the promoter is 
more promiscuous being active despite no telomerase activity in the cells (Weinrich et 
al. 1997, Bodnar et al. 1998, Yin et al. 2004, Cairney & Keith 2008). The use of the TR 
promoter as a telomerase specific promoter to target gene expression to cancer cells is 
therefore questionable (Gu and Fang 2003).
It has been shown that transfection of cells with a TERT expressing plasmid 
allows for telomerase activity in cells and maintenance of telomeres and it is therefore 
suggested that the hTERT promoter activity is rate limiting for telomerase expression 
(Bodnar et al. 1998). This supports the use o f this promoter for telomerase targeted gene 
therapy.
The TR and TERT promoters have been applied to gene therapy for cancer both 
as simple plasmid systems in which the promoters transcribe a suitable transgene and in
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more complex systems including further regulatory mechanism and viral vectors (Irving 
et al. 2004, Bilsland et al. 2005, Wang et al. 2006, Bilsland et al. 2007).
1.3.1.7 The canine TERT promoter.
The telomerase expression pattern in dog cells follow the pattern seen in humans 
as normal somatic cells do not show telomerase activity whilst stem cells and cancer 
cells do. Telomerase activity has been detected in up to 95 % of canine tumour samples 
(Yazawa et al. 1999). It has also been shown that there is a correlation between 
shortening o f telomeres and age in dogs (McKevitt et al. 2002). The canine TERT gene 
(dogTERT) has been isolated and the gene shows many homologies with its human 
counterpart (Nasir et al. 2004). The dogTERT gene promoter has also been isolated and 
studied (Long et al. 2005). Approximately 5kb DNA was sequenced and analysed 
upstream of the dogTERT gene start site. This promoter region resembles the human 
region in that it is devoid o f a CAAT and a TATA box sequence and that it is very GC- 
rich. Many o f the transcriptional regulatory protein binding sites seen in the human 
promoter are present in the canine TERT promoter. The core dogTERT promoter region 
has been isolated as consisting of the proximal 314 base pairs upstream of the dogTERT 
gene. Inclusion of further base pairs upstream of the core promoter resulted in a 
decrease in promoter activity which could reflect the location of promoter repressor 
binding sites in this region (Long et al. 2005). The properties o f the dogTERT promoter 
and the similarities in the telomerase regulation between the human and canine species 
suggests the dog as a good model for studying telomerase targeted gene therapy and 
also suggests that human TERT promoter driven therapies could be used cross species. 
It has also been shown that expression of the human hTERT gene in canine 
chondrocytes can increase the cellular lifespan without neoplastic transformation of the 
cells (Nicholson et al. 2007).
1.3.2 Improving efficacy of transgene expression.
The use of tissue or disease specific promoters in gene therapy allows the gene 
expression to be selectively targeted to cells in which the promoters are active. While 
these systems are promising with regard to selectivity, they are limited in their 
application due to the relative weak activity of the tissue and disease specific promoters. 
To overcome this obstacle a two step transcriptional amplification system has been
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developed in which the weak signal from the tissue or disease specific promoter is 
amplified resulting in a high level o f transgene expression. Other improvements which 
are applied to these systems are the incorporation of regulatory elements to be able to 
control transgene expression by induction.
1.3.2.1 Two step transcriptional amplification (TSTA) system.
The TSTA system is a two promoter system in which a relatively weak tissue or 
disease specific promoter transcribes a transcriptional activator protein which when 
expressed activates a second promoter which in turn transcribes a transgene as seen in 
figure 1.4. The second promoter is placed downstream of specific transcriptional 
activator binding sites. By binding o f the transcriptional activator protein to the binding 
sites the second promoter becomes highly active resulting in a high level of transgene 
expression. In tissues where the first promoter is not active and hence the transcriptional 
activator protein is not expressed, the second promoter will be inactive and the 
transgene will not be transcribed.
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1.3.2.2 The Gal4-VP16 transcriptional activator fusion protein
The Gal4VP16 transcriptional activator fusion protein has been used in TSTA 
systems. This is a fusion between the Gal4 DNA binding domain derived from the 
Saccharomyces cerevisiea yeast Gal4 protein and the acidic C-terminal domain of the 
VP 16 transcriptional activator derived from human herpes virus type 1 (HSV-1). The 
Gal4 DNA binding domain is a protein consisting of 147 amino acids and it has been 
shown that this protein binds to a specific 17 base pair Gal4 binding sequence and in 
combination with VP 16 activates transcription of downstream genes (Fang et al. 1998).
The VP 16 is a regulatory protein responsible for stimulating transcription of 
immediate early genes in the HSV-1. The full length VP 16 protein is 490 amino acids 
and can be divided into two domains; the N-terminal domain is responsible for targeting 
VP 16 to specific promoter sequences while the C-terminal domain is an acidic domain 
that is responsible for stimulation of transcription (Flint & Shenk 1997). The C-terminal 
domain fused to a DNA binding domain can activate transcription at the binding site by 
promoting the assembly of RNA polymerase II at the site (Sadowski et al. 1988, Liu et 
al. 1999). The size of the VP 16 C-terminal activation domain is 80 amino acids. This 
can be further divided into two sub domains of which the more C-terminal portion is 
important when used to stimulate promoters with only one DNA binding site, while the 
other part contributes to stimulation of promoters with more than one DNA binding site 
(Walker et al. 1993, Flint & Shenk 1997). The length of the VP16 fragment can vary in 
size but commonly the last 78 amino acids o f the carboxyl-terminal of the VP 16 are 
used (Sadowski et al. 1988).
Various promoters can be used to drive the transcription of the Gal4VP16 in the 
TSTA system. The second promoter used in the system which is responsible for 
transcribing the transgene is commonly a minimal Gal4 responsive promoter consisting 
o f a TATA box derived from the adenovirus E lb  region which is placed downstream of 
multiple Gal4 binding sites (Sadowski et al. 1992)
1.3.2.3 The use of the Gal4VP16 in the TSTA system
The Gal4VP16 fusion protein has been used in the TSTA system in conjunction 
with various disease and tissue specific promoters, transgenes and gene delivery 
vectors.
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The hTERT promoter has been used in the TSTA system in conjunction with a 
Gal4VP16 fusion protein of which the VP 16 consisted of the 78 amino acids of the 
carboxyl-terminal of the VP 16 protein. The transcriptional activator in this system 
bound to a minimal Gal4 responsive promoter with 5 upstream Gal4 specific binding 
sites as seen in figure 1.5 a) (Fang et al. 1998). The system was delivered using an 
adenovirus vector system initially as a two vector system but later as a one vector 
system in which all the elements from the TSTA system were placed in the E l region of 
one adenovirus vector (Gu & Fang 2003). As a transgene the system was tested first 
with a LacZ reporter gene and later with a sequence coding for a fusion protein between 
green fluorescent protein (GFP) and the full length TRAIL gene (Kagawa et al. 2001, 
Lin et al. 2002, Gu & Fang 2003) or a Bcl-2-associated X protein (BAX) gene (Gu et 
al. 2000, Kagawa et al. 2000). The system encoding the BAX gene was used as a two 
vector system since the toxic nature o f the BAX gene made it difficult to produce viral 
vectors with the whole TSTA system due to the lethal effect on the cells with BAX 
expression (Kagawa et al. 2000). In summary from this work it was shown that the 
TSTA system was able to increase the transcriptional activity o f a reporter gene 150 
fold compared to using the hTERT to drive the transcription of the reporter gene on its 
own (Gu & Fang 2003). It was furthermore shown that using the TRAIL-GFP fusion 
protein cellular apoptosis was induced specifically in cancer cells both in vitro and in 
vivo in animal models with a good bystander effect and minimal toxicity to “off target” 
cells (Kagawa et al. 2001, Lin et al. 2002). The use of the system with the BAX gene 
did show significant apoptosis of normal hepatocytes suggesting that using the BAX 
gene in the system would cause pronounced side effects (Kagawa et al. 2000).
The prostate specific antigen (PSA) promoter and enhancer has been used with 
the TSTA system in order to target transgene expression to prostate cancer cells. This 
has been done using a Gal4VP16 fusion protein in which the VP 16 consists of a tandem 
repeat o f the VP 16 protein base pairs 413-454 and in conjunction with a Gal4 
responsive promoter with 5 upstream Gal4 binding sites as seen in figure 1.5 b). This 
was done in a single vector plasmid (Iyer et al. 2004, Hattori & Maitani 2006), 
adenovirus (Dzojic et al. 2007, Sato et al. 2008) and a lentivirus (Zhang et al. 2002) 
delivery system. Reporter genes were incorporated into these systems as transgenes 
used to monitor the tissue specific gene expression. From all these studies it was shown 
that using the PSA promoter and enhancer in conjunction with the Gal4VP16 and the 
TSTA system, cell specific gene expression was seen in prostate cells both in vitro and
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in vivo in animal models (Zhang et al. 2002, Iyer et al. 2004, Dzojic et al. 2007, Sato et 
al. 2008). It was also shown that the TSTA system was stronger than a one step system 
with a 640 fold increase in transcriptional activity (Zhang 2002, Hattori & Maitani
2006). One study investigated the effect o f incorporating the HSV-tk gene in the TSTA 
system with the PSA promoter and enhancer or a midkine promoter as tissue or disease 
specific promoters and showed selective inhibition of prostate tumour cell growth in 
vitro (Hattori & Maitani 2006). The midkine promoter used in this study is a promoter 
responsible for transcription of a growth factor and this promoter has been shown to be 
active in various cancer types (Hattori & Maitani 2006).
The TSTA system in conjunction with the Gal4VP16 fusion protein has also 
been used to transcribe two transgenes simultaneously (Ray et al. 2004). In this study 5 
Gal4 binding sites were placed in between two Gal4 responsive promoters which each 
transcribed a reporter gene as seen in figure 1.5 c). A SV40 promoter was used to 
transcribe the Gal4VP16 protein in this study to prove the concept of the system without 
restricting transcription to a specific cell type. The study showed that both reporter 
genes were expressed in this TSTA system. This could be an advantage for monitoring 
gene expression in tissues in vivo (Ray et al. 2004).
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1.3.2.4 Other transcriptional activators used with the TSTA system
m i ^
Transcriptional activator fusion proteins other than the Gal4VP16 have been 
used in conjunction with the TSTA system. A Gal4p65 fusion protein consisting of the 
Gal4 DNA binding domain fused to the p65 transcription activation domain which is 
derived from mammalian cells has been studied (Liu et al. 2006, Liu et al. 2008).
A tetracycline responsive system in which the VP 16 protein is fused to a 
tetracycline transactivator protein (tTA) has also been studied (Fitzsimons et al. 2001, 
Wack et al. 2008). This system is advantageous since it allows for regulation of 
transgene expression in vivo by tetracycline. Both the Gal4p65 and VP16tTA fusion 
proteins have shown promising efficiency in amplifying the transcriptional activity from 
a tissue or disease specific promoter (Fitzsimons et al. 2001, Wack et al. 2008, Liu et al. 
2008).
In relation to the VP16tTA fusion protein it was shown that in order to save 
space the VP 16 sequence could be replaced by a triple repeat of a 12 base pair minimal 
activation domain of the VP 16 protein. This alternative shorter VP 16 fragment should 
reduce some of the squelching effect induced by interactions with the transcriptional 
activator and the cellular transcription factors (Fitzimonz et al. 2001). No comparison 
has been made between the Gal4VP16, the VP16tTA and the Gal4p65 transcriptional 
activators and it is therefore not known if one is more potent than the other.
A TSTA system containing a cancer specific promoter, a tissue specific 
transcriptional activator and a tissue specific second promoter has been developed in 
order to target gene expression to lung cancer cells specifically (Fukazawa et al. 2004). 
This system illustrates the many possibilities to optimise the TSTA system for specific 
cancer types.
1.4 Cancer gene therapy
There are many types of gene therapy that have been applied to cancer treatment 
as noted in chapter 1.1. Two areas o f cancer gene therapy are of particular interest for 
this thesis. These are effector gene therapy and oncolytic gene therapy. Oncolytic gene 
therapy which was not mentioned in chapter 1.1 is a gene therapy method which is only 
applied to cancer and is promising in the way that it circumvents two of the major
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obstacles for gene therapy be namely transgene delivery and specificity of transgene 
expression.
1.4.1 Effector gene therapy for cancer
Effector gene therapy is quite a broad gene therapy approach. In effector gene 
therapy for cancer the goal is to make the target cells express a gene which will result in 
cancer regression either by a direct or indirect effect. The transgene applied can be over 
expression of a normal cellular gene or it can be expression of a gene that is unfamiliar 
to the cells.
Both endogenous and exogenous genes have been studied for this approach. A 
major focus has been on using genes coding for antiangiogenic peptides since sustained 
vascularity is essential for tumour growth and maintenance. Endostatin and angiostatin 
are two genes which have been used either alone or in combination to restrict tumour 
growth by gene therapy (Li et al. 2008).
A direct effect on cancer cells is often sought by expressing lethal genes directly 
in the cancer cells. Lethal genes can be targeted to cancer cells by cancer specific 
promoters as described in chapter 1.3. Several lethal genes have been studied for this 
use such as TRAIL, Caspase 8, FADD and BAX (Gu & Fang 2003). TRAIL is of 
particular interest for this thesis and a more detailed description of this protein’s 
characteristics and use will follow.
1.4.1.1 Tumour necrosis factor-related apoptosis inducing ligand (TRAIL)
Tumour necrosis factor-related apoptosis inducing ligand (TRAIL), also known 
as Apo2L, is an apoptosis-inducing protein which has received great attention for its 
ability to induce apoptosis in cancer cells while not harming normal cells (Wiley et 
al. 1995, Kimberley & Screaton 2004, Koschny et al. 2007).
TRAIL is a member of the tumour necrosis factor (TNF) family. While other 
members of this family have been shown to induce severe toxicity by systemic 
administration, TRAIL appears to be less toxic (Duiker et al. 2006). The exact 
physiological role o f TRAIL has not been determined but it is presumed that it plays a 
role in anti-tumour immunity. TRAIL knockout mice have no gross phenotypic 
characteristics; however upon inoculation with tumours they develop a heavier tumour
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load than wild type mice (Sedger et al. 2002, Duiker et al. 2006). In longer term studies, 
aging TRAIL -/- mice develop more spontaneous lymphomas (Schaefer et al. 2007)
TRAIL is a type II transmembrane protein which has been shown to occur as a 
trimer (Kimberley & Screaton 2004). The protein is found to be expressed at variable 
levels in different normal human cells such as myocytes, hepatocytes and Leydig cells 
while being absent in other cells (Kagawa et al. 2001, Fulda & Debatin 2004, Spierings 
et al. 2004). The precise distribution of TRAIL expression in human tissues is not 
agreed and some studies show a much more restricted distribution than others (Daniels 
et al. 2005). The full length human TRAIL protein consists of 281 amino acids. In 
comparison the mouse TRAIL protein which has also been isolated concists of 291 
amino acids. The mouse protein shares 65% amino acid homology with the human 
counterpart (Wiley et al. 1995).
1.4.1.2 TRAIL receptors
In humans five TRAIL receptors (TRAIL-R) have been identified. TRAIL-R1 
and TRAIL-R2 are death receptors which are located on the cell surface. They are type I 
trans-membrane proteins and consist of an extra cellular binding domain and a 
cytoplasmic death domain (Zhang et al. 2000, Spierings et al. 2004). TRAIL-R1 and 
TRAIL-R2 react upon binding of TRAIL by intracellular formation of the death- 
inducing signalling complex (DISC) (Fischer & Schulze-Osthoff 2005). This complex is 
formed by the cytoplasmic death domain of the receptors which interact with the death 
domain of the adaptor protein FAS-associated death domain (FADD) which in turn 
interacts with caspase 8 or 10 to complete the complex. The formation of DISC initiates 
the caspase cascade by cleavage of caspases 3, 6 or 7 which in turn leads to cell death 
by apoptosis (Fischer & Schulze-Osthoff 2005). In some cell types very low amounts of 
caspase 8 and 10 are activated. In these cells apoptosis occurs through a mitochondrial 
activation loop resulting in release of pro-apoptotic proteins such as cytochrome C from 
the mitochondria into the cytosol (Fulda & Debatin 2004). In mice only one death 
receptor has been identified (Cretney et al. 2007, Takeda et al. 2007).
The three other TRAIL receptors are decoy receptors which are incapable of 
inducing apoptosis.
TRAIL-R3 is an extra cellular linked protein and therefore does not possess an 
intracellular death domain (Zhang et al. 2000).
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TRAIL-R4 is a type 1 trans-membrane protein but unlike TRAIL-R1 and 
TRAIL-R2 the intracellular death domain is truncated (Zhang et al. 2000).
The last receptor TRAIL-R is osteoprotegerin which is a soluble protein known 
to play a role in osteoclastogenesis (Speiring et al. 2004). The decoy receptors are 
mainly believed to inhibit apoptosis by competitive binding of the TRAIL ligand 
(MacFarlane 2003). This binding decreases TRAIL’S availability to the death receptors 
and thereby causes TRAIL resistance as seen in normal cells. Studies have been done to 
localise the TRAIL receptors in different tissues and evaluate the effect of TRAIL when 
repressing individual receptors. It has been shown that while some cell types seem 
dependent upon the decoy receptors to protect them against TRAIL induced apoptosis, 
other cells use a different mechanism which seems to be effective downstream of 
caspase activation (Zhang et al. 2000, Kimberley & Screaton 2004).
1.4.1.3 TRAIL receptor expression in vivo.
The distribution of the different TRAIL receptors varies between different cell 
types. In general the decoy receptor TRAIL-R3 has been shown to be expressed in a 
variety of human tissues whereas TRAIL-R4 has been shown to be expressed in all 
tissues tested. The death receptors TRAIL-R1 and TRAIL-R2 have been shown to be 
expressed in most tissues (Zhang & Fang 2005). A study comparing expression of 
TRAIL receptors in malignant and non-malignant tissue showed that TRAIL-R 1 and 
TRAIL-R2 expression was increased in some malignant tissues while it was down 
regulated in others suggesting this to be the reason that some cancer cells are very 
responsive to TRAIL induced apoptosis while others seem more resistant (Daniels et al.
2005). Studies show great homology of TRAIL and TRAIL-receptor distribution 
between non-human primates and humans. Homology between the protein sequences of 
these constructs between the species has also been found and the human TRAIL protein 
binds and cross-reacts with the non-human primate receptors (Spierings et al. 2004). 
Even though the dog genome differs more from the human than the non-human 
primates it is reasonable to expect a similar cross-reactivity between the human TRAIL 
protein and the canine TRAIL receptors. A study used the combination o f siRNA 
against the anti-apoptotic x-linked inhibitor of apoptosis (XIAP) gene and treatment 
with recombinant human TRAIL on multiple dog cell lines in vitro. This study also 
showed the ability of human TRAIL to induce apoptosis in dog cells, indicating that
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there must be cross reactivity between these species and that TRAIL death receptors 
must exist in the dog (Spee et al. 2006).
1.4.1.4 TRAIL for cancer therapy
The ability o f TRAIL to induce apoptosis in transformed cells while not in 
normal cells has made this gene promising for cancer gene therapy (Wiley et al. 1995, 
Kimberley & Screaton 2004, Duiker et al. 2006, Koschny et al. 2007). This ability was 
initially believed to be due to the distribution of death receptors versus decoy receptors 
in cancer cells. A significant correlation between TRAIL susceptibility and expression 
o f receptors on cancer cells has not been found (Zhang & Fang 2005).This also means 
that cancer cell resistance to TRAIL treatment is not correlated with the expression of 
decoy receptors. Other mechanisms of cancer cell resistance to TRAIL treatment have 
been proposed, such as dysfunctional death receptors due to mutagenesis, or 
dysfunction in any of the other important elements in the TRAIL-induced apoptosis 
pathway such as assembly of DISC and recruitment of FADD (Zhang & Fang 2005). It 
has also been shown that TRAIL can activate NFkB which in turn antagonises apoptosis 
by up-regulating the transcription of antiapoptotic genes (Shetty et al. 2002, MacFarlane
2003). An in vitro study also showed that expression of HPV16 E6 protein could protect 
HCT116 colon cancer cells against TRAIL-induced apoptosis. This effect was not seen 
in U20S cells expressing the same protein, indicating that TRAIL might activate 
different pathways in different cell types (Garnett et al. 2007). Studies on hypoxia and 
cancer cell TRAIL resistance have also been performed. The results from these studies 
are conflicting whilst some suggest that hypoxia, which is commonly present in the 
tumour cell environment, inhibits TRAIL-induced apoptosis by blocking BAX 
translocation to the mitochondria (Kim et al. 2004a), others find a synergistic effect of 
hypoxia on TRAIL induced apoptosis in breast cancer cells (Fitzgerald et al. 2007). 
Some suggests that over expression of certain oncoproteins may play a role in 
sensitising tumour cells to TRAIL induced apoptosis, and in this aspect it was found 
that Myc sensitised cells to TRAIL induced apoptosis while hTERT and SV40 large T 
antigen did not (Huang & Sheikh 2007).
The data on normal cell resistance to TRAIL is diverse. Most studies indicate 
that while some normal human cells are refractory to TRAIL-induced apoptosis other 
cell types are categorised as partially resistant (Steele et al. 2006). Liver cells in
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particular have been shown to be sensitive to TRAIL toxicity (Jo et al. 2000, Zheng et 
al. 2004).
Studies on the interaction between the TRAIL ligand and its receptors have 
shown that the trimeric TRAIL binds to 3 monomeric receptors leading to the 
suggestion of a ligand induced trimerisation model (Kimberley & Screaton 2004). It has 
also been suggested that the receptor trimerisation occurs under influence o f a ligand 
independent extra cellular oligomerisation domain known as the pre-ligand assembly 
domain. These studies have led to multiple proposals to explain how some cell types 
and tumour types are resistant to TRAIL. A better understanding of this system is 
required before TRAIL can be seriously used for cancer cell killing (Kimberley & 
Screaton 2004).
A marked bystander effect has been shown with the transfection o f the full 
length TRAIL gene into cells (Kagawa et al. 2001). This has been observed as the death 
o f non-transfected cells surrounding transfected cells. This effect is not transferable with 
the media suggesting that it is not a secreted form of TRAIL that accounts for this effect 
(Kagawa et al. 2001).
To counteract the possible toxicity of the human wild type TRAIL in normal 
cells TRAIL has been used in gene therapy experimental trials under transcriptional 
control by tissue specific promoters (Lin et al. 2002).
The effects of different recombinant soluble forms of TRAIL have been studied 
in normal and cancerous cell lines. The soluble form of TRAIL consists of amino acids 
114-281 of the TRAIL protein. Some studies however do use a larger fragment 
consisting of amino acids 95-28 l(M a et al. 2005). Data indicate that the soluble form of 
TRAIL is more effective in killing cancer cells (Kim et al. 2004b, Kim et al. 2006). 
Further alterations have been done to make the soluble TRAIL protein even more 
efficient in cell killing. Adding a trimerisation signal in the form of an isoleucine zipper 
stabilises the trimerised form of soluble TRAIL which is needed for optimal death 
receptor binding (Kim et al. 2004b). Furthermore, the addition of a special cleavable 
secretion signal to avoid unwanted immune responses has shown great potential. This 
modified TRAIL construct has shown to be more efficient in tumour cell killing than 
the normal TRAIL protein and in addition is less toxic to normal cells (Kim et al. 
2004b). Studies have shown that when transfecting this modified TRAIL gene into 293- 
T cells, the cell media can be transferred to a culture of TRAIL sensitive cells and
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induce apoptosis. In the same study the TRAIL construct was transfected in to a range 
of normal cell types without showing signs of toxicity (Kim et al. 2004b). In practise 
this indicates that systemic administration of TRAIL could be performed with normal 
and cancer cells expressing and excreting TRAIL which in turn would only be able to 
induce apoptosis in cancer cells. The same TRAIL construct has been tested in vivo in 
mouse tumour models and it is shown that this construct is able to suppress tumour 
growth when injected intra-tumourally (Kim et al. 2006).
The major obstacle regarding TRAIL cancer gene therapy is its possible toxicity 
to normal cells and the possibility of cancer cells becoming resistant. Studies have 
compared the effectiveness of cancer cell killing by soluble TRAIL and adenoviral 
delivered full length TRAIL gene (Voekel-Johnson et al. 2002, Seol et al. 2003). These 
studies show that the full length TRAIL delivered by an adenoviral vector combination 
was able to induce apoptosis in cancer cell lines resistant to soluble TRAIL and showed 
minimal toxicity in normal cells (Voekel-Johnson et al. 2002, Seol et al. 2003). This 
indicates that controlled expression of the full length TRAIL gene might be a safe and 
effective treatment for cancer.
In summary the TRAIL gene has shown great potential for use in cancer gene 
therapy. TRAIL is competent when used on its own however to increase the cancer cell 
killing TRAIL can be used synergistically with other therapies such as chemotherapy 
and radiation therapy (Cretney et al. 2006).
1.4.2 Oncolytic gene therapy
Oncolytic viruses offer a great promise for cancer gene therapy. The reason is 
that this type of therapy utilises the properties of viruses to infect, replicate and induce 
cell death in cells while simultaneously releasing viral progeny which can then readily 
infect neighbouring cells. This strategy shows many promising advantages but also 
includes various risk factors such as immunogenic reactions and recombination of 
viruses (Ko et al. 2005, Liu & Kim 2008).
Early in the 20th century it was observed that viral infections could alleviate or 
cure cancer, bringing forth the interest of using engineered viruses for cancer therapy 
(Liu et al. 2007). Two vims groups have been of particular interest for oncolytic cancer 
therapy due to their characteristics and pathogenesis. These are adenoviruses and 
herpes viruses, in particular herpes simplex vims type 1, which are double stranded
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DNA viruses (Guo et al. 2008). Other virus types have also been used for oncolytic 
virus therapy and have been tested in late phase clinical trials such as vaccinia virus, 
Newcastle disease virus, and reovirus (Liu & Kim 2008).
Some viruses need to be modified to be able to selectively infect and replicate 
in cancer cells while others have a natural phenotype that allows for replication in 
tumours only. The avian Newcastle disease vims depends on defective interferon 
signalling for successful replication and cell death and also the vaccinia vims is 
naturally oncolytic though by unknown mechanisms (Liu et al. 2007, Guo et al. 2008).
Other unmodified wild type vimses including adenovims, reovims, West Nile 
vims and mumps vims have been used for cancer therapy with variable response rates 
(Liu et al. 2007).
1.4.2.1 Engineered viruses.
Adenovimses and herpes simplex vims type 1 are typically modified for use as 
oncolytic vimses and to target their replication to cancer cells. This can be done either 
on a cell targeting level by modifying viral receptors to specific target cancer cells or at 
the transcriptional or translational level of viral gene expression by restricting this to 
cancer cells. As in other cancer gene therapy approaches it is important that the viral 
replication shows a high level of specificity for cancer cells but also has a high level of 
efficacy allowing for efficient killing of target cells. Early data from clinical trials 
showed that cancer therapy using oncolytic viruses is safe but did not show high 
treatment efficacy and there is an essential demand to improve current systems (Liu & 
Kim 2008). The development of oncolytic vimses for cancer therapy has gone from 
unmodified wild type vimses, to deletion mutants in which replication depends on 
phenotypic alterations in the cancer cells, to transcriptionally regulated vimses in which 
transcription of essential viral replication elements is under transcriptional control of a 
cancer or tissue specific promoter to the latest armed oncolytic vimses which as well as 
inducing cell lysis also encode therapeutic or suicide genes (Liu & Kim 2008). The 
oncolytic vimses offer a great plasticity and an opportunity to engineer vimses which 
are optimised to target certain cancer types. Some engineered vimses have several 
cancer and tissue specific promoters incorporated to increase the specificity for certain 
cancer types (Wang et al. 2008), and some are armed with several therapeutic genes 
such as the Ad5-CD/TKrep vims which on top o f having a E1B deletion making it
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dependant on p53 defects for replication, also encodes the two suicide genes thymidine 
kinase and cytosine deaminase making it able to convert two pro-drugs into active 
cytotoxic metabolites to kill the cancer cells (Barton et al. 2006). Many clinical trials 
have been performed using viruses as single agents or in combination with 
chemotherapy, radiotherapy or surgery and it has been shown that virus therapy has a 
synergistic or additive effect when used in combination with other therapies. Several 
different routes o f administration have been used and it is now known that circulating 
host antibodies do not have an effect on the viral treatment efficacy when virus is 
administered locally and also that the immune system can sometimes improve the 
efficacy of the virus treatment (Liu & Kim 2007). The first genetically engineered 
cancer selective vims to be used in human cancer treatment was the ONYX-015. This 
human adenovims with a E1B and E3 deletion showed some antitumoural effect in 
clinical trials however the efficacy was too low. In 2005 the first oncolytic vims was 
approved for marketing for use in cancer therapy in China. This H I01 oncolytic 
adenovims which has obtained cancer selectivity by deletion in the E1B region 
resembles the earlier ONYX-015 vims but has retained the viral E3 region and thereby 
has improved cytolytic effect. Results from phase III clinical trials with this vims in 
combination with chemotherapy showed increased tumour response rate leading to the 
approval of the vims for clinical use as a combination therapy for cancer (Liu et al. 
2007, Guo et al. 2008).
Rodent models are generally used as preclinical models for studying human 
oncolytic vims therapy, however, these models are limited by the size of the animals, 
the difference in immune response and the species specificity o f the viruses making 
better models necessary for future progress (Hemminki et al. 2003, Zhu et al. 2006).
1.4.2.2 Conditionally replicative adenoviruses (CRAds)
CRAd is a term used specifically about adenovimses and often refers to 
adenovimses in which the transcription of genes essential for viral replication have been 
put under the control of a disease or tissue specific promoter allowing the vims to 
replicate and induce lysis in target cells only. This if  often accomplished by replacing 
the E l or E4 promoters with exogenous promoters.
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The OBP-301 virus and the CRAd-CXCR4.RGD virus are good examples of 
CRAds used to target cancer cells. The OBP-301 virus also known as telomelysin is a 
CRAd which has been made selective for replication in cancer cells by replacing the 
promoter responsible for transcription of the E l adenoviral gene region with the human 
telomerase promoter hTERT (Huang et al. 2008). This virus has shown anticancer 
activity against different human cancer cells in vitro. It was also shown in a nude mouse 
tumour model that the virus when applied intratumourally could eradicate tumour cells 
and also showed an oncolytic effect on distant untreated tumour sites (Huang et al. 
2008).
The CRAd-CXCR4.RGD is a virus in which the promoter responsible for the 
transcription of the adenoviral El region has been replaced with a CXCR4 promoter 
(Zhu et al. 2007b). This promoter has been shown to be active in multiple cancer cell 
types while remaining silent in normal cells. This CRAd has further been modified to 
increase its infectivity by a capsid modification. This virus was shown to be able to 
replicate and induce cytotoxicity in multiple cancer cell lines in vitro and also to be able 
to replicate in excised human lung tumour slices accessed in vitro (Zhu et al. 2007b).
The viruses described above are both examples of CRAds which could 
potentially be used for cancer therapy in humans. The extrapolation of data from 
preclinical trials to clinical trials in humans is difficult due to the lack of good animal 
model systems for testing species specific CRAds.
1.4.2.3 CRAds and immunity.
The pre-existing host immune response against adenoviruses is a major concern 
in adenovirus based gene therapy. The mode of application could have a great impact on 
the efficacy of the treatment. Local oncolytic therapy such as intra tumoural treatment is 
not initially affected by circulating neutralizing antibodies however the innate immune 
response is still a concern (Hay 2003). In studies using the herpes simplex virus type 1 
as an oncolytic virus to target sarcoma cells in an immune competent mouse model, it 
was shown that seropositive mice had a better antitumour response than serom negative 
mice (Zhu et al. 2007a). In this experiment the mice were vaccinated against herpes 
simplex virus and subsequently inoculated with sarcoma cells which were treated by 
intra tumoural injection with an oncolytic herpes simplex virus (Zhu et al. 2007a). 
These results indicate that for gene therapy in cancer the immune response might
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participate in eliminating tumour cells and the pre-existing host immune response 
against viruses can have a complimentary effect on cancer therapy.
1.4.2.4 Studying CRAds in animal models.
CRAds for targeting cancer cells have been developed using the CAV-2 virus. 
This has not been done as an attempt to treat human patients but in order to investigate 
in vivo effects of a CRAd in a comparative naturally occurring immune competent 
animal model system (Hay 2003, Hemminki et al. 2003). The many similarities between 
human and canine cancer pathology and epidemiology have made the canine pet 
population a valuable model for studying cancer and cancer therapy (Ostrander et al. 
2000, Bergman et al. 2003, Hemminki et al. 2003, Hansen & Khanna 2004, Bergman et 
al. 2006, Palonni & Khanna 2007).
Viral replication of human adenovirus in canine cells has been reported but no 
cell killing effect was observed, indicating that the cytopathic effect exerted by the virus 
is species specific (Temovoi et al. 2005). This is a particular problem with regard to the 
use of preclinical rodent animal models for testing human CRAd’s. The rodents will 
often be immunocompromised animals with human tumour xenografts which grow in 
situ and form tumours. When testing a human CRAd in these animal models, the CRAd 
can replicate in the human derived tumour cells but will not be able to replicate in the 
normal rodent cells due to the species difference. Therefore the model will not give 
valuable information about the CRAds safety or the risk of killing normal cells in the 
host. The host immune response to adenovirus vectors is an important factor when 
testing both adenovirus vectors but also CRAds in vivo. The rodent preclinical models 
often have an immunosupressed phenotype such as SCID and therefore no information 
regarding the host immune response is achieved by studying these models. Another 
aspect is the xenograft derived tumours which might not be representative with regard 
to architecture and tumour environment (Hay 2003, Hemminki et al. 2003, Le et al.
2006). Using an animal model such as the dog with spontaneously occurring cancers for 
studying the effect of a CRAd in vivo is more informative however in order for this to 
succeed the CRAd must be derived from a canine adenovirus (Hemminki et al. 2003).
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1.4.2.5 CAV-2 based CRAd
A CRAd based on CAV-2 in which the E l a gene o f the virus is under 
transcriptional control of the osteocalcin promoter has been created (Hemminki et al. 
2003, Le et al. 2006). This CRAd was developed to specifically replicate in 
osteosarcoma cells in which the osteocalcin promoter has been shown to be active. The 
choice to use the CAV-2 virus was based on this virus’ pathophysiological similarities 
with the human adenovirus serotypes 2 and 5 which are commonly used for gene 
therapy in humans (Hemminki et al. 2003). As in humans where 90 % of the population 
are seropositive with antibodies against human adenoviruses (Russell 2000, Muruve
2004) then dogs, as mentioned previously, are commonly vaccinated against CAV-1 
using attenuated CAV-2 and therefore the immunological status in this model system 
resembles the human condition (Hemminki et al. 2003). The CAV-2 based CRAd has 
been developed and tested in various normal and osteosarcoma cell lines and in mouse 
models in vivo (Hemminki et al. 2003, Le et al. 2006). Further improvements have been 
made to increase the infectivity of the virus in osteosarcoma cells, by incorporating a 
polylysine polypeptide to the viral fiber knob which has been shown to increase virus 
transduction (Le et al. 2006). The canine CRAd system has been taken forward and has 
been tested in healthy dogs to determine if any virus associated cytotoxicity could be 
detected. No adverse effects were observed in any of the dogs after intravenous 
systemic administration of the virus. Furthermore, no replication of the virus was 
observed, indicating that the virus was not able to replicate in normal healthy canine 
cells (Smith et al. 2006). The system was therefore taken further forward to be tested in 
clinical canine osteosarcoma cases. Canine patients received a systemic injection of the 
CAV-2 based CRAd 48 hours after limb amputation due to osteosarcoma. The viral 
load was monitored for 5 days and viral particles could be detected in the blood stream 
for at least 48 hours after administration. The patients received chemotherapy and were 
regularly monitored. At the time of publication the 4 patients were still alive indicating 
a possible beneficial effect with the CAV-2 CRAd (Smith et al. 2007).
1.5 Cancer and comparative oncology
Cancer is a disease of age and therefore it is predicted that as the lifespan of the 
population is extended due to better medical care and decrease in other particularly 
infectious diseases that the cancer incidence will increase. (Parkin 2001, M a & Yu 
2006, Higginson & Costantini 2008). In humans, in certain age groups in the developed
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world, cancer is the leading cause of death (Jemal et al. 2007). The lack o f gold standard 
curative treatments for cancer and the morbidity and mortality of the disease has made 
cancer a candidate disease for developing new drugs and treatment protocols.
It is not only in the human species that cancer is a common cause o f death. The 
canine population has during the last years gained a more central position in the 
household in the developed world. Vaccination and regular veterinary check ups have 
resulted in an increase in the average life expectancy of the dog with accompanying 
increase in age related diseases such as arthritis and cancer.
Studies indicate that the same cancer forms are of relevance in the canine 
population as in the human population and also that it is the most common disease to 
cause death in the canine pet population in the developed world (Bonnett et al. 1997, 
Mitchell 1999, Dobson et al. 2002, Proschowsky et al. 2003, Hansen & Khanna 2004, 
Merlo et al. 2008).
As in humans there are many factors that lead to the development of cancer in 
dogs. Several breeds are genetically predisposed to certain forms of cancer because o f 
the intensive inbreeding that has occurred in the canine population. Mating between 
close relatives is not uncommon which increases the risk of certain recessive disease 
genes being expressed (Ostrander et al. 2000).
As in humans, environmental exposure to carcinogens, lifestyle, diet and activity 
level also play major roles in the development o f cancer in the dog. For instance it has 
been shown that there is increased risk of lung cancer and cancer in the nasal cavity in 
dogs that are exposed to passive smoking in their home environment (Reif et al. 1998).
Epidemiological studies in human cancer and the corresponding canine cancer 
form showed that there was a connection between cancer cases in a spatial and temporal 
manner between humans and canines indicating that factors causing cancer in humans 
affect the canine population as well (O’Brian et al. 2000). Due to the shorter lifespan of 
the dog and hence the earlier cancer development, one could regard at the canine 
population as a “canary in a mine” reflecting environmental carcinogens.
The conventional cancer treatment methods used for cancer in canines are 
similar to those employed in human cancer treatment. One aspect in which canine 
cancer treatment differs from human is the aggressiveness o f the treatment. In humans 
the goal of cancer treatment is to cure the disease and prolong the lifespan of the patient. 
In the canine patient cancer treatment is less aggressive and rather palliative than
52
curative. The perception o f life quality in animals is different from humans and 
therefore severe side effects from medication are less tolerable in animals compared to 
humans. The general life span of a dog is also shorter than the human life span and 
therefore a treatment that increases the lifespan a couple of months or even years is a 
long prolongation relative to the dog’s natural lifespan.
The high prevalence of cancer in the canine population and the many similarities 
in lifestyle between the human and canine pet population has made the dog an ideal 
comparative model system for human cancer. The relatively shorter life span of the dog 
and the shorter generation time has made the dog a suitable model for studying genetic 
relations in cancer development since many generations can be alive at the same time 
point. The full dog genome was amongst the first to be fully sequenced allowing for 
comparison with the human genome and related disease genes (Ostrander & Wayne
2005). Many dog breeds are inbred and genome analysis for cancer related gene 
mutations therefore need far fewer probes than for a similar approach in humans. It has 
now been shown that many human and canine cancer types share the same phenotypic 
and histopathological characteristics. Similarities between the histopathology o f canine 
and human mammary cancers have been shown. From this it was concluded that these 
lesions which are highly prevalent in females of both human and canine origin share 
many similarities and that canine breast cancer is a good model for studying breast 
cancer progression, treatment and prevention in general (Antuofermo et al. 2007).
Rodent models are often used as preclinical models in human cancer research. 
However rodent physiology, lifespan and the environment in which they are kept under 
laboratory settings differ significantly from humans. Dogs being physically both in size, 
but also in regard to metabolism, more similar to humans are sometimes used in 
experimental settings to study cancer development. Working with dogs in a laboratory 
setting is both very expensive and removes the advantage of the animals sharing an 
environment with humans and thereby adds distance to the translation and comparison 
with humans. Working with experimental animals in a laboratory, regardless o f species, 
also gives rise to ethical implications (Bukowski & Wartenberg 1997). It is difficult to 
maintain laboratory animals in a stress free environment and therefore these animals 
could release stress factors or other substances that could mislead the interpretation of 
experimental results (Eriksson et al. 2004, Everitt & Schapiro 2006).
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The canine population in the UK is estimated to be 6 million and in the USA 
about 55 million. This gives rise to a large naturally occurring population at risk for 
spontaneously developing cancer (Hansen & Khanna 2004, Starkey et al. 2005). This 
opens the possibility for epidemiological studies and clinical trials to be performed 
using domestic pet dogs, and removes the ethical dilemma encountered with 
experimental animals. Clinical trials for a new therapeutic agent in a dog study require 
about 1-3 years while in comparison a human trial takes 5-15 years (Hansen & Khanna
2004). Several therapeutic protocols have already been developed in dogs and then later 
transferred to humans. A good example is the limb spare therapy for osteosarcoma 
which was originally developed for use in dogs however is now routinely used in both 
humans and dogs (Withrow et al. 1993, Hansen & Khanna 2004).
A DNA vaccine containing the human tyrosinase antigen has been developed 
and clinically tried for treatment of canine malignant melanoma with a high success 
rate. In this case the human xenogeneic antigen was used to stimulate a better immune 
response in the dog (Bergman et al. 2003, Bergman et al. 2006, Bergman 2007). After 
the success in this canine trial a similar trial was initiated in humans. This trial showed 
good effect o f the vaccine with only minor side effects. Furthermore the human study 
augmented the use of xenogeneic DNA since the patients in the human trial received 
boosters with mouse tyrosinase and human tyrosinase DNA (Wolchok et al. 2007).
Since the size and physiology between humans and canines is similar it is easy 
to transfer treatment protocols between these species (Hansen & Khanna 2004). 
Methods developed in experimental animals are also more easily applied to pet animals 
which function as a transition step before applying the method to humans (Cook 2007).
The use o f pet animals however does not eliminate the use of simple in vivo 
rodent models to check for initial carcinogenicity or toxicity (Mack 2006).
1.5.1 Comparative medicine and gene therapy models.
The canine population is a valuable model system for studying cancer and is a 
potential population in which to test upcoming gene therapy drugs prior to human trials. 
There is a whole range o f other non cancerous genetic and acquired disorders for which 
gene therapy is being developed and for which the naturally occurring diseases in the 
dog will likewise be a good model systems. Gene therapy for skin disorders as an 
example has received a lot of attention due to the easy accessibility of this organ making
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topical gene therapy treatment an option. Many skin diseases are of genetic origin, 
either caused by mutations or inheritance and their effects can have detrimental and 
fatal outcomes. Ichthyosis and epidermolysis bullosa are two cutaneous disorders 
which occur in both humans and canines and for which gene therapy is being 
considered as a treatment option (Hargis & Ginn 2001, Hengge 2005).
Degenerative joint disease is another disease which is currently being exploited 
for treatment with gene therapy (Evans et al. 2004). The geriatric canine population has 
a high prevalence of osteoarthritic disease and is therefore a good candidate for studying 
gene therapy in a spontaneous in vivo model. Other musculo-skeletal disorders o f non 
genetic origen such as fractures, ligament and cartilage damage often traumatically 
induced, are also being exploited for gene therapy purposes. In this manner canines 
which frequently suffer from traumatic injuries from road traffic accidents are likewise 
a good model for studying the effect of gene therapy in vivo (Evans et al, 2004, 
Carofino & Lieberman 2008). Duchenne’s muscular dystrophy which is a genetically 
X-linked disorder causing premature death in humans, has a counterpart in the canine 
population and gene therapy trials have already been carried out in dogs in which a 
functional dystrophin gene was restored and trials are now ongoing in humans (Tsai et 
al. 2007). Ophthalmic disorders are being exploited for gene therapy. The eye is a good 
organ for gene therapy due to the blood retina barrier allowing the eye to avoid the 
immune system, the easy accessibility of the organ, the small volume of the organ and 
the ease with which it can be monitored by visual inspection. Dogs suffer from retinal 
degenerative disease similar to humans and gene therapy trials in dogs were able to 
restore eyesight which has led to consideration of similar trials in humans (Rex 2007, 
Tsai et al. 2007). Another genetic disorder shared between humans and canines is 
haemophilia B. This disease has been exploited for gene therapy treatment and in dogs 
expression of a therapeutic gene by gene therapy has already been tested providing 
evidence proof that the method can potentially be used in humans (Tsai et al. 2007).
The large canine pet population in the developed world, the motivation of 
compliant owners to treat their animals and the presence o f high standard veterinary 
hospitals with state of the art equipment provides a good base for treating dogs with 
gene therapy for various disorders in order to cure the disease in this species and to 
function as a preclinical model for human trials.
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1.6 Objectives of this project.
The efficacy of gene therapy is restricted in vivo due to challenges in restricting 
transgene expression to target cells, assuring adequate therapeutic levels o f transgene 
expression and efficacy o f in vivo delivery systems. The aim of this thesis is to target 
each o f these problem areas in order to create better gene therapy systems. This work 
also focuses on using the canine population as a representative naturally occurring 
spontaneous animal model for studying cancer gene therapy.
The major aims of this thesis are:
I. To develop a TSTA system which is more potent than the commonly used 
systems.
II. To target transgene expression to cancer cells and in conjunction with the 
TSTA system induce cell death in these.
III. To develop a CRAd based on the CAV-1 virus to be used for treating canine 
cancer and as a model system for human cancer gene therapy including the 
developed TSTA system.
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Chapter 2
Material and Methods.
2.1 Materials
2.1.1 Antibodies
Abeam Pic (Cambridge, United Kingdom)
Rabbit polyclonal IgG anti human adenovirus type 5.
Rabbit polyclonal IgG anti TRAIL 
Rabbit polyclonal IgG anti VP 16 tag
Acris Antibodies GmbH (Hiddenhausen, Germany)
Sheep polyclonal IgG anti purified canine IgG, Horseradish peroxidise conjugated.
New England Biolabs Ltd (Hertfordshire, United Kingdom)
Rabbit anti cleaved caspase 3 (Asp 175)
Rabbit anti caspase 3
Rabbit anti cleaved PARP (human)
Sigma Aldrich Company Ltd. (D orset, United Kingdom)
Goat anti Rabbit IgG, peroxidise conjugated.
Mouse anti gammatubulin clone GTU-88
Rabbit anti mouse IgG (whole molecule), peroxidise conjugated.
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2.1.2 Bacteriology
2.1.2.1 Antibiotics and selection indicators
Sigma Chemical Co Ltd (Dorset United Kingdom)
Ampicillin
Streptomycin
5-Bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X-GAL)
2.1.2.2 Competent cells
BJ5183s cells were a kind gift from Dorothy Montgomery, University o f Glasgow. 
JM-109 cells were a kind gift from Dr Philippe Gobeil, University o f Glasgow.
Invitrogen Ltd (Paisley, United Kingdom)
One Shot® TOP 10 Electrocompetent™ E. coli 
MAX Efficiency® Stbl2™ Competent Cells 
Subcloning Efficiency™ DH5a™ Competent Cells
2.1.2.3 Growth medium
Institute of Comparative Medicine Central services (University of Glasgow, United 
Kingdom)
Luria Broth (L-Broth), 1 litre: 10 g Tryptone, lOg NaCl, 5g yeast extract, 1000 ml 
ddH20 .
Luria Bertai agar, 1 litre: lOg tryptone, lOg NaCL, 5g yeast extract, 15g bacteriological 
agar, 1000 ml ddH20 .
Super Optimal Catabolite repression broth (SOC) 1 litre: 20 g Tryptone, 5 g yeast 
extract, 0.5 g NaCl, 2.5 ml 1M KC1, 1000 ml ddH20 .
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2.1.3 Cell Culture
2.1.3.1 Cell lines
293-T: Human Embryonic Kidney 293T cells are derived from the 293 cell line in 
which the SV40 T-antigen has been inserted. 293-T cells exert a high level of 
telomerase activity (Nasir et al. 2001). This cell line was a kind gift from Dr. Brian 
Willett, University of Glasgow.
C33a: C33a cells are derived from a human papilloma virus negative cervical 
carcinoma. C33a cells are telomerase positive (Kyo et al. 1998). This cell line was 
obtained from Cancer Research UK (Cancer Research United Kingdom (CRUK), 
London).
GM-847: GM-847 cells are SV40-immortalized human fibroblasts. The cell line 
maintains its telomerase by an alternative lengthening of telomeres (ALT) mechanism 
(Perrem et al. 2001). GM-847 cells were a kind gift from Professor Nicol Keith,
Beatson Institute, Glasgow.
MCF-7: MCF-7 cells derived from a Human Caucasian breast adenocarcinoma. This is 
a telomerase positive cell line (Raymond et al. 1999). MCF7 cells were purchased from 
Cancer Research UK (CRUK, London United Kingdom).
MDCK: Madin-Darby Canine Kidney (MDCK) is a canine epithelial cell line derived 
from kidney tissue. This is a telomerase positive cell line (Nasir et al. 2001). MDCK 
cells were originally bought from EC ACC (EC ACC 85011435)
MDCK P 3.1: MDCK P 3.1 cells are derived from the MDCK cell line and are stably 
expressing the canine adenovirus El gene under Geneticin (Invitrogen) selection. These 
cells were a kind gift from Dorothy Montgomery, University o f Glasgow.
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MDCK Rvd 1.9: MDCK Rvd 1.9cells are derived from the MDCK cell line and are 
stably expressing the canine adenovirus El gene under Geneticin (Invitrogen) selection. 
These cells were a kind gift from Dorothy Montgomery, University of Glasgow.
MRC5: MRC5 is a primary foetal fibroblast cell line derived from humans. MRC5 cells 
are telomerase negative cell and it is not an immortal cell line (Keys et al. 2004). The 
cell line was purchased from CRUK (CRUK, London United Kingdom).
Primary canine chondrocytes: These cells were primary cells derived from the femur 
o f a white Alsatian dog. Cells were a kind gift from Dr. Iain Nicholson, University of 
Glasgow.
Primary canine fibroblasts: These cells were primary cells which were cultured from 
an abdominal skin sample from an euthanized dog. Cells were dissociated from a canine 
abdominal skin sample and cultured as described in methods.
Primary canine fibrosarcoma These cells were primary cells which were cultured 
from an excised fibrosarcoma from the Small Animal Hospital, University of Glasgow. 
Cells were dissociated from the tumour mass and cultured as described in methods.
Primary canine sertoli cell tumour These cells were primary cells which were 
cultured from an excised sertoli cell tumour from the Small animal hospital, University 
of Glasgow. Cells were dissociated from the tumour mass and cultured as described in 
methods.
U 20S: U 20S cells are oesteosarcoma cells, expressing wild type p53. This is a 
telomerase negative cell line which uses the ALT mechanism to maintain its telomeres 
(Savage et al. 2005). U 20S cells were purchased from CRUK (CRUK, London United 
Kingdom).
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2.1.3.2 Media and additives
Invitrogen Ltd (Paisley, United Kingdom)
DMEM 1 x w/GlutaMAX™/Glucose Na Pyr 
Distilled water 
Foetal bovine serum 
Fungizone® antimycotic liquid 
Geneticin® selective antibiotic
GIBCO™ Hanks' Balanced Salt Solution (HBSS) (IX) liquid, no calcium chloride,
magnesium chloride, or magnesium sulphate
HEPES buffer solution
L-Glutamine 200 mM (lOOx), liquid
Non-essential amino acids
Opti-MEM® I Reduced Serum Media
Penicillin-Streptomycin Solution
RPMI Medium 1640 (IX), liquid
Trypan blue stain
Trypsin-EDTA (lx) 0.05% trypsin 0.53mM EDTANa
2.1.3.3 Transfection reagents
Amaxa Biosystems (Cologne, Germany)
Nucleofector™ II device 
Cell line Nucleofector Kit L
Cambridge BioScience Ltd (Cambidge, United Kingdom)
TransIT LT1 Transfection Reagent
2.1.4 Chemicals and Reagents
Sigma Chemicals Co. Ltd (Dorset, United Kingdom)
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3 ',5 ',5 "-Tetrabromophenolsulfophethalein (Bromphenol Blue)
4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES)
3-Hydroxy-4-(2-sulfo-4-[4-sulfophenylazo] phenylazo)-2, 7-naphthalenedisulfonic acid 
sodium salt (Ponceau S)
Acetic acid sodium salt (Sodium acetate)
Bicinchonoinic Acid (BCA) solution 
Boric Acid -99%
Calcium Chloride
Copper (II) sulphate (pentahydrate 4% (w/v) solution)
Ethidium bromide 
Nonidet P-40 (NP40)
Paraformaldehyde
Phenol: Chloroform: Isoamyl Alcohol (25:24:1)
Poly-L-lysine 
Sodium Acetate 
Sodium Chloride
Tween 20 (Polyoxethylene sorbitan nonolaurate)
Tris Base (2-Amino-2-(hydroxymethyl)-l, 3-propanediol)
University of Glasgow Stores (Glasgow, United Kingdom)
Crude ethanol
VWR International (Leicestershire, United Kingdom)
Absolute 99.7-100% AnalaR® ethanol 
AnalaR® Sodium Hydroxide pellets 
AnalaR® Glycine molecular biology grade 
AnalaR® D-(+)-Glucose 
AnalaR® Glycerol 
Crystal Violet
Dimethyl sulfoxide (DMSO)
Ethylene diamine tetra acetate (EDTA) disodium salt 
Hydrochloric acid 
Methanol AnalaR®
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Propan-2-ol (Isopropanol) Molecular Biology Grade 
Sodium dodecyl sulphate (SDS) AnalaR®
2.1.5 Enzymes
All enzymes were supplied with optimal reaction buffers and supplements if required.
2.1.5.1 Ligase
Cambrex Bioscience (Wokingham, United Kingdom)
Takara DNA ligation Kit (version 2.1)
2.1.5.2 Phosphatase
New England Biolabs (Hitchin, United Kingdom)
Antarctic Phosphatase
Promega Ltd (Southampton, United Kingdom)
TSAP Thermosensitive Alkaline Phosphatase
2.1.5.3 Polymerase
Invitrogen Ltd (Paisley, United Kingdom)
Platinum ® Taq DNA polymerase
T4 DNA Polymerase
Taq DNA Polymerase, Native + W1
Merck Chemicals Ltd (Nottingham, United Kingdom)
KOD Hot Start DNA Polymerase
Promega Ltd (Southampton, United Kingdom)
Pfu DNA Polymerase
63
2.1.5.4 Restriction enzymes
Invitrogen Ltd (Paisley, United Kingdom)
Bam HI 
Bgl II 
Dpn I 
EcoR I 
EcoRV 
Hind III 
Kpn I 
Nhe I 
Sma I 
Xba I 
X ho l
New England Biolabs (Hitchin, United Kingdom)
Fse I 
Fsp I 
I-Sce I 
Pme I
Promega Ltd (Southampton, United Kingdom)
I-Ppo I
2.1.6 Kits
Applied Biosystems (Warrington, United Kingdom)
BigDye® Terminator v3.1 Cycle Sequencing Kit 
RNAqueous® Kit
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Invitrogen Ltd (Paisley, United Kingdom)
Charge Switch ® Plasmid ER mini prep Kit 
Charge Switch ® PCR Clean-Up Kit 
PureLink™ Gel Extraction Kit 
Purelink™ Plasmid maxi prep kit 
Superscript™ III Reverse Transcriptase kit
TOPO TA Cloning® Kit (with pCR®2.1-TOPO® and TOP 10 cells Electrocomp™)
Millipore (Herts, United Kingdom)
TRAPeze® ELISA Telomerase Detction Kit
Promega Ltd (Southampton, United Kingdom)
DeadEnd™ Fluorometric TUNEL System 
Luciferase Assay System 
Reporter Lysis Buffer (5x solution)
Qiagen Ltd (Crawley, United Kingdom)
QIAprep® Spin Miniprep Kit 
Quiagen Large Construct Kit
Fisher Scientific UK Limited (Leicestershire, United Kingdom)
NucleoBond® Xtra Maxi Plus Kit 
NucleoBond® Xtra Midi Kit
2.1.7 Miscellaneous
Applied Biosystems (Warrington, United Kingdom)
Hi-Di™ Formamide
Bio-Rad Laboratories Inc. (Hertfordshire, United Kingdom)
Certified Molecular Biology Agarose
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Promega Ltd (Southampton, United Kingdom)
dATP lOOmM (40pmol) 
dCTPlOOmM (40nmol) 
dGTPlOOmM (40|imol) 
dTTP lOOmM (40pmol)
Invitrogen Ltd (Paisley, U.K.)
100 bp DNA Ladder
1Kb DNA Ladder
X DNA/Hind III Fragments
Agarose (ultrapure electrophoresis grade)
See Blue® Pre-stained protein standard
Morrisons Supermarket (Anniesland, United Kingdom)
Marvel dried skimmed milk
Roche Biosystems (Basel, Switzerland)
Complete Protease Inhibitor Cocktail Tablets
Thermo Labsytems Corporation (Warwickshire, United Kingdom)
Luminoskan Acsent Luminometer and Ascent software (version 2.4.2)
Ultra Violet Productions (UVP) (Cambridge, United Kingdom)
UVP Multi-doc gel documentation system
High performance ultra-violet transilluminator (UVP VB-26)
Vector Laboratories, Ltd., (Peterborough, United Kingdom)
VECTASHIELD® Mounting Medium with DAPI
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2.1.8 Oligonucleotides 5’-3’
2.1.8.1 Oligonucleotides for PCR (5’- 3’)
Primer Sequence Purpose
HINDIII-GAL4 CCGAAGCTT ACG ACTC ACT AT AGGCT AGC Cloning of Gal4VP16 down stream of telomerase 
promoters.
3’VP16(XBAI) CGGTCTAGATCACTCGTCAATTCCAAG Cloning of Gal4VP16 down stream of the 
telomerase promoters.
5’HINDIIImay20
06
CGGAAGCTT AT GTCG ACGGCCCCCCCGACC Cloning of VP16E2 down stream of the hTR 
promoter.
3’E2JULY2006 CGCGTCT AGATCAG AAGTCCAAGCTGGC Cloning of VP16E2 down stream of the hTERT 
promoter.
5’VP16JULY200
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CCGG AAGCTT AT GTCG ACGGCCCCCCCGACC Cloning of VP16E2 down stream of the hTERT 
promoter.
3’E2XBAI CGCTCT AG ATCAGAAGTCCAAGCTGGC Cloning of VP16E2 down stream of hTR promoter.
5’HINDIII-
TRAIL
CGC AAGCTT GCC ACC AT GGCT AT GAT GG AGGT C Cloning of TRAIL downstream of 3’bpTATA or 
CMV promoter.
3’XBAI-TRAIL CGCT CT AGATT AGCC AACT AAAAAGGCCCC Cloning of TRAIL downstream of 3’bpTATA or 
CMV promoter.
3’BGLII E2 CCGAGATCTT C AGAAGTCCAAGC Cloning of hTERT-VP16E2 into one vector system.
5’BGLII HTERT CCGAGATCTGTCCGGCATTCGTGG Cloning of hTERT-VP16E2 into one vector system
5’BGLII HTR CCGAGAT CT AGCT ACT C AGGAGGC Cloning of hTR-VP16E2 into one vector system
Leftend 5’EcoRV CCGCGAT ATCGTTTAAACCGATCAAGGCGAGTT AC Cloning of leftend CAV-1
3’bpwith-r-sites CCGCGTCG ACGTTT AAACCCCGGGC ACCAAAT CCGC ACT 
GCT
Cloning of 3’bpTATA into virus
5’bpxhol CCGCCTCG AG ATCCACCG AAAACG Cloning of 3’bpTATA into virus
Leftend3’XHOI CCGCCT CG AGGCCGGGT GTGGAAAATT GG Coning of leftend CAV-1
Pcg-pmeI-2 CCGCGTTT AAACT AGTT ATT AAT AGT AATC Cloning ofCMV-VP16 into E3 region
3TMEIE2 CCGGTTT AAACTCAGAAGTCCAAGC Cloning of CMV-VP16 into E3 region
polyAAA 5’April CCGGGTCGACCGGCCGCAATAAAATATC Cloning of PolyAAA
polyAAA 3’April GGCCCTCGAGGGTACCT ATCGAT AGAG Cloning of PolyAAA
Leftend 3 G AAAAGT GCC ACCT G ACGT C Per of mutant and wild type virus
Leftend3’XHOI CCGCCT CG AGTT CTCGCGGGT GCGGT CCT G PCR of mutant and wild type virus
2.1.8.2 Oligonucletides for Sequencing (5’to 3’)
Primer Sequence Purpose
Vpl6e2seql GGATCCGGACTCGTCAATTCC For sequencing of VP16
Vpl6e2seq2 G AAGTCGGCCAT ATCCAGAGC For sequencing of VP 16
Vpl6e2seq3 GCT AACC AGGT AAAGT GCT ATCG For sequencing of E2
T-7 T AAT ACG ACTCACT AT AGGG Sequencing of T-7sites
GLPRIMER2 CTTT AT GTTTTT GGCGTCTTCC Sequencing of GL2 sites
RVPRIMER3 CT AGC AAAAT AGGCT GTCCC Sequencing of RV3 sites
5’virus det GACGATCTGCAGCTTCCAG Sequencing of CAV-1 El region
3’virus det G ACT AT GTGCGATAGT GC Sequencing of CAV-1 El region
SEQHTERTREV CGGGCT CCGGGC ACC ACG Sequencing of hTERT
SEQHTRREV GATT CTCGTGTCT C AGCC Sequencing of hTR
SEQE2REV GGACCGTCCCGT ACCCAAC Sequencing of VP16E2 with double VP 16
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2.1.8.3 Oligonucleotides for sequencing, isolation and cloning of dog TRAIL (5’to 
3’)
Primer Sequence Target
TRAIL3’upstr GAATAGAGTCCATATTC Upstream of dog TRAIL TAA
TRAIL5’ATG GGCAGCGAGATGCAGGCC dogTRAIL start site ATG
TRAIL5’DS CAGG AC AAGT ACTCC Downstream of dogTRAIL ATG
TRAIL3’TAA TT AGCCG ATT AAAAAGGC dogTRAIL end site TAA
2.1.8.4 Oligonucleotides for site directed mutagenesis
Primer Sequence Target
3’MUT E2 CTTCCTCT GT GGCGT CGGGCGAC E2 serine 301 mutation
5’MUT E2 GTCGCCCGACGCCACAGAGGAAG E2 serine 301 mutation
2.1.9 Plasmids and cosmids
3 ’Bp-TATA: This is a PGL3-Basic vector into which six E2 binding sites have been 
cloned in using the Bgl II restriction site. Downstream from this a minimal BPV-4 
promoter has been cloned with a 5’ deletion leaving only 3 base pairs upstream from the 
TATA box. This promoter was cloned in to the vector using Bgl II and Hind III 
restriction sites. This vector was constructed by Dr. Keith Vance (Vance et al. 2001).
dogTERT-hTRAIL: This vector is based on the pCR3.1-TRAIL vector (Invitrogen). In 
this construct the Cytomegalovirus promoter has been deleted and instead the canine 
telomerase promoter has been cloned in together with the full length 843 bp human 
TRAIL gene which was per amplified from the pORF-hTRAIL vector (Invivogen). This 
vector was constructed by Dr. Sam Long, Glasgow University.
fAElAE3: This is a cosmid containing the canine adenovirus type 1 (CAV-1) genome 
with the virus El and E3 coding regions removed. The cosmid is based on the Supercos 
cosmid (Stratagene) This cosmid was provided by Dorothy Montgomery, Glasgow 
University.
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LASC: This is a cosmid containing the complete canine adenovirus type 1 (CAV-1) 
genome. The E3 region has been removed from this cosmid. This cosmid was provided 
by Dorothy Montgomery, Glasgow University.
pBind-Gal4VP16: This vector is based on the P-Bind vector (Promega). This vector 
contains the 147 amino acid yeast Gal4 DNA binding domain under transcriptional 
control of a CMV promoter. It has a VP 16 fragment consisting of amino acids 410-487 
of the full length VP 16 protein. This has been cloned into the pBind vector downstream 
from the Gal4 site using the restriction sites BamH I and Kpn I.
pCG-VP16E2: This vector contains the Cytomegalovirus promoter which transcribes a 
fusion protein made up by amino acids 410-487 of the full length VP 16 protein and 161 
amino acids of the BPV-1 E2 gene including the full length DNA binding domain. This 
plasmid was a gift form Dr. Mart Ustav (Estonian Biocenter).
pCR 2.1-TOPO: This is a commercial plasmid that comes with the TOPO TA Cloning 
kit (Invitrogen). The plasmid is 3.9kb and contains an ampicillin resistance gene as well 
as a kanamycin resistance gene. A multiple cloning site is present in this plasmid and 
binding sites are present for use of the T-7 and M l 3 sequencing primers.
pDNA: This vector contains the cytolomegalus promoter upstream from a multiple 
cloning site. This vector was provided by Ed Dornan (Glasgow University).
pDNAVP16E2: This vector is based on the pDNA vector in which the VP 16E2 
sequence has been inserted downstream of the CMV promoter using the EcoR I and 
Xho I restriction sites.
pGL3-Basic: This vector contains the firefly luciferase gene and a multiple cloning 
region but lacks promoter and enhancer activity (Promega Ltd. Southampton, United 
Kingdom).
pGL3 control: This vector contains SV40 promoter and enhancer sequences driving the 
expression of firefly luciferase gene (Promega Ltd. Southampton, United Kingdom).
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pGL3hTP19: This vector is based on the pGL3-Basic vector (Promega). It contains the 
536 bp human telomerase reverse transcriptase (hTERT) minimal promoter fragment 
cloned in using the Xho I and Hind III restriction sites. This promoter controls the 
transcription of the downstream firefly luciferase gene. This vector was a gift from 
Professor Nicol Keith, Beatson Institute, Glasgow.
pLh2023: This vector is based on the pGL3-Basic vector (Promega). It contains the 867 
bp human telomerase RNA template (hTR) minimal promoter fragment cloned in using 
the Xho I and Hind III restriction sites. This promoter drives the transcription o f the 
downstream firefly luciferase gene. This vector was a gift from Professor Nicol Keith, 
Beatson Institute, Glasgow.
pTK-Gal4-6xE2: This vector contains 5 Gal4 binding sites and 6  E2 binding sites 
upstream of a TK promoter transcribing a luciferase gene. This was constructed by Dr 
Roni Wright (Glasgow University) by cloning 5 Gal4 binding sites which were 
amplified by PCR from the pG5Luc vector, into the tk 6E2 vector (Vance et al.1999) 
using the Kpnl and Nhel restriction sites.
pSwaPme: this vector is a modified version of the pBluescript vector (Stratagene, 
Cheshire UK). This vector has been modified to contain a multiple cloning site with two 
Swa I sites and two Pme I sites. This vector was provided by Dorothy Montgomery, 
Glasgow University.
PV2 x4E2: The PV2 x4E2 plasmid was made previously (Vance et al. 1999). This 
plasmid contains a mutated minimal promoter derived from the BPV-4 promoter 
responsible for transcription o f a firefly luciferease reporter gene and has 4 upstream E2 
binding sites
PV2 x8E2: As PV2 x4E2 but with 8 upstream E2 binding sites.
PV2 x!2E2: As PV2 x4E2 but with 12 upstream E2 binding sites.
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2.1.10 SDS-Polyacrylamide Gel Electrophoresis and western blotting
2.1.10.1 Buffers and solutions
Invitrogen Ltd (Paisley, United Kingdom)
NuPAGE® Antioxidant
NuPAGE® MES SDS Running Buffer (20X)
NuPAGE® Sample Reducing Agent (10X)
NuPAGE® Transfer Buffer (20X)
2 .1 .1 0 .2  Chemiluminescence film
Perbio Science UK Ltd (Northumberland, United Kingdom)
CL-XPosure™ Film
2.1.10.3 Developing solution
GE Healthcare UK Ltd (Buckinghamshire, United Kingdom)
ECL Plus™ Western Blotting Detection Reagents
2.1.10.4 Gels and membranes
Invitrogen Ltd (Paisley, United Kingdom)
NuPAGE® 4-12% Bis-Tris 12 well 1.0 mm gels 
NuPAGE® 4-12% Bis-Tris 10 well 1.0 mm gels
2.1.10.5 Protein transfer systems
Bio-Rad Laboratories Inc. (Hertfordshire, United Kingdom)
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell
Invitrogen Ltd (Paisley, United Kingdom)
iBlot ™Transfer Stack, Mini (Nitrocellulose) 
iBlot™ Transfer Stack, Regular (Nitrocellulose) 
iBlot™ Gel Transfer Device (UK)
Nitrocellulose membrane, 0.2 pm pore size 
Nitrocellulose membrane, 0.4 pm pore size
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2.2 Methods
2.2.1 Molecular biology protocols
2.2.1.1 Chemical transformation of competent bacteria.
For chemical transformation of E.coli (Subcloning Efficiency™ DH5a™ 
Competent Cells, Invitrogen) the following protocol was used. Cells stored at -80°C 
were thawed on ice. 5 pi ligation or 1 pi (lng/pl) plasmid DNA was added to a 30 pi 
aliquot of competent E.coli cells in a sterile microcentrifuge tube. The tubes were then 
left on ice for 30 minutes. Cells were heat shocked at 42°C for 1 min. After this 100 pi 
SOC medium was added to each tube and the tubes were incubated at 37°C for 1 hour 
with rotation at 225 rpm. The contents of each tube were then spread on L-agar plates 
with the appropriate selective antibiotic, allowed to dry then inverted and incubated 
over night at 37°C.
For chemical transformation of JM-109 cells the protocol was as follows. Cells 
stored at -80°C were thawed on ice. 100 pi cells were mixed with 7 pi ligation or lng 
plasmid DNA in a sterile microcentrifuge tube and left on ice 1 hour. Cells were heat 
shocked at 46°C for 50 seconds. After this they were put back on ice for two minutes 
and following 700pl SOC medium was added to each tube and the tubes were incubated 
at 37°C for 1 hour with rotation at 225 rpm. 300pl of each cell suspension was then 
spread on L-agar plates with the appropriate selective antibiotic, allowed to dry then 
inverted and incubated over night at 37°C.
Stbl 2 cells where transformed according to manufacturers manual (MAX Efficiency® 
Stbl2™ Competent Cells, Invitrogen).
2.2.1.2 Small scale preparation of plasmid DNA (Miniprep).
Transformed bacteria were grown on selective antibiotic plates. A single colony 
was used to inoculate 2ml L-Broth with antibiotic to select growth of plasmid carrying 
cells. The culture was allowed to grow for 10-12 hours at 37°C with rotation at 225 rpm.
1.5 ml culture was then pelleted by centrifugation in a sterile microcentrifuge tube at 
20800 x g for 10 minutes at room temperature. The plasmid DNA was prepared using
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the Invitrogen Charge Switch ER mini kit according to manufacture’s manual. Purified 
DNA was resuspended in 50 pi elution buffer.
2.2.1.3 Large scale preparation of plasmid DNA (Maxiprep).
Colonies were selected from agar plates and grown up in 2ml L-Broth with 100 
pg/ml ampicillin over night 37C°with rotation at 225rpm. This culture was then either 
prepared as a small scale DNA preparation as described (2.2.1.2) or was amplified 
without this step. 100 pi of the 2 ml bacterial culture was inoculated into 100ml L-Broth 
with antibiotic. The culture was allowed to grow over night at 37°C with rotation at 225 
rpm. The bacteria culture was transferred into two 50 ml tubes and the bacteria cells 
where pelleted by centrifugation at 2000 x g for 15 minutes. The plasmid DNA was 
then prepared using the Purelink Highpure plasmid maxiprep kit (Invitrogen) according 
to manufacturer’s manual.
2.2.1.4 DNA clean-up with phenol chloroform isoamyl alcohol followed by ethanol 
precipitation.
Restriction digest and blunt ending reactions were cleaned with phenol 
chloroform isoamyl alcohol and then ethanol precipitated. An equal volume of phenol: 
chloroform: isoamyl alcohol (24:25:1 v/v/v) was added to a microcentrifuge tube 
containing the DNA and the tube was vortexed. The sample was then centrifuged for 15 
minutes at room temperature at 20800 x g. This procedure resulted in separation o f the 
aqueous and organic phases. The top aqueous phase containing the DNA was 
transferred to a new microcentrifuge tube and 1/10th the volume o f 3M sodium acetate, 
pH 5.2 was added together with 2x volume 100% ethanol. The DNA was then allowed 
to precipitate at -20°C for 30-60 minutes. Following this the samples were centrifuged 
for 30 min, 20800 x g at 4°C. The ethanol was decanted and discarded and the pellet 
was washed by adding 100 pi 70% ethanol. An additional centrifugation was performed 
for 20 min under same condition as the previous one. The ethanol was removed and the 
remaining pellet was allowed to air dry and then resuspended in ddFLO or buffer (TE 
buffer, Invitrogen).
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2.2.1.5 DNA gel electrophoresis on agarose gels.
DNA gel electrophoresis was performed on 1% agarose gels. These gels were 
made by dissolving powdered agarose in TBE Buffer (10 x TBE: 900mM Tris base, 
900mM boric acid, 25mM EDTA, pH8.0) by heating. Ethidium bromide was added to 
visualise the DNA at a concentration of 0.25pg/ml. DNA was mixed with 1/10th volume 
loading buffer (10 x loading buffer: 65% (w/v) sucrose, lOmM Tris-HCl pH 7.5, lOmM 
EDTA, 0.3%(w/v) bromophenol blue). DNA samples were loaded onto the gel and as a 
comparison for size a 100 bp ladder (Invitrogen) and a lkb ladder (Invitrogen) was run 
in parallel. The gel was run in an electric field at approximately 80 Volts for 1 hour. 
DNA bands were visualised under a UV light and photographed using a UVP Gel 
Documentation System (UV Productions). For large cosmids a phage Hind III ladder 
was used to allow for determination o f large size DNA fragments.
2.2.1.6 Restriction endonuclease digest of DNA.
The required amount of DNA was added to a sterile microcentrifuge tube. 
Restriction enzyme buffer was added at 1/10th of the final reaction volume, lp l of each 
restriction enzyme was added and the reaction was completed with ddH2 0  to the desired 
volume. The digest was incubated at the optimal temperature for the chosen restriction 
enzymes for 1-2 hours for diagnostic purposes, 2-3 hours for plasmid DNA for cloning 
and 3-18 hours for PCR products.
Restriction endonuclease activity was ended by cleaning the DNA with phenol 
chloroform isoamyl alcohol and following ethanol precipitation or by heat inactivation 
at 65°C for 20 minutes.
2.2.1.7 Phosphatase Treatment of restriction digested vectors for cloning.
Plasmids cut with restriction endonucleases were phosphatase treated prior to 
gel or phenol chloroform extraction, to prevent vector religation. This was performed by 
using either Antartic Phosphatase (New England Biolabs) or Thermosensitive Alkaline 
Phosphatase (Promega). Antartic phosphatase is derived from recombinant E.coli 
carrying the gene encoding alkaline phosphatase (AP) isolated from the psychrophilic 
strain TAB5. This enzyme shows high activity at low temperatures and is heat sensitive
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(Rina et al. 2000). Phosphatase reaction buffer was added to the reaction in a volume of 
1/10th o f the total. l-2pl phosphatase was added and the reaction was incubated at 37°C 
for 30-45 min. Following this the reaction was cleaned with phenol chloroform isoamyl 
alcohol and following ethanol precipitation as described (2.2.1.4).
2.2.1.8 Blunt ending of restriction enzyme digested DNA
DNA was digested with the appropriate restriction enzyme as described
(2.2.1.6). Following this the reaction was cleaned by phenol chloroform extraction and 
ethanol precipitation. The DNA was resuspended in 50pl ddFLO, 2pl T4 DNA 
polymerase, 20 pi T4 DNA polymerase 5x buffer, 5 pi 2mM dNTP mixture and 23 pi 
ddH2 0  was added to the DNA and the reaction was incubated at 11°C for 15 minutes. 
The reaction was cleaned up with phenol chloroform isoamyl alcohol followed by 
ethanol precipitation as described (2.2.1.4) and could then be used in normal ligation 
reactions. If it was a plasmid that was blunt ended then this was phosphatase treated
(2.2.1.7) prior to ligation.
2.2.1.9 Gel purification of DNA
For DNA gel purification DNA was loaded and run on a 1% agarose gel as 
described (2.2.1.5). The DNA was visualised under low energy UV exposure to avoid 
DNA damage. The DNA band of interest was excised from the agarose gel using a 
sterile scalpel and transferred to a microcentrifuge tube. The DNA was then purified 
using the PureLink™ Gel Extraction Kit (Invitrogen) according to the manufacturer’s 
instructions. For cloning where a higher purity DNA was required, certified molecular 
biology agarose (BioRad Laboratories Inc.) was used.
2.2.1.10 DNA Ligation
DNA ligations were carried out by mixing 0.05-0. lpg  linearised plasmid DNA 
with cut insert DNA with compatible ends. This was done in a plasmid versus insert 
ratio o f 1:4 to a total volume of 5pi. To this mixture 5 pi ligase was added (Takara 
solution I DNA Ligation Kit ver.2.1, Amersham). Ligations were incubated at 16°C for
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40-60 min according to the manufacturer’s instructions. For complicated cloning or for 
blunt end cloning ligations were incubated overnight at 16°C.
2.2.1.11 TOPO TA Cloning.
TOPO TA Cloning was performed using TOPO TA Cloning system with pCR 
2.1-TOPO vector and TOP 10 electrocompetent cells according to the manufacturer’s 
manual (Invitrogen).
2.2.1.12 Polymerase Chain Reaction (PCR)
PCR reactions were performed in a total volume of 50pl in a 0.5 ml flat cap 
tube. PCR products to be used for cloning were generated using the KOD Hot Start 
polymerase (Merck Chemicals Ltd.).
lng template DNA was mixed with lOpmol of 3’ and 5’ primer, 5 pi 2 mM dNTP 
mixture, 1.5pl 25 mM MgS0 4 , 5pl KOD hot start lOx buffer, lp l KOD hot start 
polymerase and the reaction was completed with distilled water until 50pl. 
Amplification was carried out using a MJ Research PTC200 gradient cycler. Cycle 
conditions were adjusted according to size of PCR products, primer length and melting 
temperature.
For cloning using the TOPO TA cloning kit (Invitrogen) PCR reactions were set 
up using Platinum Tag DNA polymerase with supplied buffers and supplements 
according to manufacturer’s protocol (Invitrogen).
Diagnostic PCR reactions were set up similarly using Taq DNA polymerase 
(Invitrogen) with supplied buffers and additives according to manufacturer’s protocol.
2.2.1.13 PCR clean up.
PCR products were cleaned by using ChargeSwitch® PCR Clean-Up Kit 
(Invitrogen) according to manufacturer’s protocol.
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2.2.1.14 Site directed mutagenesis
5’ and 3’ primers for site directed mutagenesis were designed as 23 base pairs 
long primers containing the desired point mutation and annealing to the same DNA 
sequence on opposite strands o f the plasmid. Primer sequence is shown in section 
2.1.8.4.
Site directed mutagenesis was performed as a normal PCR reaction using the pfu  
polymerase and buffer (Promega) however extension times were increased to 10 
minutes and the PCR cycle was only repeated 18 times. PCR products were digested 1 
hour with lp l Dpn I in 37°C waterbath to remove the parental methylated template 
DNA. Following this the DNA was cleaned by phenol chloroform isoamyl alcohol and 
ethanol precipitation and resuspended in 10-20 pi distilled water. 5-10 pi DNA was 
transformed into JM-109 cells. Colonies were grown up and amplified and DNA 
prepared using Charge Switch® Plasmid ER mini prep Kit (Invitrogen). Clones 
containing the correct mutation were identified by DNA sequencing.
2.2.1.15 DNA sequencing.
The reactions were set up in 0.5 ml flat cap tubes in a total volume of 20 pi. 
Approximately 500 ng plasmid DNA was mixed with 3.6pmol primer, 2pl Big Dye 
Terminator Reaction mix and 4pl 5 x Big Dye Buffer (BigDye® Terminator v3.1 Cycle 
Sequencing Kit, Applied Biosystems) and distilled water was added to a total volume of 
2 0  pi.
Sequencing reactions were performed on a MJ Research PTC200 gradient cycler. 
Samples were heated to 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 4 
minutes. This cycle was repeated 25 times. The reactions were then purified by ethanol 
precipitation. The DNA volume was made up to lOOpl with distilled water in a sterile 
microcentrifuge tube. 200pl 100% ethanol and 1 pi 3M Sodium Acetate, pH 5.2 was 
added to the tube and it was incubated on dry ice for 30 minutes. Then this the tube was 
centrifuged for 30 minutes, 20800 x g at 4°C. The ethanol was decanted and the pellet 
was washed in 150 pi 70% ethanol. An additional centrifugation step was performed for 
20 minutes under the same conditions as the previous one. The purified extract was
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dried under a vacuum and then resuspended in 20pi Hi-Di formamide (Applied 
Biosystems). The samples were then transferred to a 96-well plate and analysed using 
an ABI 300 automatic sequencer.
2.2.1.16 RNA isolation from dog blood.
1.5 ml canine blood samples in EDTA sampling tubes were spun at 2000 x g for
15 minutes at room temperature. The plasma layer was removed with a Pasteur pipette. 
The buffy coat layer was removed and transferred to a sterile micro centrifuge tube. 
RNA was isolated using the RNAqueous kit (Applied Biosciences) according to the 
manufacturer’s protocol. The RNA concentration was measured by spectrophotometer 
and RNA was frozen at -20°C until further use.
2.2.1.17 Reverse transcriptase PCR
Superscript™ III Reverse Transcriptase kit (Invitrogen) was used to perform 
this reaction.
16 pi RNA isolated from canine blood was mixed with 2 pi 10 mM dNTP mixture and 2 
pi 3’ primer 2mM in a sterile 0.5ml micro centrifuge tube. The mixture was then 
incubated at 65 °C for 5 minutes and then incubated on ice for 1 minute. 4 pi RT lOx 
buffer, 8 pi MgCl2 25mM, 4 pi DTT 0.1 M , 2 pi RNase OUT and 2 pi Superscript™ III 
Reverse Transcriptase made up as a mix was added to each sample as a master mix. 
Controls were set up without template or without reverse transcriptase.
The mixture was incubated at 50°C for 50 minutes and then at 85°C for 5 minutes. Next 
2 pi RNAse H was added to each sample to remove the RNA and the sample was 
incubated at 37°C for 20 minutes and subsequently the reactions were ready to be used 
as template for PCR reactions.
2.2.1.18 PCR reaction using template from reverse transcriptase PCR products
PCR reactions were set up as described (2.2.1.12) using 2-4 pi cDNA from 
reverse transcriptase reactions as template for the reaction. Taq polymerase was used for 
the reactions so PCR products could be cloned directly into the pCR 2.1-TOPO vector 
using the TOPO TA Cloning system (Invitrogen).
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2.2.2 Cell culture protocols
2.2.2.1 General growth of cells
All cell culture experiments were carried out in a room specifically for the 
purpose and under strict sterile conditions. Cell culture work was performed inside a 
flow hood (Class II Microbiology Safety Cabinets, Gelaire BSB4). 293T, C33a, 
GM847, MCF7, MDCK, MRC5 and U20S cell lines were grown in DMEM 
supplemented with 10% FCS, 1% penicillin and streptomycin solution in an atmosphere 
at 37°C containing 5% CO2 (v/v) (Napco model 5410, Napco Scientific). Cells were 
trypsined and split 1/10 when they reached 90% confluence.
2.2.2.2 Subculturing cells
When cells were reaching confluence in their flask they were washed twice with 
PBS and then trypsinised by adding sufficient trypsin EDTA solution to cover the cells. 
The cells where then incubated at 37°C for approximately 5 minutes until they had 
detached. The cells where then washed off the flask with warm growth medium and 
transferred to a sterile universal tube and pelleted by centrifugation for 5 minutes at 170 
x g at room temperature. The pellet was washed with PBS and the centrifugation was 
repeated. The cells were then resuspended in growth medium, counted using a 
haemocytometer and then seeded into a flask at the required concentration or seeded 
into cell plates for assays. For TUNEL staining, cells were seeded on sterilised glass 
cover slips in a 6  well plate.
2.2.2.3 Dissociation of primary cells from tissue.
Tumour tissue was obtained directly after resection from canine patients at the 
Small Animal Hospital, University of Glasgow. Normal skin samples were obtained 
from euthanized dogs from the Veterinary Anatomy department, University of Glasgow 
with ethical approval. To isolate cells of interest, a representative piece of tissue
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approximately 0.5-lcm  was placed in a Petri dish and dissected into 2-3mm pieces 
with a scalpel. The tissue was washed twice in a balanced salt solution without calcium 
and magnesium (Invitrogen). A 0.25% trypsin solution made up in the same balanced 
salt solution was added to the tissue (approximately 1ml solution for every 1 0 0  mg 
tissue). The tissue was incubated for 14-18 hours at 4°C in trypsin solution, and for a 
further 30 minutes at 37°C. Warm DMEM or RMPI medium was added and the tissue 
was mechanically manipulated by pipetting. Tissue and media were then filtered 
through a 100pm cell strainer (BD Biosciences) to remove unwanted tissue pieces. The 
cell suspension was centrifuged for 5 minutes at 170 x g and resuspended in 10ml 
medium. A viable cell count was performed by making a 1:1 solution of cell suspension 
and Trypan blue stain (Invitrogen). Cells were then seeded in T-25 flasks at 
approximately 5x10s cells per flask. Primary cells were fed every 3-5 days and were 
maintained in either RMPI or DMEM with added Glutamax 1%, Fungizone 1%, 
penicillin and streptomycin solution 1% and ciprofloxacin solution 0 .1%.
2.2.2.4 Telomerase repeat amplification PCR (TRAP) assays and freezing of cell 
pellets prior to assay.
Cells growing in tissue culture flasks were washed twice in PBS and enough 
trypsin to cover the cells was added to the cells. The trypsin treated cells were incubated 
at 37°C for 5 minutes which allowed the cells to lose their adherence to the culture 
flask. The cells were washed off the flask using normal cell medium and pelleted by 
centrifugation at 170 x g for 5 minutes at room temperature. The supernatant was 
removed and the cells were resuspended in PBS and counted using a haemocytometer. 
l x l 0 6 cells in PBS were transferred to an Ependorf tube and the cells were pelleted by 
centrifugation at 110 x g for 5 min. Following this the supernatant was removed and the 
cell pellets were frozen immediately at -80°C.
TRAP assays were performed on cell pellets, using the TRAPeze ELISA 
telomerase detection kit (Millipore) according to manufacturer’s instructions including 
strict separation of working areas to avoid contamination of samples. Results were 
detected by gel electrophoresis. Gel electrophoresis was carried out by running 10 pi of 
PCR product mixed with 2 pi Bromophenol blue 1 Ox dye on a polyacrylamide gel for 1 
hour at 150 volts. The gel was then stained with Ethidium bromide 0.25pg/ml for 10-20
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minutes. TRAP ladders bands were visualised under a UV light and photographed using 
a UVP Gel Documentation System (UV Productions).
2.2.2.5 Transfection of cells using calcium phosphate
Cells were plated at a concentration of 2x105 cells (3x105 for MRC-5 and C33a 
cells due to their smaller size) in a 60mm tissue culture dish and incubated for 24 hours 
to allow cells to adhere and grow. A mixture was made up by adding a solution o f 500 
pi plasmid DNA in 250 mM CaCl2 dropwise. into 500 pi 2 x HEPES buffered saline 
(pH 7.05 ) under rotation. The mixture was left for 15 minutes to allow for formation of 
a precipitate. 500 pi of the mixture was then added dropwise into the media of each of 
the tissue culture cell plates. If tranfections were performed in duplicate, the remaining 
500pi was added onto a second plate. For single tranfections the remainder was 
discarded. The cells were incubated with the precipitate for 14-18 hours after which 
time they were washed twice with PBS and re-incubated in fresh growth media. 
Approximately 24 hours later (unless otherwise stated) the cells were harvested. As a 
positive control in luciferase assays two plates were always transfected with 1 pg pGL3- 
Control vector. This vector contains the firefly luciferase gene under transcriptional 
control by the SV40 promoter and therefore exhibits a high level of transcriptional 
activity in many cell lines.
2.2.2.6 Transfection of cells using Trans-IT
Cells were plated at a concentration of 2x105 cells for each 60 mm tissue culture 
plate. They where incubated for 24 hours to allow for adherence and growth. A 
transfection mixture was made by adding Trans-IT transfection reagent to Optimem 
medium (Invitrogen) in a microcentrifuge tube. The amount of Trans-IT lipid 
transfection and Optimem medium depended on the amount o f DNA being transfected. 
In general 3 pi lipid transfection reagent was added into 97pl Optimem medium for each 
1 pg DNA being transfected. The lipid transfection reagent-Optimem mixture was 
flicked and incubated for 5 min at room temperature. DNA was then added and the tube 
was flicked and further incubated for 25-35 minutes at room temperature. The 
transfection mixture was then added directly into the media in the tissue culture plate
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and incubated for a further 36 hours (unless otherwise stated) before the cells were 
harvested with no change of media in between.
2.2.2.1 Luciferase assay
Approximately 40 hours after transfection, transfected cells were washed twice 
with PBS. PBS was carefully removed using a Pasteur pipette and 300 pi Reporter lysis 
buffer (Promega) was added to each 60 mm cell plate and the cells were incubated for 
1 0  minutes at room temperature before the cell lysate was then scraped from the plate 
using a cell scraper and transferred to a sterile 1.5 ml microcentrifuge tube. The lysate 
was then centrifuged for 10 min at 20800 x g, at 4°C to pellet the debris, and the 
supernatant was transferred to a fresh tube and stored on ice.
80 pi of each harvested cell supernatant was transferred into an opaque 96 well plate 
and assayed for luciferase activity using a Luminoscan Ascent luminometer and Ascent 
software with the Luciferase Assay System substrate (Promega). 80 pi of Luciferase 
assay system substrate diluted 1:3 was used for each sample. The luciferase expression 
readings were adjusted by accounting for protein content in each sample by performing 
a BCA-CuSC>4 protein assay on the cell lysate as described (2 .2 .3.2 ).
2.2.2.8 TUNEL staining.
2x105 U20S and 293-T cells were plated out in 6  well plates in which a glass 
coverslip was placed in each well. For the 293-T cells the coverslips were treated with 
poly-L-Lysine prior to plating o f cells to allow for better attachment. 24 hours after 
plating U20S and 293-T cells were transfected using Trans-IT and calcium phosphate 
respectively. 24 hours later cells on cover slips were fixed in 4% formaldehyde in PBS. 
At this stage the cells could be stored for up to 2 weeks. TUNEL staining of the cells on 
coverslips was performed using the DeadEnd™ Fluorometric TUNEL System 
(Promega) according to manufacturer’s protocol for adherent cell lines. This kit stains 
apoptotic cells in which the DNA is fragmented by catalytically incorporating 
fluorescein-12-dUTP at 3'-OH DNA ends using the terminal deoxynucleotidyl 
transferase recombinant enzyme (rTdT).
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After staining, coverslips were mounted and counterstained using Vectashield 
mounting medium with DAPI stain (Vector Laboratories). Stained coverslips were 
visualised using a fluorescent microscope and 5 random pictures were taken of cells 
using a filter with an excitation spectrum of 594 nm to excite and visualise the 
flourescein stain and a filter with an excitation spectrum of 358nm to excitate and 
visualise the DAPI stain. The number of DAPI stained and flourescein stained cells for 
each exposure was quantified and the percentage of DAPI stained cells which were also 
fluorescein stained was determined. The difference in flourescein staining between 
groups was determined by statistical analysis using Yates corrected chi square analysis.
2.2.3 Protein preparation and analysis
2.2.3.1 Preparation of protein extracts for western blots
Cells were transfected using either calcium phosphate or Trans-IT as described 
in 2.2.2.5 and 2.2.2.6 . Cells were harvested 40 hours after transfection or at the times 
stated. At harvest, cells were washed twice with PBS and then trypsinised by adding 1 
ml trypsin EDTA to each 60mm tissue culture plate. The cells were incubated with the 
trypsin for approximately 3-5 minutes until they detached. The cells were then washed 
off the plate using normal cell growth medium and transferred to a universal tube. The 
cells were then pelleted by centrifugation at 170 x g for 5 minutes at room temperature. 
The supernatant was then removed and the pellet resuspended in 1 ml ice-cold PBS and 
transferred to a sterile microcentrifuge tube. The cells were pelleted by centrifrugation 
at 420 x g for 5 minutes at room temperature. The supernatant was discarded and the 
pellet was then either frozen at -80°C until further use or resuspended in 100 pi lysis 
buffer (0.5% NP40, 150mM NaCl, 50mM Tris pH 8.0 containing 1/25 volume protease 
inhibitor cocktail tablet) and put on ice to incubate for 30 minutes. After incubation the 
lysed cells were centrifuged for 30 minutes at 20800 x g at 4°C and the supernatants 
were transferred to a new sterile tube. The protein content o f the protein lysates were 
measured by a BCA-CuSCL protein assay and were then ready to be used for 
polyacrylamide gel electrophoresis and Western blot analysis.
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2.23,2 BCA-C11SO4 Protein assay
To account for diversity in cell numbers, protein concentration was determined 
to reflect cell quantity. This was done using bichinchoninic acid ((BCA), Sigma)) and 
copper II sulphate pentahydrate 4% w/v solution (Sigma).
A volume of 10 pi harvested cell lysate was added to wells of a transparent 96 well 
plate. Bovine serum alkaline protein solutions at known concentrations were added to 6  
wells at different concentration to be used as a protein standard for determining the final 
concentration in the samples. 200pl developing solution were then added (5ml BCA 
mixed with lOOpl copper II Sulphate pentahydrate. The plate was incubated at 37°C for 
30-60 minutes. The protein in the lysates reduces Cu(II) to Cu(I) which then reacts with 
BCA to form a purple complex, in a concentration specific manner such that the colour 
intensity reflects the amount of protein in the sample. The light absorbance of each 
sample was measured at 562nm using a Dynatech MR7000 automated plate reader. 
Based on the known protein content in the bovine serum alkaline protein samples a 
standard curve could be conducted and the protein concentrations extrapolated.
2.2.3.3 Polyacrylamide gel electrophoresis (PAGE).
Protein concentrations were determined using a BCA/CUSO4 assay as described 
(2.2.3.2). Equal amounts of protein in a volume of 13pl in ddfEO were mixed with 2pl 
sample reducing agent (NuPAGE sample reducing agent (lOx), Invitrogen) and 5 pi 
sample buffer (NuPAGE LDS sample buffer (4x), Invitrogen) in a sterile 
microcentrifuge tube and then incubated on a heat plate at 70°C for 10 min.
A precast gel (NuPAGE® Novex Bis-Tris Gels, Invitrogen) was transferred to a tank 
and mounted in lx  buffer (NuPAGE MES SDS Running Buffer 20x, Invitrogen, (50ml 
in 1 litre)). 400 pi antioxidant was added to the tank. Each sample was then loaded into 
the wells of the gel. In parallel with the samples a standard protein ladder (SeeBlue Plus 
2 Prestained Standard, Invitrogen) was loaded to determine the sizes of the proteins in 
the samples. The tank in which the gel and buffer was sited was then connected to a 
power source and run at 200V until the mobile front reached the bottom of the gel. The 
gel was then ready to be used for Western blotting.
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2.2.3.4 Western blot.
Proteins in polyacrylamide gel were transferred to a nitrocellulose membrane 
using either a semidry blotter (Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell, 
Bio-Rad) or the iBlot protein transfer system (iBlot™ Gel Transfer Device, Invitrogen). 
The protocol for using the semidry blotter for protein transfer was as follows. The gel 
was soaked in lx  transfer buffer with 10% methanol (NuPAGE Transfer Buffer 20x, 
Invitrogen) together with a nitrocellulose membrane and 6  pieces of filter paper. These 
where all transferred to the semidry blotter as a sandwich consisting o f 3 pieces of filter 
paper, then the nitrocellulose membrane, then the polyacrylamide gel and then 3 pieces 
o f filter paper again. It was ensured that no air bubbles were sited between the layers. 
The semidry blotter was then assembled and an electric supply was connected. The 
proteins were left to transfer to the membrane for one hour at 10V.
The method for protein transfer using the iBlot protein transfer system was 
carried out according to themanufacturer’s instructions but the polyacrylamide gel was 
soaked for 10 min in 2x transfer buffer with 10% methanol (NuPAGE Transfer Buffer 
20x, Invitrogen) prior to transfer.
After protein transfer using either system the membrane was stained with 
Ponceu S (Sigma) to confirm complete protein transfer. The membrane was then 
transferred to a container and blocked in 5% Marvel in PBS-T (1 x PBS 0.1% tween) 
for an hour at room temperature or overnight at 4°C. The membrane was then gently 
washed with PBS-T and then incubated for one hour with a primary antibody diluted in 
5% Marvel PBS-T under gentle rotation. Next the membrane was washed 4 times in 
PBS-T over a period of 20 minutes. The membrane was then incubated for 1 hour at 
room temperature in a solution containing the secondary antibody in PBS-T 5% Marvel 
under gentle rotation. This was followed by washing 4 times with PBS-T over 20 
minutes. After this washing step the membrane was developed with developing solution 
for 5 min (ECL PLUS Western blot detection system, Amersham biosciences). Protein 
bands where visualised by exposing a chemiluminescence film (CL-XPosure™ Film, 
Perbio Science) to the membrane in a film cassette for 1 min and 3 min. If bands came 
out either too strong or too pale additional exposures at shorter or longer time periods 
would be performed.
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2.2.3.5 Stripping off antibodies from nitrocellulose membrane.
Removal o f antibodies from nitrocellulose membranes was carried out by 
incubating the nitrocellulose membrane for 10 minutes under gentle rotation in a 0.2M 
NaOH solution. Then the membrane was washed 3 times for 10 minutes in PBS-T (1 
x PBS 0.1% tween) and could be blocked with 5% Marvel in PBS-T and reprobed with 
a different antibody.
2.2.4 Protocols for generation of recombinant adenovirus
2.2.4.1 Generation of electrocompetent cells
Electrocompetent BJ5183s cells were generated by plating out approximately 30 
pi of BJ5183s glycerol stock on an agar plate containing streptomycin as a selective 
antibiotic. The plate was incubated overnight in a 37°C incubater. The next day colonies 
were picked and grown in 3 ml L-broth with streptomycin 50pg/ml overnight in a 37°C 
incubator under rotation at 225 rpm. The following day 200pl culture was inoculated 
into 200 ml L broth with streptomycin and grown until the culture reached an optical 
density of OD600 = 0.5-0.7. The cells were then chilled in an iced water bath for 20 
minutes and then centrifuged for 20 minutes at 1000 x g, 2°C. The supernatant was 
removed and the cell pellet resuspended in 200pl ice cold ddfbO and then a further 20 
ml of ice cold ddE^O was added. The centrifugation and resuspension steps were 
repeated. Then the supernatant was decanted off the cells and the cells were 
resuspended in the remaining liquid and centrifuged again for 10 minutes at 2000 x g, at 
2°C. The supernatant was removed and a volume o f ddfkO  equivalent to the cell pellet 
volume was added to resuspend the cells. The cells were used immediately for 
electroporation.
2.2.4.2 Homologous recombination
Homologous recombination is a method commonly used to insert, remove or 
change DNA sequences in viruses (Chartier et al. 1996).
The basic concept of this method is that the recipient DNA is linearised by restriction 
digest at the site of interest. The DNA insert should contain DNA homologous to the
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recipient DNA flanking the linearization site. By mixing the recipient DNA and the 
DNA insert and electroporating this in BJ5183s cells (which allow for recombination of 
DNA), the insert should be inserted into the recipient DNA by recombination o f the 
homologous DNA sequences.
In this project cosmid DNA was linearised with the appropriate enzyme and was 
cleaned by phenol chloroform isoamyl alcohol and ethanol precipitation. The DNA 
insert was cut out of its cloning vector and was gel purified. Approximately 300ng of 
cut cosmid DNA was mixed with 1 OOng of DNA insert in a volume of 10 pi and was 
added to 50 pi BJ5183s cells. Cells and DNA was then transferred to a cuvette and 
electroporated using a Gene Pulser Transfection Apparatus (BIO-RAD) with the 
machine set at 200 Ohms, 25 pF and 2.5 volts. Immediately afterwards the cell-DNA 
mixture was transferred to a bijou and mixed with 1ml SOC medium and was incubated 
while shaking at 225 rpm, 37°C for 1 hour. Then 300-400 pi o f incubated cell 
suspension was plated on agar plates containing ampicillin and incubated over night at 
37°C. Colonies were selected and grown as for normal transformations.
2.2.4.3 Small scale preparation of cosmid DNA
Colonies on agar plates from homologous recombination were picked and grown 
overnight in 3 ml L-Broth with 100 pg/ml ampicillin at 225 rpm 37°C. DNA was 
following prepared using the QIAprep® Spin Miniprep Kit according to the 
manufacturer’s instructions.
2.2.4.4 Large and medium scale preparations of cosmid DNA
Colonies from cosmid DNA transformed into Stbl 2 cells were picked and 
grown up in 2 ml L-Broth with 100 pg/ml ampicillin for 6  hours. For large scale DNA 
preparation 0.5ml of this culture was inoculated into 400 ml L-broth with ampicillin. 
Cultures were grown over night at 225 rpm 37°C. DNA was prepared using Qiagen 
Large Construct Kit or NucleoBond® Xtra Maxi Plus Kit. For medium scale 
preparation, 0.5ml of this culture was inoculated into 200 ml L-broth with ampicillin. 
Cultures were grown overnight at 225 rpm 37°C. DNA was prepared using 
NucleoBond® Xtra Midi Kit according to the manufacturer’s manual.
2.2.4.5 Transfection of MDCK cells with virus DNA to generate live virus.
This was done using the Nucleofector L-kit according to manufacturer’s cell 
type specific manual for MDCK cells (Amaxa Biosystems).
2.2.4.6 Infection of cells with virus
Cells were plated out and either left to adhere and grow for 24 hours or infected 
instantly. Virus was recovered from storage at -80°C and thawed in a 37°C water bath. 
Virus was diluted to the appropriate concentration using DMEM media and added drop 
wise to the cells.
2.2.4.7 Harvest of live virus for virus stock
Virus was harvested from cells when significant cytopathic effect was observed 
but before 100% cell death. Cell media were collected in 15 ml falcon tubes. Cells were 
scraped from the cell plate and collected in the same tube. The tube and contents were 
then centrifuged for 10 minutes at 170 x g, the supernatant was removed from the cell 
pellet and collected in a separate tube. The pellet was then freeze-thawed 3 times 
between -80°C and 37°C using dry ice and a 37°C water bath. The pellet was then 
resuspended in the supernatant and centrifuged for 10 minutes 170 x g at room 
temperature. The supernatant containing the virus particles was then stored as aliquots 
at -80°C. The pellet containing cellular debris was discarded.
2.2.4.8 Tissue Culture Infectious Dose where 50 % cells show cytopathic effect 
assay (TCID50 assay).
The TCID50 assay is an assay used to determine concentrations of infectious 
particles in viral stocks. The concept of the assay is that multiple cell containing wells 
in a 96 well plate are infected with a serial dilution of the viral stock and monitored for 
cytopathic effect (CPE) until no further changes are observed. At this stage the lowest 
concentration of virus that causes CPE in 100% of the infected wells is noted together 
with the concentrations and number of wells at which CPE is observed in less than 
100% of the infected wells.
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The TCID50 assay that has been used in this project is a modified assay in which 
half log dilutions are used to determine the TCID50. This should allow for a more 
accurate estimate o f virus concentration. In this assay 4 wells in a 96 well plate are
1 1 7 r
infected with half log dilutions of the virus stock starting from 10* - 10" .
Cells were plated in a 96 well plate at a density o f 1.5 x 10 cells per well in a 
volume of 150 pi media. Virus dilutions were made by preparing 12 bijou tubes with 
1.8 ml media and 12 bijou tubes with 0.8 ml media. Whole log dilutions were made by 
transferring 200 pi of virus stock into a bijou with 1.8 ml media to make up the 10'1 
dilution and then transferring 200 pi of this dilution into the next bijou containing 1.8
• 9 19ml media to make up the 10' dilution. This was repeated until the 10' dilution was 
reached. The half log dilutions were following made by transferring 200 pi o f each 
dilution into a bijou containing 0.8ml media. 4 wells in the prepared 96 well plate were 
infected with 100 pi of each dilution as shown in figure 2.1. Cells were observed on a 
daily basis and CPE was noted. When no further CPE was observed all the wells 
showing CPE and the concentration of virus in these were noted.
The TCID50 was following calculated using the Karber formula.
log TCID50 = L -  d (S -  0.5), where:
L = log o f highest dilution in which 100% of wells showed CPE. 
d = difference between log dilution steps
S = sum of proportion of cultures showing cytopathic at dilutions higher than the 
dilution which showed 100% CPE.
From this result the concentration of virus as reflected by plaque forming units (PFU) 
can be determined as:
PFU per ml = l/10logTCID“x 10 x 0.69
The multiplication with 10 is to get the concentration per ml and the 0.69 constant is 
applied to obtain a more accurate estimate of PFU by application of the Poisson 
distribution. For better understanding of the formula a calculated example would be:
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Virus dilution Number o f well showing CPE Fraction of wells showing CPE
1 0 -4 4/4 1.00
10-45 2/4 0.50
10'5 1/4 0.25
10'5'5 0/4 0.00
From this S = 1.00 + 0.50 + 0.25 + 0.00 = 1.75
The calculated log TCID50 from this example would then be:
log TCID50= -4 -0.5(1.75-0.5) = -4.625
Pfu would then be: 1/10"4 625 x 0.69 xlO = 2.9xl05
2.2.3.9 Staining of 96 well plates with crystal violet stain.
Media was removed from wells by pipetting. The wells were stained with 0.5% 
crystal violet solution (25% methanol, ddFbO) and incubated for 5 minutes at 80 rpm at 
room temperature. The crystal violet solution was removed and the cells were washed 
with H2O until no excess dye was present. Stained 96 well plates were dried and the cell 
staining evaluated by visualisation on a light box.
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Figure 2.1
1 2 3 4 5 6 7 8 9 10 11 12
A -1 - 1.5 -2 - 2.5 -3 - 3.5 -4 - 4.5 -5 - 5.5 -6 - 6.5
B -1 - 1.5 -2 - 2.5 -3 - 3.5 -4 - 4.5 -5 - 5.5 -6 - 6.5
C -1 - 1.5 -2 - 2.5 -3 - 3.5 -4 - 4.5 -5 - 5.5 -6 - 6.5
D -1 - 1.5 -2 - 2.5 -3 - 3.5 -4 - 4.5 -5 - 5.5 -6 - 6.5
E -7 - 7.5 -8 - 8.5 -9 - 9.5 -10 - 10.5 -11 - 11.5 -12 - 12.5
F -7 - 7.5 -8 - 8.5 -9 - 9.5 -10 - 10.5 -11 - 11.5 -12 - 12.5
G -7 - 7.5 -8 - 8.5 -9 - 9.5 -10 - 10.5 -11 - 11.5 -12 - 12.5
H -7 - 7.5 -8 - 8.5 -9 - 9.5 -10 - 10.5 -11 - 11.5 -12 - 12.5
Figure 2.1 Schematic presentation of half log dilutions used in TCIDso assay.
Model of 96 well plate in which cells were plated and infected with half log dilutions of 
virus stock to determine the concentration of the virus.
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Chapter 3.
Results
3.1 Development of a gene therapy system.
The two step transcriptional amplification (TSTA) mechanism as described 
(chapter 1.3.2) has been used by others in conjunction with the human telomerase 
promoter and the Gal4VP16 transcriptional activator fusion protein. In our laboratory 
the VP16E2 transcriptional activator fusion protein has been studied. VP16E2 is a 
fusion protein between the acidic c-terminus of the VP 16 protein from the human 
herpes simplex virus type 1 and the E2 DNA binding domain from the bovine 
papillomavirus type 1 (BPV-1) (Vance et al. 1999, Vance et al. 2001). Papillomaviruses 
are viruses that have evolved to recruit the mammalian cell replication and transcription 
machinery to be able to function efficiently in mammalian cells. We anticipated that 
incorporating the VP16E2 fusion protein into the TSTA system would allow for a 
higher transcriptional activity in mammalian cells than the Gal4VP16 due to the fungal 
origin of the Gal4 domain.
Another improvement we anticipated we could include in this system was the 
use of a unique minimal promoter. The TSTA system is commonly used with a Gal4 
responsive minimal promoter as a secondary promoter. This promoter consists of 
multiple Gal4 binding sites upstream of a TATA box promoter derived from the 
adenovirus E lb  promoter (Sadowski et al. 1992). Previous work in our laboratory 
identified a minimal promoter from bovine papillomavirus type 4 (BPV-4) (Vance et al. 
2001). This promoter named 3’BpTATA consists of a TATA box and 3 upstream base 
pairs. 6 upstream E2 binding sites are located immediately upstream to activate the 
promoter. A strength o f this promoter is that it is a very strong promoter when activated 
in the presence of E2, however in the absence of E2 the 3’BpTATA promoter only 
shows minimal activity.
3.1.1 Comparison of the VP16E2 and the Gal4VP16 transcriptional activators.
The pCG-VP16E2 plasmid which contains the VP16E2 sequence under 
transcriptional control of a CMV promoter, was a gift from a collaborator (Dr. Mart 
Ustav, Estonian Biocenter). For manipulation purposes the VP16E2 fragment was
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sequenced using primers as described in Materials and Methods. The full VP16E2 
sequence is 729 base pairs, encoding 242 amino acids. The VP 16 and the E2 fragments 
are linked together with a Bsp El restriction site. The VP 16 fragment consists o f the 
terminal 78 amino acids of the acidic C terminal of the VP 16 protein from the human 
Herpes simplex virus type 1. The E2 fragment consists of the c-terminal 161 amino 
acids of the BPV-1 E2 DNA including the full length DNA binding domain. The full 
length VP16-E2 fusion protein cDNA is presented in figure 3.1.1.
To be able to compare the activation potential of VP16E2 with Gal4VP16, a 
Gal4VP16 fusion protein containing the same 78 amino acid domain as in the pCG- 
VP16E2 was cloned. The VP 16 fragment was amplified as a PCR product using the 
pCG-VP16E2 as a template and primers with overhanging BamH I and Kpn I 5’ and 3’ 
restriction sites. The cut PCR product was inserted into the pBIND plasmid which 
encodes the Gal4 DNA binding domain downstream from a CMV promoter. This was 
done using the BamH I and Kpn I sites in the multiple cloning region of the plasmid. 
The new plasmid was entitled pBind-Gal4VP16.
To compare the transcriptional activator potential of the VP16E2 and the 
Gal4VP16 in conjunction with the two step transcriptional amplification system a series 
of transcription assays was carried out in 293-T cells. Cells were transfected with 
titrated concentrations of either pCG-VP16E2 or pBind-Gal4VP16; both transcriptional 
activators were transcribed by a CMV promoter. 1 pg pTK-Gal4-6xE2 reporter plasmid 
was co-transfected into all samples. Schematic models o f the pCG-VP16E2, pBind- 
Gal4VP16 and pTK-Gal4-6xE2 are illustrated in figure 3.1.2 a). The pTK-Gal4-6xE2 
reporter plasmid contains 6 E2 and 5 Gal4 binding sites located upstream of a tyrosine 
kinase (TK) promoter which is responsible for transcription of a firefly luciferase gene. 
The ability o f the two transcriptional activator fusion proteins to activate the promoter 
in this plasmid was reflected as relative light units (rlu) from the expressed firefly 
luciferase gene. The experiment was carried out 3 times in duplicate and results were 
adjusted for protein content of the harvested cells. In figure 3.1.2 b) the summarised 
results from the 3 experiments are shown as fold transcriptional increase compared to 
cells transfected with lpg pTK-Gal4-6xE2 only. A large increase in transcriptional 
activity is seen in samples transfected with the VP16E2 coding plasmid compared to the 
Gal4VP16 coding plasmid. This effect is particularly pronounced at transfection doses 
of O.Olng, O.lng and lng and statistically significant at the O.lng dose as seen by the 
low P-value.
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The standard error bars seen in figure 3.1.2 b) are relatively large reducing the 
statistical significance o f the results. This is a general tendency seen throughout the 
luciferase assays presented in this thesis. There are several reasons for the high 
variability between repeated experiments. The major reason is the results being 
presented as fold activity compared to a control plasmid. Due to the great sensitivity of 
the firefly luciferase detection, variability seen in the low activity control plasmid led to 
a relatively large difference in the results for the other plasmids.
Other factors that led to variability were the different passage number o f the cell 
lines used leading to variable transfection efficiency. The variation between DNA 
quality of different batches plasmid preparations and the measurement of DNA 
concentration in these were other variables which affected results. Also the 
measurement of protein content in samples and adjustment of results according to these 
led to variability. Throughout the results section the sample means in the graphs 
represent the general tendency that was observed in the individual assays before pooling 
results.
To determine if the effect seen in the transcription assay was related to protein 
expression o f the transcriptional activator, Western blots were performed. 293-T cells 
were transfected with lpg or 0.1 pg of either pCG-VP16E2 or Gal4-VP16 or with water 
as a negative control. The membrane was probed with an antibody against VP 16 and an 
antibody against gammatubulin as a loading control. In figure 3.1.3 the Western blot is 
shown. The estimated size of the two fusion protein calculated on the estimate that 1000 
base pairs of DNA equals approximately 37 kilo Dalton protein is 26.8 and 25.6 for 
VP16E2 and Gal4VP16 respectively. There is a clear difference in the protein detected 
from cells transfected with pCG-VP16E2 in lane 1 and 2 compared to cells transfected 
with pBind-Gal4VP16 seen in lane 3 and 4 with the pCG-VP16E2 samples showing 
considerably stronger bands.
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Figure 3.1.1
ATGTCGACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGGCGAGG
ACGTGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGG
GGATTCCCCGGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTCTGGATATGG
CCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGAATTGACGAGTCCGGATCCCTC
GGTTGGGTACGGGACGGTCCTCGCTCGCACCCCTACAATTTTCCTGCAGGCTCGGGGGGCTC
TATTCTCCGCTCTTCCTCCACCCCGGTGCAGGGCACGGTACCGGTGGACTTGGCATCAAGGC
AGGAAGAAGAGGAGCAGTCGCCCGACTCCACAGAGGAAGAACCAGTGACTCTCCCAAGGC
GCACCACCAATGATGGATTCCACCTGTTAAAGGCAGGAGGGTCATGCTTTGCTCTAATTTCA
GGAACTGCTAACCAGGTAAAGTGCTATCGCTTTCGGGTGAAAAAGAACCATAGACATCGCT
ACGAGAACTGCACCACCACCTGGTTCACAGTTGCTGACAACGGTGCTGAAAGACAAGGACA
AGCACAAATACTGATCACCTTTGGATCGCCAAGTCAAAGGCAAGACTTTCTGAAACATGTAC
CACTACCTCCTGGAATGAACATTTCCGGCTTTACAGCCAGCTTGGACTTCTGA
Figure 3.1.1: Sequence of VP16E2 cDNA.
Figure shows the full length 729 base pair VP16E2 cDNA. ATG start codon highlighted 
in green. TGA stop codon highlighted in red. In blue connecting sequence between 
VP 16 and E2 is seen. Sequence codes for 242 amino acids.
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Figure 3.1.2
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Figure 3.1.2: VP16E2 transcriptional activator is a stronger activator than 
Gal4VP16.
a) Schematic model of the vectors used in the experiments shown in b).
b) Cells were transfected with different amounts of pCG-VP16E2 or pBind-Gal4VP16 
as indicated. lOOOng of the reporter plasmid pTK-Gal4-6xE2 was co-transfected into all 
samples. Results are shown as fold increase in luciferase expression compared to 
sample transfected with lOOOng pTK-Gal4-6xE2 only. Experiments were carried out 3 
times in duplicate. Standard error bars are shown. * = P-value <0.05
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Figure 3.1.3
Gammatubulin 
VP 16E2/Gal4VP 16
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Figure 3.1.3: Protein expression of transcriptional activators.
Western blot showing the expression o f  the VP16E2 and the Gal4VP16 fusion proteins 
in 293-T cells using antibody against VP 16. Arrow to the left o f  the blot indicates the 
approximate location o f  the proteins. Gammatubulin loading control shown above. Cell 
lysates were harvested as described in Materials and Methods. The location o f  the kilo 
Dalton (kDa) molecular weight marker is shown on the right o f  the blot.
1: pCG-VP16E2 lOOOng. 2: pCG-VP16E2 lOOng, 3: pBind-Gal4VP16 lOOOng.
4: pBind-Gal4VP16 lOOng, 5: Negative control. The amount in ng is reffering to the 
amount o f  DNA transfected into the cells and not to the amount o f  protein loaded on the 
gel.
2 8 k D a
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3.1.2 Targeting the TSTA system to cancer cells by incorporating a telomerase 
promoter.
As described in the introduction a way to target gene expression to certain cell 
types is by using cell type or disease specific promoters. To target the two step 
transcriptional amplification system to cancer cells we exchanged the CMV promoter 
which is active in most mammalian cells with hTR and hTERT telomerase promoters 
which should be transcriptionally active in telomerase expressing cells. Most cancer cell 
lines express telomerase as described in chapter 1.3.1.
The hTERT-VP16E2, hTR-VP16E2, hTERT-Gal4VP16 and hTR-Gal4VP16 
plasmids were made by digesting the pLh2023 and pGL3hTP19 plasmids (see materials 
and methods) with the restriction enzymes Xba I and Hind III. The digested plasmids 
were run on a 1% agarose gel and the upper band was cut out and gel purified. This 
process removed the firefly luciferase gene in the plasmids. PCR products of the 
VP16E2 and Gal4VP16 sequences were made using the pCG-VP16E2 and pBind- 
Gal4VP16 respectively as templates. The primers were designed with a 5’ Xba I and a 
3’ Hind III overhang. The PCR products were digested with Xba I and Hind III and 
ligated into the pGL3hTP19 (hTERT-LUC) and pLh2023 (hTR-LUC) plasmids. 
Ligations were transformed into JM-109 cells. Correct inserts were confirmed by 
restriction digest and sequencing. Schematic illustrations of the cloned constructs are 
shown in figure 3.1.4.
To compare the transcriptional activity of the two step amplification system with 
the incorporation of the hTERT or the hTR promoter, a series o f transcription assays 
was performed in telomerase positive cell lines. 293-T, MCF-7 and C33a cells (see 
materials and methods) were transfected using calcium phosphate with titrations of 
either hTERT-VP16E2, hTERT-Gal4VP16, hTR-VP16E2 or hTR-Gal4VP16. Cells 
were co-transfected with lpg o f the luciferase reporter plasmids pTK-Gal4-6xE2 
(previously illustrated in figure 3.1.2 a). The transfections were carried out in duplicate 
5 times in the 293-T cells and 3 times in the MCF-7 and C33a cell lines. The 
transcriptional activity was measured as rlu from the firefly luciferase gene expression 
and all results were adjusted for protein content in the sample.
In figure 3.1.5 the results from the transcription assay in the 293-T cell line are 
illustrated as fold transcriptional increase compared to cells transfected with lpg 
pTKGal4-6xE2 only. It is seen in the figures that the VP16E2 transcriptional activator
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elicits a higher level o f transcriptional activity than Gal4VP16 up to 100 ng where the 
effect is lost probably due to saturation. This effect is present in conjunction with the 
hTERT promoter as seen in figure 3.1.5 a) and in conjunction with the hTR promoter as 
seen in figure 3.1.5 b). The hTERT and the hTR promoter initiate the two step 
amplification system to a similar level although the hTR does show an increased 
activity at the low lng and lOng concentrations indicating that this is a relatively 
stronger promoter than the hTERT promoter.
In figure 3.1.6 and 3.1.7 the results from the transcription assays in the MCF-7 
and the C33a cell lines respectively, are shown as fold transcriptional increase 
compared to cells transfected with 1 pg pTKGal4-6xE2 only. The increase in 
transcriptional activity from cells transfected with VP16E2 compared to Gal4VP16 is 
even more pronounced in these cells than the effect seen in the 293-T cell line and the 
effect is still present at the highest concentration. The hTR promoter shows an increase 
in transcriptional activity compared to the hTERT promoter in both cell lines with the 
effect being most prominent in conjunction with the VP16E2 transcriptional activator.
In the MCF-7 and C33a cell lines a squelching effect is observed in cells transfected 
with pCG-VP16E2 at high concentrations. This is an effect in which the recruitment of 
cellular transcription factors exceeds the cellular capacity and hence a reduction in gene 
expression is seen with high concentration of powerful transcriptional activators.
Western blots were performed in 293-T, MCF-7 and C33a cells to examine at 
the protein expression of VP16E2 and the Gal4VP16 in conjunction with the telomerase 
promoters. Due to the lower transfection efficiency and telomerase activity in the MCF- 
7 and C33a, cells the Western blots from these cell lines were inconclusive and are 
therefore not shown. Cells were transfected with lp g  or 0.1 pg either pCG-VP16E2 as a 
positive control, hTERT-VP16E2, hTR-VP16E2, hTERTGal4VP16 or hTRGal4VP16. 
The membrane was probed with an antibody against VP 16 and an antibody against 
gammatubulin as a loading control. In figure 3.1.8 the western blot performed in 293-T 
cells is shown. The VP16E2 fusion protein runs as a double band which could be a 
degradation product or protein modification. The Gal4VP16 runs as a single band. An 
increase in VP 16 protein detection is seen in the VP16E2 transfected samples lanes 3-6 
compared to the Gal4VP16 transfected samples lanes 7-10. Great difference is not 
observed in protein detection levels o f the hTR and the hTERT samples for either 
VP16E2 or Gal4VP16. High level o f protein expression is detected in the pCG-VP16E2 
transfected samples lane 1 and 2, whilst no protein expression is detected in the negative
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control sample lane 11. The gammatubulin loading control indicates that an equal 
amount of input has been loaded to all lanes.
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Figure 3.1.4
|  TERT promoter 536bp VP16-E2
------------- ►
|  TERT promoter 536bp GAL4-VP16
------------- ►
|  TR promoter 867bp VP16-E2
------------- ►
B T R p r o m o t e r  867bp GAL4-VP16
Figure 3.1.4 : Telom erase constructs.
a) Schematic reproduction o f  the hTERT-VP16E2 and the hTERT-Gal4VP16.
b) Schematic reproduction o f  the hTR-VP16E2 and the hTR-Ga!4VP16.
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Figure 3.1.5
a)
293-T
350
300
c 250 
o
o
COc  
05 
-*—> 
73 
O
200
150
100
50
0
1 ng 10ng
■  hTERT-VP16E2
□  hTERT-Gal4VP16
□  pCG-VP16E2
100ng 1000ng
b)
293-T
350
300
c  250 
o
’§  200
coc03
O
150
100
50
hTR-VP16E2
□  hTR-Gal4VP16
□  pCG-VP16E2
1 ng 10ng 100ng 1000ng
104
Figure 3.1.5: VP16E2 induces stronger activation of transcription than Gal4VP16 
in telomerase positive 293-T cells.
a) Comparison of the VP16E2 and the Gal4VP16 transcriptional activators under 
control of the hTERT promoter in telomerase positive293-T cells.
b) Comparison of the VP16E2 and the Gal4VP16 transcriptional activators under 
control of the hTR promoter in telomerase positive 293-T cells.
The pCG-VP16E2 is included in both a) and b) as a positive control independent of 
telomerase activity. Cells were transfected with different amounts of transcriptional 
activator plasmid as indicated. In addition all cells were co-transfected with lOOOng 
pTK-Gal4-6xE2 firefly luciferase reporter plasmid. Bars represent fold increase in 
luciferase expression compared to cells transfected with lOOOng pTK-Gal4-6xE2 firefly 
luciferase reporter plasmid alone. Each figure represents summary of 5 experiments 
carried out in duplicate. Standard error bars are shown. * = P-value <0.05 when 
comparing hTR-VP16E2 with hTR-GalVP16.
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Figure 3.1.6
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Figure 3.1.6: VP16E2 induces stronger activation of transcription than Gal4VP16 
in telomerase positive MCF-7 cells.
a) Comparison of the VP16E2 and the Gal4VP16 transcriptional activators under 
control of the hTERT promoter in telomerase positive MCF-7 cells.
b) Comparison o f the VP16E2 and the Gal4VP16 transcriptional activators under 
control of the hTR promoter in telomerase positive MCF-7 cells.
The pCG-VP16E2 is included in both a) and b) as a positive control independent of 
telomerase activity.
Cells were transfected with different amounts of transcriptional activator plasmid as 
indicated. In addition all cells were co-transfected with lOOOng pTK-Gal4-6xE2 firefly 
luciferase reporter plasmid. Bars represent fold increase in luciferase expression 
compared to cells transfected with lOOOng pTK-Gal4-6xE2 firefly luciferase reporter 
plasmid alone. Each figure represents summary of 3 experiments carried out in 
duplicate. Standard error bars are shown. * = P-value <0.05 when comparing 
hTR/hTERT-VP 16E2 with hTR/hTERT-Gal4VP 16
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F ig u r e  3.1.7
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Figure 3.1.7: VP16E2 induces stronger activation of transcription than Gal4VP16 
in telomerase positive C33a cells.
a) Comparison of the VP16E2 and the Gal4VP16 transcriptional activators under 
control o f the hTERT promoter in telomerase positive C33a cells.
b) Comparison o f the VP16E2 and the Gal4VP16 transcriptional activators under 
control o f the hTR promoter in telomerase positive C33a cells.
The pCG-VP16E2 is included in both a) and b) as a positive control independent of 
telomerase activity.
Cells were transfected with different amounts of initiator plasmids as indicated. In 
addition all cells were co-transfected with lOOOng pTK-Gal4-6xE2 firefly luciferase 
reporter plasmid. Bars represent fold increase in luciferase expression compared to cells 
transfected with lOOOng pTK-Gal4-6xE2 firefly luciferase reporter plasmid alone. Each 
figure represents summary of 3 experiments carried out in duplicate. Standard error bars 
are shown. * = P-value < 0.05 when comparing hTR/hTERT-VP16E2 with 
hTR/hTERT-Gal4 VP 16
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Figure 3.1.8
3 8 k D a
V p l 6 E 2  /  G a l 4 V P 1 6 2 8 k D a
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Figure 3.1.8: Protein expression of transcriptional activators.
Western blot showing the expression o f  the VP16E2 and the Gal4VP16 fusion proteins 
in 293T eells using antibody against VP 16. Gammatubulin  loading control is shown 
above. Arrows indicate the approximate location o f  the proteins. The location o f  the 
molecular weight marker (kDa) is shown to the right o f  the blot. 1: pCG-VP16E2 
lOOOng, 2: pCG-VP16E2 lOOng, 3: hTERT-VP16E2 lOOOng. 4: hTERT-VP16E2 
lOOng. 5: hTR-VP16E2 lOOOng, 6: hTR-VP16E2 lOOng, 7: hTERT-Gal4VP16
lOOOng. 8: hTERT-Gal4VP16 lOOng, 9: hTR-G al4VP16 lOOOng. 10: hTR-Gal4VP16 
lOOng, 11: Negative control. The amount in ng is reffering to the amount o f  DNA 
transfected into the cells and not to the amount o f  protein loaded on the gel.
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3.1.3 Testing the specificity of the telomerase TSTA system with VP16E2.
To investigate whether the sensitivity of the two step amplification mechanism in 
conjunction with the telomerase promoters and the VP16E2 fusion protein could coexist 
with a high level of specificity to the telomerase activity of the transfected cells, 
transcription assays were carried out in telomerase negative cell lines.
Telomerase negative cell lines GM-847, U20S and MRC-5 (see materials and 
methods) were transfected using Trans-IT (GM-847) or calcium phosphate (U20S, 
MRC-5) with titrated amounts of either hTERT-VP16E2, hTR-VP16E2 or pCG- 
VP16E2 as a positive control independent of the cellular telomerase activity. All cells 
were co-transfected with lp g  o f the 6xE2-3’BpTATA reporter vector. This plasmid 
contains the E2 activated 3’BpTATA promoter which is responsible for transcription of 
a firefly luciferase gene as seen in figure 3.1.9. Transcription assays were performed 3 
times in duplicate and all results were normalised against protein present in each 
sample. Results are shown as fold increase in transcription compared to cells transfected 
with lpg  6xE2-3’BpTATA only. Results from all three telomerase negative cell lines 
are collected in figure 3.1.10. In all three cell lines the pCG-VP16E2 transfected 
samples show a higher level of luciferase activity than hTERT-VP16E2 and hTR- 
VP16E2 at all DNA concentrations. In the GM-847 cell line 3.1.10 a) it is noted that the 
hTERT promoter shows very little transcriptional activity, however the hTR shows 
pronounced transcriptional activity at all DNA concentrations. This effect is apparent 
but less prominent in the U20S cell line figure 3.1.10 b). In the MRC-5 cell line this 
effect is not seen and the hTR and hTERT promoters appear to be equally active. The 
high transcriptional activity of the hTR promoter in the GM-847 cell line signifies that 
this promoter’s activity is less reflective o f telomerase activity correlating with existing 
literature (Weinrich et al. 1997, Bodnar et al. 1998, Yin et al. 2004, Caimey and Keith 
2008).
I l l
Figure 3.1.9
>
1 6xE2 sites 3’BpTATA promoter Firefly Luciferase
Figure 3.1.9: Schematic representation of the 6xE2-3’bpTATA plasmid.
Schematic model o f  the luciferase reporter plasmid 6xE2-3 'BpTA TA . Reporter vector 
contains the short 3 'B pT A T A  promoter, driving the expression o f  the firefly luciferase 
gene, activated by six upstream E2 binding sites.
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Figure 3.1.10
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Figure 3.1.10: Relative activity of the two telomerase prom oters and the CMV 
prom oter driving VP16E2 transcription in telomerase negative cells.
a) GM -847 cells, b) U 2 0 S  cells, c) MRC-5 cells. Cells were transfected with different 
amounts o f  either hTERT-VP16E2, hTR-VP16E2 or pCG-VP16E2 plasmid as 
indicated. In addition lOOOng 6xE 2-3 'B pT A T A  luciferase reporter plasmid was 
transfected into each sample. Each bar represents fold increase in luciferase expression 
compared to cells transfected with lOOOng 6xE2-3 'B pTA TA  alone. Each figure 
represents summary o f  3 experiments carried out in duplicate. Standard error bars are 
shown.
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3.1.4 Testing of the two step transcriptional amplification system in canine cell 
lines.
To investigate if the two step transcriptional amplification system in conjunction 
with the VP16E2 fusion protein and the human telomerase promoter could function in 
canine cell lines, transcription assays were carried out in the telomerase positive MDCK 
cell line and a canine primary chondrocyte cell line. The primary chondrocyte cell line 
was predicted to be telomerase negative due to its origin (see materials and methods). 
Cells were transfected using Trans-IT with titrated amounts o f either hTERT-VP16E2, 
hTR-VP16E2 or pCG-VP16E2 as a positive control. All cells were co-transfected with 
lpg  o f the 6xE2-3’BpTATA firefly luciferase reporter plasmid as shown in figure 3.1.9. 
Transcription assays were performed 3 times in duplicate and all results were 
normalised against protein present in each sample. Result are shown as fold increase in 
transcription compared to cells transfected with 1 pg 6xE2-3’BpTATA only.
In the telomerase positive MDCK cell line seen in figure 3.1.11 transcriptional 
activity equal to the CMV promoter construct pCG-VP16E2 is seen in cells transfected 
with hTERT-VP16E2 and hTR-VP16E2 indicating that the human telomerase 
promoters and the two step amplification mechanism with VP16E2 does function very 
efficiently in canine cells.
In the primary chondrocyte cell line seen in figure 3.1.12, the hTR promoter is 
seen to be as transcriptionally active as the CMV promoter at the two highest DNA 
concentrations. The hTERT promoter shows a very low level of transcriptional activity 
at the two lower DNA concentrations but this effect is lost at the highest DNA 
concentration. Here the hTERT promoter shows transcriptional activity comparable to 
the CMV and hTR promoters. A squelching effect is observed at the highest 
concentration of the pCG-VP16E2 transfected cells.
This experiment shows that the human derived telomerase promoters and the 
VP16E2 two step amplification system functions in canine cells. The transcriptional 
activity seen in the primary canine chondrocyte cell line, suggests that these cells are 
telomerase positive which was confirmed by later investigations (chapter 3.1.5).
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Figure 3.1.11
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Figure 3.1.11: Relative activity of the two telomerase prom oters and the CMV 
prom oter driving VP16E2 transcription in canine telomerase positive cells.
Telomerase positive M D C K  cells were transfected with different amounts o f  either 
hTERT-VP16E2, hTR-VP16E2 or pCG -VP16E2 plasmid as indicated. In addition 
lOOOng 6xE2-3‘BpTATA luciferase reporter plasmid was co-transfected into each 
sample. Each bar represents fold increase in luciferase expression compared to cells 
transfected with lOOOng 6xE 2-3 ‘BpTATA alone. Figure represents summary o f  3 
experiments carried out in duplicate. Standard error bars are shown.
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Figure 3.1.12
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Figure 3.1.12: Relative activity of the two telomerase prom oters and the CMV 
prom oter driving VP16E2 transcription in canine prim ary cells.
Primary canine chondrocytes were transfected with different amounts o f  either hTERT- 
VP16E2. hTR-VP16E2 or pCG-VP16E2 plasmid as indicated. In addition lOOOng 
6xE2-3 'BpTA TA  luciferase reporter plasmid was co-transfected into each sample. Each 
bar represents fold increase in luciferase expression compared to cells transfected with 
lOOOng 6xE2-3?BpTA TA  alone. Figure represents summary o f  3 experiments carried 
out in duplicate. Standard error bars are shown. * = P-value < 0.05 when comparing
hTR-VP 16E2 with hTERT-VP16E2.
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3.1.5 Measurement of telomerase activity in cell lines.
In order to determine the telomerase activity in the cell lines used in sections 
3.1.4-3.1.6 telomerase repeat amplification protocol (TRAP) assays were carried out 
using the TRAPeze kit as described in materials and methods. 293-T, MCF-7, C-33a, 
GM-847, U20S, MRC-5, MDCK and primary chondrocytes were tested. In addition a 
primary canine fibrosarcoma cell line and a primary canine fibroblast cell line which 
were used in later experiments (chapter 3.2) were tested. A primary canine testes 
tumour cell line was tested however this cell line was not used for further experiments. 
Results from the TRAP assay are shown as TRAP ladders run on a SDS polyacrylamide 
(PAGE) gel as seen in figure 3.1.13. In this figure each sample was run alongside its 
heat inactivated negative control. The internal band present at arrow should be present 
in all samples. This is a control indicating that no polymerase inhibiters were present in 
the tested sample. Lack o f an internal band in a sample can result in false negative 
results due to reduced polymerase activity. The interpretation of the PAGE gel results 
are shown in table 3.1.1. The intensity of the ladders and the number of bands were used 
to interpret the telomerase activity. Ladders with several bands of strong intensity were 
interpreted as having more telomerase activity and samples in which the heat inactivated 
control was absent were interpreted as being more telomerase active than the ladder 
indicated. Important results to notice from the TRAP assay are that the canine primary 
fibrosarcoma cell line, the primary canine fibroblast cell line and the primary canine 
testes tumour were telomerase negative. Another important result was that low 
telomerase activity was observed in primary canine chondrocytes cells correlating well 
with the hTERT promoter activity observed in this cell line in chapter 3.1.4. The quality 
of the TRAP ladder in the MRC-5 sample shown on figure 3.1.13 a) is very poor and an 
artefact is disturbing the image of the internal standard. The TRAP ladder in this sample 
appears to run at a smaller size which could be due to artefacts and the telomerase 
activity detected in this cell line is therefore questionable.
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Figure 3.1.13: Telomerase ladders on PAGE g e l.
10 jliI o f each TRAP reaction were examined on a on a gel in parallel with a 100 base 
pair ladder. The gels were stained with ethidium bromide and DNA was visualised 
under UV light. Arrows indicate the location of the internal control band.
Table 3.1.1
Cell line HI control Internal
standard
Telomerase
status
293-T Not tested + +++
MCF-7 - + +++
GM-847 - + +
U20S - + +
Canine fibroblast - +++ -
Chondrocytes - ++ ++
Testes tumour - +++ -
C-33a - ++ +++
Fibrosarcoma - +++ -
MRC-5 - ++ (+)
MDCK - + +++
Table 3.1.1: Results from TRAP assay.
Interpretation of the page gel trap analysis schematically represented. Plus signs are 
used to indicate quality of controls or telomerase activity. HI = Heat inactivated control. 
+=low, ++=moderate, +++=high - = negative.
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3.1.6 Testing efficiency and overlap of co-transfection with two plasmids.
The two step amplification system used throughout section 3.1.1-3.1.5 is based 
on a transcriptional activator and a reporter two plasmid system. For this system to 
function it is necessary that both plasmids are taken up by the transfected cell. As 
illustrated in figure 3.1.14 a-c) cells have different transfection efficiencies and for cells 
with a low transfection efficiency the number of cells that take up both plasmids could 
be as low as the percentage of transfected cells squared unless there is a correlation 
between cells taking up both plasmids. To test this, co-tranfection experiments were 
performed in 3 cell lines using green fluorescent protein (GFP) and red fluorescent 
protein (RFP) expressing plasmids. MDCK, U 20S and 293-T cells were used for this 
experiment; the latter was transfected with calcium phosphate and the two former were 
transfected with Trans-IT. Transfection efficiency was determined for each cell line by 
transfection with 1 pg GFP expressing plasmid. 40 hours post transfection the cells were 
visualised under fluorescent light at a wavelength specific for GFP expression and the 
GFP versus non GFP expressing cell ratio was determined. The approximate 
transfection efficiency for the MDCK, U20S and 293-T cells was 15-20%, 60-70% and 
95-99 % respectively. Co-transfection was performed by co-transfecting each of the 
cell lines with lpg  GFP and lp g  RFP expressing plasmid. 40 hours later cells were 
visualised using a fluorescent microscope and the co-localisation of GFP and RFP 
expressing cells was determined. The transfection efficiency of the RFP expressing cells 
in general seems a bit lower than for GFP however this is due to the weaker expression 
of RFP in general due to its slow folding and tendency to form tetramers which can 
reduce its expression (Shrestha & Deo 2006). In general it was estimated that 
approximately 95 % o f cells expressing RFP also expressed GFP suggesting that there 
may be a correlation between uptakes of both plasmids. In figure 3.1.15, 3.1.16 and 
3.1.17 pictures are shown of the MDCK, U20S and 293-T cells used in the 
experiments. Cells are shown using a filter specific for GFP expression, a filter specific 
for RFP expression and phase contrast exposure. A merge of the GFP and RFP images, 
shows the transfection co-localisation. The figures show that the outcome of the 
transfection most resembles the model in figure 3.1.14 f) in which both plamids are 
taken up by transfected cells.
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Figure 3.1.14
Transfection with one vector
a) Untransfected ce lls  on plate b) 100% cells transfected c) 20% cells transfected
Transfection with two vectors
d) 100% cells transfected e) 20%  x 20%  cells transfected f)20%  o f  cells transfected
with both vectors = 4% with both vectors
Figure 3.1.14: Possible transfection efficiency models for co-transfections with two 
plasmids
Figure illustrates possible outcom es for cells w ith either 100% or 20%  tranfection 
efficiency, transfected with either one or two plasm ids.
Black represents untransfected cells, green represents cells transfected with GFP 
expressing plasm id, red represents cells transfected RFP expressing plasm id and yellow  
represents cells transfected with both GFP and RFP expressing plasm ids
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Figure 3.1.15
C o-localisation
Figure 3.1.15: Transfection overlap in MDCK cells co-transfected with GFP and 
RFP expressing plasmids.
Top left, GFP expressing M DCK cells visualised. Top right, RFP expressing M DCK 
cells visualised. Bottom left, phase contrast picture o f  M DCK cells. Bottom  right, 
m erged image o f  pictures top left and top right show ing transfection co-localisation.
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Figure 3.1.16
Figure 3.1.16: Transfection overlap in U 20S cells co-transfected with GFP and 
RFP expressing plasmids.
Top left, GFP expressing U 2 0 S  cells visualised. Top right. RFP expressing U 2 0 S  cells 
visualised. Bottom left, phase contrast picture o f  U 2 0 S  cells. Bottom right, m erged 
image o f  pictures top left and top right show ing transfection co-localisation.
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Figure 3.1.17
Figure 3.1.17: Transfection overlap in 293-T cells co-transfected with GFP and 
RFP expressing plasmids.
Top left, GFP expressing 293-T  cells visualised. Top right, RFP expressing 293-T cells 
visualised. Bottom left, phase contrast picture o f  293-T cells. Bottom  right, m erged 
image o f  pictures top left and top right show ing transfection co-localisation.
125
3.1.7 Development of a single plasmid two step vector.
To develop the two step transcriptional amplification system further the two 
vector system was incorporated into a one vector system by placing the telomerase 
promoter transcribing the transcriptional activator fusion protein and the 6xE2- 
3’BpTATA promoter transcribing the reporter gene into one plasmid. The results in 
section 3.1.3 and the literature indicate that the hTERT promoter is more specific for 
telomerase activity than the hTR promoter and therefore only the hTERT promoter 
construct was taken forward into a one vector system.
3.1.7.1 Cloning of the hTERT-VP16E2 one vector system.
To reduce the two plasmid system to one plasmid it was decided to clone the 
hTERT-VP16E2 sequence into the 6xE2- 3’BpTATA plasmid. This could be done with 
the 3’BpTATA promoter and the hTERT promoter transcribing in the same direction or 
the two promoters transcribing in opposite directions. It was decided to clone both 
constructs to test if  there would be a difference between these.
The 6xE2-3’BpTATA vector was digested with BamH I and phosphatase 
treated. A hTERT-VP16E2 PCR product with 5’ and 3’ overhanging Bgl II restriction 
sites was made using primers as described in materials and methods. The PCR product 
was digested with Bgl II and ligated into the cut 6xE2-3’BpTATA plasmid and 
transformed into JM-109 cells. The Bgl II and BamH I have compatible ends that at 
ligation destroy both sites. This method allowed for the insertion of the insert in either 
direction. Inserts were confirmed and direction determined, by sequencing and 
restriction digest. The resulting plasmids were named 6xE2-3’BpTATA-hTERT- 
VP16E2 Forward (FOR) and 6xE2-3’BpTATA-hTERT-VP16E2 Reverse (REV) as 
shown on figure 3.1.18.
3.1.7.2 Testing the one vector system.
To investigate the ability o f the two step amplification system to function in a 
one plasmid system, transfection assays were performed in telomerase positive 293-T 
cells and telomerase negative GM-847 cells. Cells were transfected with titrated 
concentrations of either 6xE2-3’BpTATA-hTERT-VP16E2 FOR or 6xE2-3’BpTATA- 
hTERT-VP16E2 REV. In parallel cells were transfected with lpg  pCG-VP16E2 and
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1 (j,g 6xE2-3’BpTATA as a two vector system. Transcription assays were performed 3 
times in duplicate and all results were normalised against protein present in each 
sample. Results are shown as fold increase in transcription compared to cells transfected 
with 800ng 6xE2-3’BpTATA reporter vector on its own. In figure 3.1.19 the results 
from the transcription assays are shown. It is seen that sensitivity and specificity to 
telomerase activity is still conserved in the one plasmid system. This is seen as high 
transcription activity relative to the pCG-VP16E2 in telomerase positive cells 3.1.19 a) 
and low transcriptional activity relative to the pCG-VP16E2 in telomerase negative cells 
3.1.19 b). A slight difference in transcriptional activity is observed between the 6xE2- 
3 ’ BpT AT A-hTERT -VP 16E2 FOR and 6xE2-3’BpTATA-hTERT-VP16E2 REV 
constmcts with the reverse associated with a higher level of activity. The TERT 
promoter lacks a TATA box which is a common characteristic of bidirectional 
promoters (Dong et al. 2000, Yang & Elnitski 2008). It is a possibility that the extra 
activity seen with the 6xE2-3’BpT ATA-hTERT-VP 16E2 REV could be due to reverse 
transcription from the TERT promoter. Such activity could compromise the specificity 
of the system. It is seen that the 6xE2-3’BpTATA-hTERT-VP16E2 FOR shows a low 
er level of transcriptional activity than the REV constmct in telomerase negative cells 
and therefore it was elected to take the FOR constmct forward and the subsequent work 
using the single plasmid two step system was done with the 6xE2-3’BpTATA-hTERT- 
VP16E2 FOR.
3.1.7.3 Evaluating the effect of the two step amplification system compared to the 
telomerase promoter on its own.
To look at the advantage of incorporating the telomerase promoter into the two 
step amplification system in order to target gene expression to telomerase positive cells, 
transcription assays were performed comparing the transcriptional activity o f the 
hTERT-LUC plasmid and the 3’BpT AT A-hTERT-VP 16E2 FOR. 293-T cells were 
transfected with serial dilutions of either plasmid using calcium phosphate. 
Transcription assays were performed 3 times in duplicate and all results were 
normalised against protein present in each sample. Results are shown as fold increase in 
transcription compared to cells transfected with lpg pGL3-Basic reporter vector on its 
own. The results from the experiment are summarised in figure 3.1.20 Transcriptional 
activity for both plasmids is negligible at concentrations below lOOOng. At the lOOOng
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concentration a great increase in transcriptional activity is seen and an over 30 fold 
increase in transcriptional activity is observed in the 3’BpT AT A-hTERT-VP 16E2 
compared to the hTERT-LUC confirming the advantage of including a two step 
amplification system into targeted gene therapy.
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Figure 3.1.18
a) b)
Figure 3.1.18: Schematic models of one plasmid system.
a) Schematic representation of one plasmid system 6xE2-3’BpT ATA-hTERT-VP 16E2 
Forward, in which the TERT promoter and the 6xE2-3’BpTATA promoter both 
transcribe clockwise.
b) Schematic representation o f one plasmid system 6xE2-3’BpTATA-hTERT-VP16E2 
Reverse, in which the TERT promoter transcribes clockwise and the 6xE2-3’BpTATA 
promoter transcribes counter clockwise.
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Figure 3.1.19
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Figure 3.1.19: One plasmid system in telomerase positive and negative cells
a) 293-T telomerase positive cells, b) GM-847 telomerase negative cells. Cells were 
transfected with different amounts of 6xE2-3’BpT AT A-hTERT-VP 16E2 FOR or REV 
as indicated. For comparison, cells were co-transfected with lOOOng pCG-VP16 E2 and 
lOOOng 6xE2-3’BpTATA. Results are shown as fold increase in luciferase expression 
compared to sample transfected with 800ng 6xE2-3’BpTATA only. Experiments were 
carried out 3 times in duplicate. Standard error bars are shown.
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Figuire 3.1.20 TSTA system increases transcription significantly.
29 3- T cells w ere transfected with hTERT-LUC or 3 ’ B pT A T A -hT E R T V P16E2 FO R  as 
in d ica ted . Each bar represents fold increase in transcription relative to cells transfected 
wiith 1 pig 6xE 2-3 ‘BpTATA. Figure represents sum m ary o f  3 experim ents carried out in 
dupliicate. Standard error bars are shown. *= P-value < 0.05
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3.1.7.4 Cloning of the hTERT-Gal4VP16 one vector system.
To compare the hTERT-VP16E2 with the hTERT-Gal4VP16E2 in the one 
plasm id system, a one vector plasmid fusion with the 6xE2-3’BpTATA plasmid and the 
hTERT-Gal4VP16 insert was made. The 6xE2-3’BpTATA plasmid does not contain 
Gal4 binding sites so in order for the promoter to be responsive to the Gal4VP16 fusion 
pro tein, 5 Gal4 binding sites were cloned in upstream of the 6 E2 binding sites present 
in the 6xE2-3’BpTATA plasmid. The pTK-Gal4-6xE2 plasmid was digested with Nhe I 
and KpN I to cut out the 5 Gal4 binding sites in the plasmid. The 5xGal4 fragment was 
isolated by gel electrophoresis and purification. The 6xE2-3’BpTATA plasmid was 
digested with KpN I and Nhe I and phosphase treated. The 5xGal4 fragment was ligated 
w ith the cut 6xE2-3’BpTATA plasmid and transformed into Dh5a cells. Correct inserts 
were confirmed by restriction digest. The resulting vector was named 5xGal46xE2- 
3 ’BpTATA.
The hTERT-Gal4VP16 fragment was inserted into the 5xGal46xE2-3’BpTATA 
plasmid in a similar manner as described for the hTERT-VP16E2 3.1.7.1 however only 
the forward construct was cloned. The resulting vector was named 5xGal46xE2- 
3 ’BpTATA-hTERT-Gal4VP16 and is schematically illustrated in figure 3.1.21
3.1.7.5 Comparison of the VP16E2 and the GaI4VP16 one plasmid system.
To compare the transcriptional potential o f the hTERT-VP16E2 and hTERT- 
Gal4VP16 in the one plasmid system, transcription assays were performed in 293-T 
cells. It was decided to use the forward versions o f the one plasmid system for the 
comparison. 293-T cells were transfected with titrations o f either 6xE2-3’BpTATA- 
hTERT-VP16E2 or 5xGal46xE2-3’BpTATA-hTERT-VP16E2. Transcription assays 
were performed 3 times in duplicate and all results were normalised against protein 
present in each sample. Results are shown as fold increase in transcription compared to 
cells transfected with lpg  5xGal46xE2-3’BpTATA reporter vector on its own. The 
higher transcriptional activity seen previously in conjunction with the VP16E2 
transcriptional activator compared to the Gal4VP16 is preserved in the one plasmid 
system as shown in figure 3.1.22.
To look at the protein expression of 6xE2-3’BpTATA-hTERT-VP16E2 or 
5xGal46xE2-3’BpTATA-hTERT-VP16E2 293-T cells were transfected with either lpg
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or 0.1 fig o f either plasmid and normal protocol was carried out for Western blot. The 
membrane was probed with an antibody against VP 16 and gammatubulin as a loading 
control. As seen in figure 3.1.23 protein is detected for both transcriptional activators at 
lpg  concentrations. No bands were detected at 0.1 pg concentrations or in the negative 
control lane. The gammatubulin loading control indicated that equal amounts of protein 
had been loaded in each lane. No difference was observed in the strength of the bands 
between the two transcriptional activators. It is noted that the VP16E2 only ran as a 
single band on this blot, corresponding to the smaller band of the two seen in previous 
blots (figure 3.1.3 and 3.1.8).
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Figure 3.1.21
a) b)
Figure 3.1.21: 5xGal4-6xE2-3’BpTATA-hTERT-VP16E2
a) Schematic representation of the 5xGal4-6xE2-3’BpTATA-hTERT-Gal4VP16 FOR.
b) Schematic representation of 6xE2-3’BpTATA-hTERT-VP16E2 FOR
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Figure 3.1.22
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Figure 3.1.22: VP16E2 is still better than Gal4-VP16 in one plasmid system.
Cells were transfected w ith different am ounts o f  6xE 2-3 'B p T A T A -hT E R T -V Pl6E 2 
FOR or 5xG al46xE2-3’BpTA TA -hTER T-G al4V P 16 FOR as indicated. Results are 
shown as fold increase in luciferase expression com pared to sample transfected with 
lOOOng 5xG al46xE2-3 'B pTA TA  only. Figure represents sum m ary o f 3 experim ents 
carried out in duplicate. Standard error bars are shown. * = P-value <0.05
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Figure 3.1.23
49kDa
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Figure 3.1.23: Protein expression of transcriptional activators in one plasmid 
system.
a) G am m atubulin  loading control, b) W estern blot show ing the expression o f  the 
V P16E2 and the G al4V P16 fusion proteins in 293-T cells, using antibody against VP 16. 
Cell lysates w ere harvested as described. A non-specific band is seen in all lanes.
The location o f  the m olecular weight m arker (kD) is shown on the right o f  the 
blot. A rrow s indicate location o f  protein.
1: 6 xE 2-3 ' BpTA TA -hTER T-V P 16 E 2 1 OOOng,
2: 6xE 2-3 'B pT A T A -hT E R T -V P16E 2 lOOng,
3: 5xG al46xE 2-3’BpTA TA -hTER T-G al4V P 16 lOOOng,
4: 5xG al46xE2-3 ’BpT AT A -hTER T-G al4 VP 16 lOOng,
5: N egative control
The am ount in ng is referring to the am ount o f  DNA transfected into the cells and not to 
the am ount o f  protein loaded on the gel.
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3.1.8 Applying the two step transcriptional amplification system to cell killing
To develop the two step amplification system towards cancer cell killing and 
therapeutic use the firefly luciferase gene was exchanged for the full length human 
TRAIL gene. TRAIL is described in the introduction (chapter 1.4.1.1).
3.1.8.1 Incorporation of the TRAIL gene in the two step transcriptional 
amplification system.
In order to incorporate the human TRAIL gene into the one vector system the 
6xE2-3’BpTATA plasmid was digested with Xba I and Hind III. The digested product 
the digest was run on a gel and the upper band was cut out and gel purified. This 
process removed the firefly luciferease gene from the plasmid. A TRAIL PCR product 
was made using the dogTERT-hTRAIL plasmid (see materials & methods) as a 
template and primers with a 5’ Hind III and a 3’ Xba I overhang. The PCR product was 
digested with the appropriate enzymes and ligated into the cut 6xE2-3’BpTATA 
plasmid and transformed into JM-109 cells. Correct inserts were confirmed by 
restriction digest and sequenced. The new plasmid was named 6xE2-3’BpTRAIL. 
Subsequently this hTERT-VP16E2 was inserted into the plasmid using the same method 
as in 3.1.7.1 in both forward and reverse directions. The resulting vectors were named 
6xE2-3’BpTRAIL-hTERT-VP 16 FOR and REV. In figure 3.1.24 the 6xE2- 
3’BpTRAIL-hTERT-VP16 FOR plasmid is schematically illustrated. As a positive 
control, a plasmid was cloned containing a CMV promoter driving transcription of the 
TRAIL gene. This plasmid was made using the TRAIL cloning method as above but 
inserting the TRAIL insert into the pDNA vector (see materials and methods). This 
plasmid was named CMV-hTRAIL.
3.1.8.2 Identifying canine TRAIL.
For the comparative aspect of this study the canine TRAIL gene was cloned. A 
DNA sequence search was performed on the UCSC Genome Browser created by the 
Genome Bioinformatics Group of UC Santa Cruz. The human full length TRAIL 
sequence was copied, NCBI accenssion number NM 003810, and was compared with 
against the canine genome using a basic local alignment search tool. The search 
identified a sequence which was highly compatible with the human TRAIL sequence
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located on the canine chromosome 34, spanning several thousand base pairs including 
introns. From this sequence primers were designed to isolate the canine TRAIL cDNA.
3.1.8.3 Cloning canine TRAIL (cTRAIL)
Normal circulating leukocytes such as neutrophils and monocytes express 
TRAIL (Ehrlich et al. 2003, Simons et al. 2008). Two canine blood samples in EDTA 
were therefore obtained from the University of Glasgow Small Animal Hospital. The 
blood samples were centrifuged and the buffy coat from each sample was isolated and 
pooled. RNA was isolated from the pooled buffy coat using Quiagen RNAqueous 
extraction kit. DNA was made by performing a reverse transcriptase reaction using 
DNA primers designed to bind to cTRAIL with the extracted RNA as a template. The 
resultant DNA was used as a template for a PCR reaction using the same DNA primers. 
Products from the PCR reaction were cloned into the TOPO cloning vector and clones 
were selected by blue-white screening. Inserts were confirmed by restriction digest and 
correctly sized inserts were sequenced to reveal the full length canine TRAIL cDNA. 
Several clones were sequenced and compared to the sequence found in the UCSC 
Genome Browser. The full length canine TRAIL cDNA as seen in figure 3.1.25 is 846 
base pairs long and codes for 281 amino acids. An alignment of the translated canine 
and human TRAIL amino acid sequences is illustrated in figure 3.1.26 and shows 79% 
amino acid identity between species.
This indicates that the TRAIL gene is conserved between dogs and humans.
3.1.8.4 Cloning CMV-cTRAIL
In order to express the canine TRAIL gene in cells and examine its effects, a 
CMV-cTRAIL construct was cloned. The full length TRAIL was excised from the 
TOPO vector using the EcoR I restriction enzyme and was gel purified. The pDNA 
vector was cut with EcoR I and the cTRAIL insert was inserted by ligation. Clones were 
checked for inserts and insert orientation by restriction digest and sequencing.
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Figure 3.1.24
sr
Figure 3.1.24: Schematic presentation of 6xE2-3’BpTRAIL-hTERT-VP16 FOR
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Figure 3.1.25
ATGCAGGCCCCGGGGGGCCCCAGCCTCGGGCTGACGTGCGTGCTGATCCTCATCTTCACTGTGCTGCTCCAGTCCCTCT
GCGTGGCCGTCACCTACATGTACTTCACCAGGGAGCTGAAGCAGATGCAGGACAAGTACTCCCAAAGTGGCATCGCTTGT
TTCTTAAAGGAAGATGATATCCCCTGGGACCCCAGTGATGAAGAGAGTATGAACAACCCCTGCTGGCAAGTGAAGTGGCA
ACTCCGCCAGTTTGTTAGAAAGATGATTTTGAAAACCTATGAGGAAACCATTCCTACAGCTCCAGAAAAGCAGCTAAATATT
CCTTACGTAGTAAGCGACCGAGGTTCTCAGAGAGTAGCTGCTCACATAACTGGAACCAGTCGGAGAAGCATGTTTCCAATT
CCAAGCTCCAAGAATGATAAAGCTTTGGGCCACAAAATAAACTCCTGGGATTCCACAAGAAAAGGACATTCATTCTTGAATA
ATTTGCACTTGAGGAACGGAGAGCTGGTTATCCATCAAAGGGGGTTTTATTACATCTACTCCCAAACATACTTTCGATTTCA
GGAACCTGAGGAAATTCCAACAGGACAGAACAGAAAGAGAAACAAACAAATGGTCCAATATATTTACAAACACACGAGTTA
TCCGGACCCTATACTGCTGATGAAAAGTGCTAGAAATAGTTGTTGGTCTAAAGATTCTGAATATGGACTCTATTCCATCTAT
CAAGGTGGGATATTTGAGCTTAAGGAAAACGATAGAA11 I I IGTCTCT GT AT CTAACG AGC AATT GATT G AC AT GG ACC AAG
AAGCCAGI I I I I ICGGGGCCTT TITAATCGGCTAA
Figure 3.1.25: The full length dog TRAIL cDNA
cDNA sequence of c TRAIL from TOPO cloned constructs. Total length is 846 bp 
coding for 281 amino acids and a stop codon. Start and stop codons are denoted in red.
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Figure 3.1.26
Identities = 225/283 (79%), Positives = 248/283 (87%), Gaps = 5/283 (1%)
CTRAIL 1 MQAPGGPSLGLTCVLILIFTVLLQSLCVAVTYMYFTRELKQMQDKYSQSGIACFLKEDDI 60
M+ GGPSLG TCVLI +1FTVLLQSLCVAVTY+YFT ELKQMQDKYS+SGIACFLKEDD 
hTRAIL 4 MEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKEDDS 63
CTRAIL 61 PWDPSDEESMNNPCWQVKWQLRQFVRKMILKTYEETIPTAPEKQLNIPYWSDRGSQRVA 120
WDP+DEESMN+PCWQVKWQLRQ VRKMIL+T EETI T EKQ NI +V +RG QRVA 
hTRAIL 64 YWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVA 123
CTRAIL 121 AHITGTSRRS-MFPIPSSKNDKALGHKINSWDSTRKGHSFLNNLHLRNGELVIHQRGFYY 179
AHITGT RS P+SKN+KALG KINSW+S+R GHSFL+NLHLRNGELVIH++GFYY
hTRAIL 124 AHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYY 183
CTRAIL 180 IYSQTYFRFQEPEEIPTGQNRKRNKQMVQYIYKHTSYPDPILLMKSARNSCWSKDSEYGL 23 9
IYSQTYFRFQE + +N K +KQMVQYIYK+TSYPDPILLMKSARNSCWSKD+EYGL 
hTRAIL 184 IYSQTYFRFQEEIK ENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGL 23 9
CTRAIL 240 YSIYQGGIFELKENDRIFVSVSNEQLIDMDQEASFFGAFLIGX 282
YSIYQGGIFELKENDRIFVSV+NE LIDMD EASFFGAFL+GX 
hTRAIL 240 YSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVGX 282
Figure 3.1.26: Alignment of cTRAIL and hTRAIL amino acid sequence.
Alignment of the amino acid sequence o f full length cTRAIL and full length hTRAIL. 
In red the shared sequence is shown. There was a 79% sequence identity found between 
species and 87% sequence homology.
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3.1.8.5 Effect of canine and human TRAIL in human cells.
The ability of human and canine TRAIL to induce apoptosis in cells was 
detected by Western blots examining the effect of TRAIL on the activation o f apoptosis 
mediators at different time points after transfection of cells.
293-T cells and U 20S cells were transfected, using calcium phosphate and 
Trans-It respectively, with lpg  CMV-cTRAIL, CMV-hTRAIL or pGL3-Basic. Cells 
were harvested at different times between 20 and 40 hours after transfection. 
Membranes were probed with antibodies recognising Caspase 3 or cleaved Caspase 3 
and gammatubulin was identified as a loading control. In 293-T cells shown in figure 
3.1.27 caspase cleavage is detected at all time points after transfection with both human 
and canine TRAIL. No cleaved caspase is detected in the pGL3-Basic transfected cells 
from the same experiment at any time point.
In the U 20S cells a similar patterns was seen and caspase 3 cleavage was 
observed in all CMV-cTRAIL3.1.28 b) and CMV-hTRAIL 3.1.28 d) transfected 
samples. No cleaved caspase was observed in cells transfected with pGL3-Basic 3.1.28 
a) and b). It should be noted that the membrane in figure 3.1.28 d) was probed with a 
Caspase antibody which detects both cleaved and uncleaved caspase 3 and therefore a 
larger band of uncleaved caspase 3 is detected in all samples including the pGL3-Basic 
transfected samples.
This experiment indicates that both the human and dog TRAIL can induce 
apoptosis in human cells and that this effect is present as early as 20 hours post 
transfection.
3.1.8.6 Effect and expression of hTRAIL and cTRAIL in canine cells.
After testing the ability of the human and canine TRAIL to activate the caspase 
pathway in human cells, the same effect was investigated in canine cells. At this stage 
the one plasmid two step transcriptional amplification system cloned in 3.1.8.1 was 
included in the experiment. Canine telomerase positive MDCK cells were transfected 
using Trans-IT with lpg  CMV-hTRAIL, CMV-cTRAIL, 6xE2-3’BphTRAIL-hTERT- 
VP16E2 FOR, 6xE2-3’BpTRAIL or pGL3-Basic. Cells were harvested 40 hours after 
transfection and cell lystates were prepared for Western blot. Membranes were probed 
with antibodies recognising cleaved caspase 3, cleaved PARP, TRAIL and
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gammatubulin as a loading control. The Western blot is shown in figure 3.1.29. It is 
seen that the human and canine TRAIL and the TRAIL incorporated in the two step 
amplification system are expressed in the canine cells and that the TRAIL antibody 
which is raised against human TRAIL cross reacts with canine TRAIL. It is also seen 
that the level of TRAIL expression from these 3 plasmids correlates with the degree of 
caspase 3 cleavage, reflecting the initiation of apoptosis. The CMV-hTRAIL and CMV- 
cTRAIL expression is also correlated with PARP cleavage which is another protein 
activated prior to apoptosis. There is no detection of caspase 3 cleavage, PARP cleavage 
or TRAIL in the sample from 6xE2-3’BphTRAIL transfected cells indicating that the 
6xE2-3’BphTRAIL is inactive in absence o f the VP16E2 fusion transcriptional activator 
protein. The 6xE2-3’BphTRAIL-hTERT-VP16E2 FOR is detected as a strong band 
with the TRAIL antibody however this is not reflected with strong expression of 
apoptosis markers. This diversity in expression between the TRAIL protein and the 
apoptosis markers in this sample could reflect the delay between the transcription of the 
TRAIL protein and its expression and effect on the cell surface as a trans-membrane 
protein. The gammatubulin loading control reflects that an equal amount of protein has 
been loaded in each well.
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Figure 3.1.27
a) 49kD
Gammatubulin
b) 17kD
14kD Cleaved Caspace
20 25 35 40 20 25 35 40 20 25 35 40 Hours after transfection
V._________________________ >  V______________________ J  V__________   >
l^tg C M V-hTR AIL I gg  C M V-cTR AIL 1 gg pGL-3 Basic Plasmid
Figure 3.1.27: Effect of TRA IL expression in 293-T cells at different time points 
after transfection detected by W estern blot.
W estern blot showing Caspase 3 cleavage in 293-Tcells transfected with plasm ids as 
indicated, and harvested at m ultip le tim e points after transfection, a) M em brane probed 
with antibody against gam m atubulin  as a loading control, b) M em brane probed with 
antibody against cleaved caspase 3. Arrows indicate the location o f the protein o f 
interest. M olecular w eight m arkers are show n to the left.
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Figure 3.1.28
a)
b)
49kD
28kD
17kD
14kD
Gam matubulin
Cleaved Caspace 3
v20 25 30 3 S  v20 25 30 35> hours after transfection
v  v
1 pg C M V-cTR AIL 1 pg pGL-3 Basic Plasmid
c)
d)
49 kD
28kD  
17 kD 
14kD
Gammatubulin
-  C leaved Caspace 3
20  25 30 35 20 25 30 35 hours after transfection
v a   __________J"■v— ■'V'"
lp g  CM V-hTRAIL 1 pg pGL-3 Basic Plasmid
Figure 3.1.28: CMV-TRAIL effect in human U 20S cells detected by W estern blot 
with a cleaved caspase 3 antibody.
W estern blot showing caspase 3 cleavage in U 2 0 S  cells transfected with plasm ids as 
indicated, and harvested at m ultiple tim e points after transfection, a) M em brane probed 
with antibody against gam m atubulin  as a loading control, b) M em brane probed with 
antibody against cleaved caspase 3. c) M em brane probed with antibody against 
gam m atubulin as a loading control, d) M em brane probed with antibody against caspase 
3. Arrows indicate the location o f  the protein o f  interest. M olecular weight m arkers 
shown to the left.
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Figure 3.1.29
Cleaved caspace 3 antibody
TRAIL antibody
Cleaved PARP antibody
Gam m atubulin antibody
Figure 3.1.29: TRAIL expression and effect in canine cells detected by W estern 
blot.
W estern blot using antibodies against cleaved caspase 3, TR A IL, cleaved PARP and 
gam m atubulin. M DCK cells were transfected and cells harvested 48 hours later. 
M olecular m arker and arrows on left indicate the location o f  the protein o f interest.
1 =C M V -hTR A IL, 2=CM V -cTRA IL, 3= 6xE 2-3 'B phT R A IL -hT E R T -V P16E 2 FOR. 4= 
6xE 2-3 'B phFR A IL  , 5=pGL3-Basic.
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3.1.8.7 Specific targeting of TRAIL induced apoptosis to telomerase positive cells 
detected by TUNEL stain.
With the incorporation of the hTERT promoter into the two step amplification 
system containing VP16E2 high levels of gene expression are detected in telomerase 
positive cells whilst not in telomerase negative cells as seen in figures 3.1.5-3.1.10. The 
TRAIL gene was introduced to the system, and to detect and quantify apoptosis in cells 
Transferase mediated dUTP Nick End Labelling (TUNEL) assays were performed in 
transfected telomerase positive and negative cells.
Telomerase positive 293-T and telomerase negative U20S cells were grown on 
glass slides and transfected with lpg  CMV-hTRAIL, CMV-cTRAIL, 6xE2- 
3’BphTRAIL-hTERT-VP 16E2 FOR, 6xE2-3’BphTRAIL or pGL3-Basic using calcium 
phosphate and Trans-IT respectively. 20 hours after transfection, cells were fixed with 
4% formaldehyde in PBS and subsequently TUNEL stained. This stain incorporates 
fluorescein into the broken ends o f apoptotic DNA strands. The 20 hour incubation 
period was chosen due to the early effect of TRAIL and the possibility that late 
apoptotic cells would float off the slide either before or during fixation. To visualise all 
cells, the slides were also counterstained with 4',6-diamidino-2-phenylindole (DAPI) 
stain. Cells were visualised using a fluorescent microscope and pictures from 5 random 
fields were taken of each slide using filters selective for emission of DAPI and 
fluorescein stained cells as seen in figure 3.1.30. The number of blue (DAPI) cells and 
green (fluorescein) cells were counted in each picture and a Yates corrected Chi square 
test were performed on the counted cells using the pGL3-Basic transfected cells as 
reference. Transfection and staining was performed 3 times in each cell line.
To determine the amount of apoptosis seen in cells transfected with the different 
plasmids we tested the null hypothesis.
Ho: There is no difference in cell killing between the pGL3-Basic and the sample of 
interest.
Tables 3.1.2 and 3.1.3 summarise the results from the 3 experiments in 293-T 
and U20S cells respectively. In the 293-T cells the null hypothesis is confirmed for the 
samples transfected with 6xE2-3’BphTRAIL. The samples transfected with CMV- 
hTRAIL, CMV-cTRAIL and 6xE2-3’BphTRAIL-hTERT-VP 16E2 all show a relatively
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high number of apoptotic cells resulting in Yates corrected p values that discard the null 
hypothesis.
In the U20S cells the null hypothesis is confirmed for the samples transfected 
with 6xE2-3 ’BpTRAIL and 6xE2-3’BpTRAIL-hTERT-VP16E2. The samples 
transfected with CMV-hTRAIL and CMV-cTRAIL show a relatively high number of 
apoptotic cells resulting in Yates corrected p values that discard the null hypothesis.
The results from the tables are summarised in figure 2.1.31 in which the 
proportion of apoptotic cells in samples is shown relative to the proportion in pGL3- 
Basic transfected cells which is set as one. The data demonstrate that the 6xE2- 
3’BpTRAIL-hTERT-VP16E2 specifically induces apoptosis in the telomerase positive 
cells but not in telomerase negative cells. Also, the 6xE2-3’BpTRAIL is not active in 
the absence of VP16E2. The ability o f both the canine and human TRAIL to induce 
apoptosis in human cells is again confirmed.
TRAIL protein expression was confirmed in 293-T cells by Western blot. Cells 
were transfected with the same plasmids as used in the TUNEL stain and cells were 
harvested 24 hours post transfection. Membranes were probed with a TRAIL antibody 
and a gammatubulin antibody as a loading control. In figure 3.1.32 the Western blot 
confirms the TRAIL induced apoptosis pattern observed in the TUNEL stain.
A Western blot was performed in the same way on lysates from the U 20S cell 
line using the same plasmids and antibodies. The cells were harvested 48 hours after 
transfection and lysates were examined by Western blotting. The results confirm the 
TRAIL induced apoptosis observed with the TUNEL stain.
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Figure 3.1.32
Figure 3.1.32: TRAIL expression in telomerase positive hum an 293-T cells 
detected by W estern blot.
W estern blot showing the expression o f  TRA IL in 293-T cells 24 hours after 
transfection, a) M em brane probed with gam m atubulin  antibody as loading control, b) 
M em brane probed with anti-TRA IL antibody. M olecular w eight m arker seen on left.
1-C M V -hT R A IL , 2=C M V -cTR A IL , 3 -  6xE 2-3 'B phT R A IL -hT E R T -V P16E 2, 4= 
6xE 2-3’BphTRAIL, 5=pG L3-Basic.
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Figure 3.1.33
4 9 k D —
1 2  3 4 5
Figure3.1.33: TRAIL expression in telomerase negative hum an U 20S cells 
detected by W estern blot.
W estern blot showing the expression o f  TRA IL in U 2 0 S  cells 48 hours after 
transfection, a) M em brane probed with gam m atubulin  antibody as loading control, b) 
M em brane probed with anti-TRA IL antibody. A rrow  m arks the location o f  the TRAIL 
protein. M olecular weight m arker seen on left.
l=pG L3-B asic, 2=C M V -hTR A lL , 3=C M V -cTR A IL , 4= 6xE 2-3’B phTRA IL-hTER T- 
VP16E2, 5= 6xE2-3 'B phTR A IL .
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3.1.9 Im proving the two step amplification system
H aving show n that the V P16E2 is m ore active transcriptional activator than the 
G al4-V P16E2 and that the hTER T prom oter allow s for higher specificity than the hTR 
prom oter and that these elem ents com bined w ith the TRAIL gene are able to 
specifically  induce apoptosis in telom erase positive w hilst not in telom erase negative 
cells it w as sought to attem pt other im provem ents to the TSTA  system  to m axim ise its 
efficiency.
3.1.9.1 Allogeneic versus xenogeneic TERT prom oter.
In chapter 3.1.4 it w as seen that the hum an telom erase prom oters are very active 
in canine telom erase positive cells. Studies have been done (H orikaw a et al. 2005) 
com paring the activity o f  the m ouse and the hum an TERT prom oter in m ouse and 
hum an cell lines. From  these studies it was revealed that the activity o f  the m ouse 
TER T prom oter is not reflected by telom erase activity in the cells due to the lack o f  a 
C C CC G C C C  sequence upstream  o f  the TERT transcriptional start site. This specific 
sequence is responsible for down regulating TER T prom oter activity  in telom erase 
negative cell lines. It was also show n that by introducing this specific sequence into the 
m ouse prom oter the prom oter could be tightly regulated in relation to telom erase 
activity. The m ouse TER T prom oter was shown to be a stronger prom oter than the 
hum an TER T prom oter in hum an cells also after introduction o f  the regulatory sequence 
(H orikaw a et al. 2005). This could suggest that the use o f  xenogeneic prom oters for 
gene therapy is an advantage and it was therefore investigated if  there was a difference 
betw een the activity o f  the core hum an and canine TERT prom oters in hum an and 
canine cells. An alignm ent o f  the prom oter sequence upstream  o f  the TERT 
transcription start site o f  the canine and hum an TER T prom oters revealed that the TERT 
repressive elem ent is conserved in the canine species as shown in figure 3.1.34.
To com pare the basic transcriptional activity o f  the hum an and canine core 
telom erase prom oters, transcription assays were perform ed using plasm ids containing a 
hum an or canine telom erase prom oter, responsible for transcription o f  a firefly 
luciferase gene. The hum an 536 base pair core hTER T (hTERT-LU C 536bp) prom oter 
was used and com pared w ith the 314 base pair (dogTERT-LU C 314bp) and the 665 
base pair (dogTERT-LU C 665bp) canine core TER T prom oters (Long et al. 2005) as
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shown schematically in figure 3.1.35. Transcription assays were carried out in human 
telomerase positive 293-T cells and canine telomerase positive MDCK cells. Cells were 
transfected with titrations of hTERT-LUC 536 bp, dogTERT-LUC 665 bp or dogTERT- 
LUC 314 bp. Calcium phosphate was used as a transfection agent for the 293-T cells 
and the MDCK cells were transfected with Trans-IT. Transcription assays were 
performed 3 times in duplicate and all results were normalised against protein present in 
each sample. Results are shown as fold increase in transcription compared to cells 
transfected with lpg  pGL3-Basic reporter vector on its own.
As seen in figure 3.1.36 all promoters are transcriptionally active in both cell 
types. The dogTERT-LUC 665 bp promoter is very active compared to the hTERT- 
LUC 536 bp promoter at lOOOng concentration in the human cell line 3.1.36 a) this 
effect is though diminished when taking the error bars into account and the effect is lost 
at the 2000ng plasmid concentration. A similar trend is evident in the canine cell line 
3.1.36 b) however, as previously when error bars are taken into account, the effect is 
diminished and the effect is lost at 2000ng. The experiment shows that the TERT 
promoters are active at the same level in cells from other species but does not show a 
direct advantage of using a xenogeneic promoter.
158
Figure 3.1.34
CCCTCCCCCGGCCCGCCCCTTCCTC-CCGCGGACCCCGCCC-CTCCCCG—GC -1  d og TERT
i l l ! ! ! !  j j j j j j j j ! I j I j ! ! ! ! ! !  ! ! ! ! ! ! ! ! !  MM II II
CCCTCCCA-GCCCC TCCCCTTCCTTTCCGCGG- CCCCGCCCTCTCCTCGCGGC -u hTERT
Figure 3.1.34: Alignment of canine and human TERT promoter repressive 
element.
Alignment of the human and canine TERT promoter upstream of the ATG start site for 
the TERT gene. Alignment shows conservation of the CCCCGCCC TERT repressive 
element in both species.
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Figure 3.1.35
w
Firefly Luciferase
|  dogTERT promoter 314bp Firefly Luciferase
Firefly Luciferase
Figure 3.1.35: Schematic model of hum an and canine telomerase plasmids
Figure represents schem atic m odels o f  the hum an and the two canine telom erase 
prom oter plasm ids.
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Figure 3.1.36
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Figure 3.1.36: Transcriptional activity of human and canine telomerase promoters 
in hum an and canine cells.
a)293-T cells, b)MDCK cells. Cells were transfected with different amounts of hTERT- 
Luc 536 bp, dogTERT-Luc 314 bp or dogTERT-Luc665 bp as indicated.
Bars represent fold increase in luciferase expression compared to cells transfected with 
lOOOng pGL-3 Basic plasmid alone. Figures represents summary o f 3 experiments 
carried out in duplicate. Standard error bars are shown.
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3.1.9.2 Introducing an extra VP16 sequence to the two step amplification system.
An increase in the number o f VP 16 coding sequences has been shown to 
increase transcriptional activity significantly in conjunction with the Gal4VP16 
transcriptional activator fusion protein. It was shown that a VP 16 tandem construct 
initiated a higher level of transcriptional activity than the single construct however by 
further increasing the number o f VP 16 sequences from two to four a reduction in 
transcriptional activity was seen due to squelching (Zhang et al. 2002). To measure this 
effect in conjunction with the VP16E2, an extra 78 amino acid VP 16 element was 
cloned upstream from the VP16E2. A schematic representation of the cloning process is 
illustrated in figure 3.1.37. A 5’ VP 16 primer was made with a 18 base pair tail coding 
for the last 18 base pairs of the VP 16 sequence. Likewise a 3’ primer was made with a 
tail coding for the 18 first base pairs o f the VP 16 sequence. A PCR reaction was set up 
with the tailed 5’ primer and a 3’ E2 primer with a Xba I tail using the pCG-VP16E2 as 
template. A second reaction was set up with the 3’ tailed primer and a 5’ VP 16 primer 
with a Hind III tail using the pCG-VP16E2 as template. Following this a third PCR 
reaction was set up using the 5’ VP 16 Hind III tailed primer and the 3’ E2 Xba I tailed 
primer using 1 pi of the product from the first and the second PCR mixed as template. 
The resulting PCR product contained two VP 16 sequences and was digested and cloned 
as previously described into the pGL3hTP19 plasmid containing the TERT promoter as 
described in section 3.1.2. The resulting plasmid was named hTERT-VP16VP16E2 and 
is schematically presented in figure 3.1.38.
In order to determine if there was any increase in transcriptional activity with 
incorporation of an extra VP 16 sequence, transcription assays were performed in 293-T 
cells. Cells were transfected using calcium phosphate with titrated amounts of either 
hTERT-VP16E2 or hTERT-VP16VP16E2. All cells were co-transfected with lpg  of the 
6xE2-3’BpTATA reporter vector. Transcription assays were performed 3 times in 
duplicate and all results were normalised against protein present in each sample. Results 
are shown as fold increase in transcription compared to cells transfected with 1 pg 6xE2- 
3’BpTATA only.
The results from the transcription assays are summarised in figure 3.1.39. The 
hTERT-VP16VP16E2 does show a higher level o f transcriptional activity than the 
hTERT-VP16E2. This effect however is diminished when taking the error bars into 
account. The small increase in transcriptional activity must also be taken into account of
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the additional size of the protein which could be a disadvantage in space limited gene 
delivery vectors.
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Figure 3.1.37 
a)
Primer 3 5 ’E2 with18bp tail o f  V P 1 6  end Primer 2 3 'V P 16  with 18bp tail of  V P 1 6  start
VP 16E2 Tem plae
Primer 1 5 ’V P 1 6  with Hindlll tail
Primer 4  3 ’E1 Xba I ta
b)
Product from PCR 1 with primers 1 and 2 Product from PCR 2 with primers 3 and 4
18bp tail of  V P 1 6  start
Hind III tail
18bp tail of  V P 1 6  end
c)
PCR 3 with primers 1 and 4
Mix of products form PCR la n d  2 u se d  a s  template
W h en  denatured  and following anneal ing  t h e s e  products can  stick together  forming a template  with a tandem  VP1t  
Primer 1 x -------------------
Primer 4
Product from PCR 3 with primers 1 and 4
Xba I tail
Hind III tail
=VP16 tem plate ■  =E2 template
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Figure 3.1.37: Cloning of a tandem VP16 construct.
a) Model o f template and primer binding sites, b) Products from PCR 1 and 2 using 
primer sets 1+2 and 3+4 respectively, c) Schematic representation o f template and 
products from PCR reaction 3. A mix o f the products from PCR 1 and 2 is used as 
template. When these are mixed they form a tandem VP 16 template which when used in 
reaction with primers 1 and 4 allows for the production of a tandem VP 16 PCR product. 
The resulting tandem VP 16 product can be cloned like a normal PCR product.
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Figure 3.1.38
>
g j hTERT 536bp E V P 1 6  | E2
----------- ►
■ hTERT 536bp 1 V P 1 6  | V P 1 6 [ E2
Figure 3.1.38: hTERT expression vector with one or two VP16 sequences
Schem atic m odels o f  hTERT driven V P16E2 expression plasm ids containing either one 
or two VP 16 coding sequences fused to one E2 coding sequence.
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Figure 3.1.39
293-T
■  hTERT-VP16E2 
□  hTERT-VP16VP16E2
1ng 10ng 100ng 1000ng
Figure 3.1.39: Effect of one versus tw o VP16 coding sequences.
293-T cells were transfected w ith different am ounts o f  either hTER T-V P16E2 or 
h f E R  T-VP16V P16E2. Cells were co-transfected with lOOOng 6xE 2-3 'B pT A T A  
reporter plasm id. Results are presented as fold increase in luciferase expression relative 
to cells transfected with lOOOng 6xE 2-3 'B pT A T A  reporter plasm id alone. Figure 
represents sum m ary o f  3 experim ents carried out in duplicate. Standard error bars are 
shown.
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3.1.9.3 The effect of increasing the number of E2 sites.
The effect of increasing the number of E2 binding sites to increase 
transcriptional activation of the BPV-4 promoter has been studied in detail (Vance et al. 
1999). Here it was shown that increasing the number of E2 binding sites increased the 
transcriptional activity proportionally. It was therefore sought to determine if  this effect 
would be seen in conjunction with the hTERT-VP16E2 two step amplification system. 
The PV2 x4E2, PV2 x8E2 and PV2 xl2E2 plasmids were previously made (Vance et al. 
1999). These plasmids contain a mutated minimal promoter derived from the BPV-4 
promoter responsible for transcription of a firefly luciferase reporter gene and have 4, 8 
and 12 upstream E2 binding sites as illustrated in figure 3.1.40. To determine the effect 
of the E2 binding sites, transcription assays were performed in 293-T cells. Cells were 
transfected using calcium phosphate with serial dilutions of PV2 x4E2, PV2 x8E2 or 
PV2 xl2E2. In conjunction all cells were co-transfected with lpg hTERT-VP16E2. 
Transcription assays were performed 3 times in duplicate and all results were 
normalised against protein present in each sample. Results are shown as fold increase in 
transcription compared to cells transfected with lpg  pGL3-Basic reporter vector on its 
own. Results from the transcription assays are shown in figure 3.1.41. As seen in the 
figure, no increase in transcriptional activity is seen in relation to increase in E2 binding 
sites. The extra E2 binding sites in fact result in a slight decrease in transcription. The 
BPV 4 promoter has been shown to be more responsive in epithelial cell lines and it was 
therefore investigated if a response to an increase in E2 binding sites could be elicited in 
an epithelial cell line. The above experiment was therefore repeated in the C33a cell line 
which is a keratinised epithelial cell line. The result from the experiment is shown in 
3.1.42. It is seen that there is a correlation between increase in transcriptional activity 
and increasing the number of E2 binding sites. This indicates that the VP16E2 system 
could be specifically suitable for targeting gene expression in epithelial cells due to the 
origin of the 6xE2-3’bpTATA promoter from an epitheliotrophic virus.
169
Figure 3.1.40
4xE2
8 x E 2
E2 E2 E2 E2 BPV-4 p rom ote r PV2 Firefly L uciferase
CMLLI
CMLLI E2 E2 E2 E2 E2 E2 BPV-4 p ro m o te r  PV2 Firefly Luciferase
12xE2
E2 E2 E2 E2 E2 E2 E2 E2 E2 E2 E2 <B P V ^>£»^m ote^P V 2 |iiM Firefly L uciferase
Figure 3.1.40: E2 responsive reporter plasmids.
Schem atic model o f  E2 responsive reporter plasm ids w ith 4. 8, and 12 E2 sites. 
P lasm ids contain the BPV-4 prom oter PV2 upstream  o f a firefly luciferase gene.
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Figure 3.1.41
293-T
300 n
250
1ng 10ng 100ng 1000ng
Figure 3.1.41: Increase in E2 sites has no effect in 293-T cells.
293-T cells were transfected with different am ounts o f  either 4xE2, 8xE2 or 12xE2 
reporter vector as indicated. In addition lOOOng hTER T-V P16E2 expression vector was 
co-transfected into the cells. Each bar represents fold increase in luciferase expression 
com pared to cells transfected with lOOOng pG L3-B asic alone. Figure represents 
sum m ary o f  3 experim ents carried out in duplicate. Standard error bars are shown. *= P- 
value < 0.05 when com paring 4xE2 with 8xE2.
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Figure 3.1.42
C33a
180
160
140
| 120 '£3 Q-
'g 100
V)
2 80 
I60
40
20
0 J---- — —  ----- ^
1ng 10ng
Figure 3.1.42: Increase in E2 sites has no effect in C33a cells.
C 33a cells were transfected with different am ounts o f  either PV 2-4xE2. PV 2-8xE2 or 
PV 2-12xE2 reporter vector as indicated. In addition lOOOng hTER T-V P16E2 
expression vector was co-transfected into the cells. Each bar represents fold increase in 
luciferase expression com pared to cells transfected with lOOOng pG L3-B asic alone. 
Figure represents sum m ary o f  3 experim ents carried out in duplicate. Standard error 
bars are shown.
100ng 1000ng
■  4xE2
□  8xE2
□  12xE2
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3.1.9.4 Stabilising E2 by mutation of serine residue 301.
It was shown that mutation o f the bovine papilloma virus E2 protein serine 
residue 301 phophorylation site allowed the virus to replicate at a higher copy number 
than the wild type virus (McBride & Howley 1991). It was therefore anticipated that 
such a mutation introduced to the VP16E2 fusion protein would create a more stable 
protein. The serine 301 in the E2 of the hTERT-VP16E2 plasmid was therefore mutated 
to an alanine. This was done by site directed mutagenesis (see materials & methods). 
Mutations were confirmed by sequencing and the mutated plasmid named hTERT- 
VP16E2 Mut 301. Western blots were then performed in order to look at the stability of 
the protein. 293-T cells were transfected with either 1 jug or 0.1 pg hTERT-VP16E2 or 
hTERT-VP16E2 Mut 301. Normal protocol for western blot was carried out and the 
membrane was probed with an antibody against VP 16 and gammatubulin as a loading 
control. As seen in figure 3.1.43 an increase in protein is detected in the hTERT- 
VP16E2 Mut 301 samples. This is especially noticeable in the 0.1 pg concentration in 
which no protein is detected in the hTERT-VP16E2 sample while a clear band is 
observed in the hTERT-VP16E2 Mut 301 sample. The gammatubulin loading control 
reflects the amount of protein loaded and indicates that less protein has been loaded in 
the lpg  hTERT-VP16E2 Mut 301 lane making the effect even more pronounced.
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Figure 3.1.43
G a m m a t u b u l i n
V P1 6E 2
4 9 k D a
2 8 k D a
h T E R T -V P1 6E 2  h T E R T -V P 1 6E 2  M ut  301
ipg o.ipg ipg o.ipg
Figure 3.1.43 Protein expression of VP16E2 and VP16E2 M ut 301.
W estern blot show ing the expression o f  the V P16E2 and the V P16E2 M ut 301 both 
under transcriptional control by the hTER T prom oter in 293-T  cells. M em brane probed 
with antibody against VP 16. G am m atubulin antibody used as loading control. 
M olecular weight m arker shown to the right.
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3.2 Applying the system to a viral system.
The results in chapter 3.1 demonstrate that the two step amplification system in 
conjunction with the VP16E2 and the hTERT promoter provides a potential means of 
targeting a strong level o f transgene expression to telomerase expressing cells. A major 
obstacle in cancer gene therapy is finding a reliable in vivo transgene delivery 
mechanism. In order to overcome this obstacle and target cell killing to cancer cells, a 
conditionally replicative cancer specific virus based on the adenovirus CAV-1 was 
constructed. The rationale of utilising such a virus was to exhibit tumour selective viral 
replication and hence cell killing.
To restrict viral replication to cancer cells the two step amplification system in 
conjunction with the hTERT promoter was incorporated into the virus. To accomplish 
this, a virus was designed in which the non-essential viral E3 region and the essential 
El promoter region were eliminated. In place of the E3 region the hTERT-VP16E2 was 
inserted and in place o f the E l promoter the 3’BpTATA with its 6 upstream E2 binding 
sites was inserted. This rendered viral E l gene expression dependent on activation of 
the 6xE2-3’BpTATA promoter by the VP16E2 fusion protein transcribed by the 
telomerase promoter. The structure of the engineered virus genome and its predicted 
function is depicted in figure 3.2.1.
The virus construct used as a starting point for the cloning was the fAEl AE3 
CAV-1 cosmid. This is a CAV-1 DNA sequence which has been cloned into a cosmid. 
The full length viral El and E3 gene has been removed from this construct such as seen 
schematically in figure 3.2.1 a).
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a ) AE1 AE3
b)
CAV-1
CAV-1 hTERT VP16E2£^TATA
AE1 promoter AE3 region
c)
-Telomerase
+ Telomerase
Figure 3.2.1 Concept of the conditionally replicative canine adenovirus
a) Schem atic representation o f  the fAElAE3 CAV-1 cosmid. b) Schematic 
representation o f  the two step am plification m echanism  in its basic form incorporated 
into the fAEl AE3 CAV-1 in order to create a conditionally replicative CAV-1 virus. 
The hTERT prom oter transcribes the VP16E2 fusion protein which binds to the E2 
binding sites upstream  o f  the m inim al promoter. This prom oter when active transcribes 
the E l gene, allow ing the virus to replicate.
c) Schem atic illustration o f  the effect o f  a telom erase dependent conditionally 
replicative virus in cells with and w ithout telom erase expression. In the telom erase 
negative cells the virus is able to infect the cell but no viral replication occurs and the 
cell survives. In the telom erase positive cell the virus infects the cell and viral 
replication results in production o f  viral progeny. These are released from the cell by 
cell lysis. Viral progeny are then available to infect neighbouring cells.
176
3.2.1 Cloning of the adenovirus AE3 region.
The initial cloning of the sequences to be inserted into the AE3 region was 
carried out in plasmids due to their relatively small size making them relatively 
uncomplicated to work with compared to large cosmids.
3.2.1.1 Preparing the VP16E2 sequence.
To clone the hTERT-VP16E2 into the virus this sequence was first cloned into a 
modified pBluescript vector due to the convenience of its restriction sites. A hTERT- 
VP16E2 PCR product was made using a 5’ and a 3’ primer with a Bgl II tail and the 
hTERT-VP16E2 plasmid as a template. The resulting PCR product was cleaned and 
digested with Bgl II. Then the cut PCR product was cleaned by phenol chloroform and 
ethanol precipitation and the Bgl II sites were blunted using a T4 polymerase. The 
blunted insert was cleaned again by phenol chloroform and ethanol precipitation and 
ligated into an EcoR V digested and phosphatase treated pBluescript vector. Ligations 
were transformed into JM-109 cells. Correct inserts were identified by restriction 
digestion and the resulting plasmid was named pBluescript-hTERT-VP16E2.
As a positive control a pBluescript-CMV-VP16E2 plasmid was created in 
parallel. A CMV-VP16E2 PCR product was made using primers with a 5 ’ and 3’ Pme I 
overhang using the pDNA-CMV-VP16E2 plasmid as a template. The PCR product was 
digested and ligated into a Pme I digested phosphatase treated pBluescript vector and 
transformed into JM-109 cells. The resulting vector was named pBluescript-CMV- 
VP16E2. The two pBluescript vectors are illustrated schematically in figure 3.2.2 a).
It was decided to insert the hTERT-VP16E2 and CMV-VP16E2 inserts into a 
KVlucXX plasmid. This plasmid is derived from the pBluescript plasmid and contains 
sequence coding for upstream and downstream regions around the E3 gene region from 
the CAV-1 genome, separated by a multiple cloning site. By using the KVlucXX 
plasmid the AE3 inserts could be inserted into the virus by homologous recombination. 
The hTERT-VP16E2 and CMV-VP16E2 sequences were cut out of the pBluescript 
vector by Pme I restriction digestion and the inserts were isolated by gel electrophoresis 
followed by gel purification. The cleaned inserts were then ligated into a Pme I 
digested and phosphatase treated KVlucXX vector. Ligations were transformed in JM- 
109 cells. Correct inserts were confirmed by restriction digestion. The inserts could be 
inserted with the promoters driving either clockwise or anticlockwise resulting in the
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following constructs KVlucXX-hTERT-VP16E2 FOR, KVlucXX-hTERT-VP16E2 
REV, KVlucXX-CMV-VP 16E2 FOR and KVlucXX-CMV-VP16E2 REV where FOR 
and REV refers to clockwise and anticlockwise directions. The clockwise constructs are 
schematically illustrated in figure 3.2.2 b).
3.2.1.2 Insertion of the VP16E2 element in the AE3 region.
The hTERT-VP16E2 and CMV-VP16E2 were inserted into the viral AE3 region 
by homologous recombination as schematically illustrated in figure 3.2.3. We took 
forward in the construct with the promoters transcribing in a clockwise direction. The 
fAEl AE3 CAV-1 cosmid was linearised by restriction digest with Pme I and cleaned by 
phenol chloroform ethanol precipitation. The Pme I restriction enzyme cuts the 
fAElAE3 CAV-1 cosmid at the place were the E3 gene was removed from the 
sequence. The KVlucXX-hTERT-VP16E2 FOR and KVlucXX-CMV-VP16E2 FOR 
plasmids were digested with Hpa I which cut out the promoters, the transcriptional 
activator and a large fragment of the upstream and down stream E3 flanking sequence. 
The excised fragments were cleaned and isolated by gel electrophoresis and gel 
purification. Approximately 300ng purified insert was mixed with 100 ng linearised 
fAElAE3 CAV-1 cosmid and electroporated into BJ5183s electrocompetent E.coli cells. 
Inserts were confirmed by restriction digestion with Pme I, diagnostic PCR and 
sequencing. Due to the poor DNA quality obtained with the BJ5183s cells, constructs 
with correct inserts were retransformed into chemically competent Stbl 2 cells to be able 
to obtain larger quantities of better quality DNA. The resulting cosmids were named 
CAV-1-hTERT-VP 16E2 and CAV-1- CMV-VP16E2.
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Figure 3.2.2
P m e l v  E c o R V  / Bglll
\ i
E c o R V /B g l l l  P m e l
hTERT VP16 E2
P m e l P m e l
i
CMV IVP16 ![ eT
b)
Hpal Pmel
pBluescript
II .- , .
W-1 ^CAV-
23127bp - 24870bp
hTERT VP16 E2 M CAV-1
Hpal
25714bp - 27152bp
pBluescript
AE3
Hpal
pBluescript
1
Hpal
CAV-1 CMV VP16 E2 CAV-1 pBluescript
23127bp - 24870bp 2 5 7 1 4 b p - 27152bp
AE3
Figure 3.2.2 Schematic illustration of the vectors cloned to clone the AE3 region 
into the CAV-1 virus.
a) Schematic representation o f  the pBluescript-hTERT-VP16E2 and pBluescript-CMV- 
VP16E2 plasmids.
b) Schematic illustration o f  the KvlucXX-hTERT-VP16E2 and KvlucXX-CM V- 
VP16E2 plasmids in which the hTERT-VP16E2 and CM V -V P16E2 inserts are placed 
in between DNA coding for viral DNA upstream and downstream o f  the E3 gene 
region.
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3.2.2.1 Insertion of the E l coding sequence.
The fAElAE3 cosmid is lacked the E l gene however still contained the E l 
promoter region. This promoter region was excised by a homologous recombination 
step in which the 6xE2-3’BpTATA and the E l coding region would be inserted into the 
cosmid. The exact extent of the El promoter sequence in the CAV-1 virus is not known. 
The E l promoter region to be excised from the final virus was therefore estimated by 
sequence comparison with other adenoviruses. The E l promoter was estimated to be 
contained in the sequence between base pairs 281-416 in the CAV-1 genome. The 
complete E l insert to be inserted by homologous recombination in the AE1 site of the 
fAEl AE3 cosmid consisted of sequence upstream of the El promoter region for 
homologous recombination, the 6xE2-3’BpTATA promoter, the full length El gene and 
sequence downstream of the El gene for homologous recombination. The sequence 
upstream of the E l promoter region was named Leftend. The Leftend consisted of viral 
sequence from base pair 0-281, thereby avoiding the E l promoter region and having 
additional base pairs upstream to allow for homologous recombination. It was decided 
to incorporate 835 base pairs of upstream cosmid sequence due to the location of 
convenient restriction sites.
As a starting point the E l insert was cloned in the pGL3-Basic vector. A PCR 
product was made of the Leftend sequence using primers with a 5’ EcoR V restriction 
site and a 3’ Xho I restriction site and using the fAElAE3 cosmid as template. The 
pGL3-Basic vector was cut with Kpn I and Xho I and following the Kpn I site was 
blunted by treatment with T4 DNA polymerase. The vector was phophatase treated and 
the PCR products were cut with EcoR V and Xho I and ligated into the vector. Ligations 
were transformed into JM-109 cells and correct clones were confirmed by restriction 
digestion and sequencing. The resulting vector was named pGL3-Basic-Leftend as 
shown in figure 3.2.4 a).
Next, the 3’BpTATA promoter and upstream E2 binding sites were inserted 
downstream of the Leftend sequence. The 6xE2-3’BpTATA insert was constructed as a 
PCR product using the 6xE2-3’BpTATA vector as template. The 5’primer used in this 
reaction had a tail encoding a Xho I restriction site while the 3’ primer had a tail 
encoding a Sma I, Pmel and a Xho I restriction site. The PCR product was digested with 
Xho I and ligated into the pGL3-Basic vector which had been digested with Xho I and 
Sal I and then phophatase treated. The Xho I and Sal I restriction sites have compatible
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ends and the PCR product could be inserted in either direction; however only the 
clockwise insertion was of interest. Correct inserts were confirmed by restriction 
digestion and the resulting vector was named pGL3-Basic-Leftend-6xE23’BpTATA as 
seen in figure 3.2.4 b).
It has been shown that viral sequence can exhibit enhancer activity which can 
affect and activate downstream promoters. In order to counteract this potential risk it 
was decided to insert a poly-AAA sequence in between the Leftend sequence and the 
6xE2-3’BpTATA sequence. Others have reported a possible positive effect on 
regulation of non viral promoters by inserting a poly-AAA sequence to isolate the 
promoter from cis-acting viral sequence (Hoffmann et al. 2005). The poly-AAA insert 
was made as a PCR product using the pGL3-Basic vector as a template and using 
primers with a 5’ Sal I restriction site and a 3’ Xho I restriction site. The PCR product 
was digested with Xho I and Sal I and ligated into the pGL3-Basic-Leftend-6xE2- 
3’BpTATA vector which had been cut with Xho I and phosphatase treated. Clones with 
inserts in the correct orientation were confirmed by restriction digestion and sequencing. 
The resulting plasmid was named pGL3-Basic-Leftend-PolyAAA-6xE2-3’BpTATA 
and is shown schematically in figure 3.2.4 c).
To test the effect of the poly-AAA sequence, transcription assays were 
performed. The pGL3-Basic contains a firefly luciferase reporter gene and therefore 
luciferease transcription assays could be performed as previously. 293-T cells were 
transfected with lpg 6xE2-3’BpTATA, lpg  pGL3-Basic-Leftendl-6xE2-3’BpTATA or 
lpg  pGL3-Basic-Leftend-PolyAAA-6xE2-3’BpTATA, alone or in conjunction with 
titrations of pCG-VP16E2. The experiment was repeated 3 times in duplicate and results 
were normalised against protein present in each sample. Results are shown as fold 
increase in transcription compared to cells transfected with lp g  pGL3-Basic only. As 
seen in figure 3.2.5, in absence of VP16E2 the Poly-AAA sequence decreases the 
activity of the 6xE2-3’BpTATA promoter downstream of the Leftend sequence. A 
small increase in transcriptional activity is seen in pGL3-Basic-Leftend-PolyAAA- 
6xE2-3’BpTATA transfected cells compared to 6xE2-3’BpTATA transfected cells in 
presence of VP16E2, arguing that the Poly-AAA sequence has a positive effect on 
promoter regulation and should be included in the final construct.
The final element to be included in the E l insert was the El gene and sequence 
downstream from this gene region. The LASC cosmid (see materials and methods) was 
digested with Fsp I and a 5080 base pair fragment was isolated and cleaned by gel
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electrophoresis and gel purification and named E1++. This fragment consists of the full 
length CAV-1 E l gene region which is 2610 base pairs in length flanked by 38 base 
pairs of upstream E l sequence and 2432 base pairs of downstream E l sequence, the 
latter to be used for homologous recombination. The PGL3-Basic-Leftendl-PolyAAA- 
6xE2-3’BpTATA vector was digested with Sma I and phophatase treated, and the E1++ 
fragment was ligated into it. The ligation was transformed in JM-109 cells and correct 
inserts confirmed by sequencing and restriction digestion. The resulting vector as 
illustrated in figure 3.2.4 d) was named PGL3-Basic-Leftendl-PolyAAA-6xE2- 
3’BpTATA-El++.
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Figure 3.2.4
a)
K pn l/E coR V  P m el
I /
PGL3-Basic 1 T — Firefly Luciferase
b)
S m al P m e l X h o l/S a ll
1 / --------- 1
Cosmid Leftend 6xE2 sites 3’BpTATA 1 Firefly Luciferase
C)
K pn l/E coR V  P m el
X h ol/S a ll X hol/X hol S m a l P m e l X hol/Sall
Cosmid Leftend AAA 6xE2 sites 3’BpTATA | Firefly Luciferase
d)
K pnl/E coR V  P m el
X h ol/S a ll X hol/X hol
F sp l/S m a l  
S m a l/F sp l \  P m el
PGL3-Basic Cosmid Leftend AAAI 6xE2 sites 1 3’BpTATA E1 ++
Figure 3.2.4: Cloning of the AE1 insert.
Schematic representation o f  the cloned constructs used to make the AE1 insert. Models 
not to scale. Cosmid fragment highlighted in light pink. Virus fragment highlighted in 
dark pink. Vector backbone highlighted in black. El promoter substitute highlighted in 
grey.
a) pGL3-Basic -Leftend.
b) pGL3-Basic -L eftend-6xE 2-3 ’BpTATA,
c) pGL3-Basic -L eftend-PolyA A A -6xE2-3‘'BpTATA,
d) pGL3-B asic-Leftend-PolyA A A -6xE2-3 'B pTA TA -El++
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Figure 3.2.5
293-T
500
450
400
c 350 o
.9- 300
g 250
200
150
100
50
0
R eporter only
■  6xE2-3'BpTA TA
□  Leftend-6xE2-3'BpTATA
□  Leftend-PolyA A A -6xE2-3'B pTA T A
100ng pCG - 
V P 1 6 E 2
1000n g  pCG- 
V P 1 6 E 2
Figure 3.2.5: Evaluating the effect of the Poly-AAA sequence on prom oter activity.
293-T cells were transfected with 1 pg 6xE2-3‘BpTATA, 1 pg Leftend l-6xE2- 
3*BpTATA or 1 pg pGL3-Basic -Leftend  1-PolyA A A -6xE2-3 'B pTA TA  alone or co­
transfected with titrations o f  pCG-VP16E2 as indicated. Results are shown as fold 
increase in luciferase expression compared to sample transfected with lOOOng pGL3- 
Basic only. Experiments carried out 3 times in duplicate. Standard error bars are shown
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3.2.2.2 Insertion of the E l region into the CAV-l-hTERT-VP16E2 and CAV-1- 
CMV-VP16E2.
The El sequence was inserted into the CAV-l-hTERT-VP16E2 and CAV-1 - 
CMV-VP16E2 cosmids by homologous recombination. The pGL3-Basic-Leftendl- 
PolyAAA-6xE2-3’BpTATA-El++ plasmid was digested with Pme I and the insert for 
the E l region was isolated and purified by gel electrophoresis and gel purification. The 
CAV-1 -hTERT-VP 16E2 and CAV-1- CMV-VP16E2 cosmids were linearised by I-Ppo 
I digest which cuts this cosmid at the site were the E l gene was originally excised. 
Approximately 300ng purified insert was mixed with 100 ng linearised CAV-1-hTERT- 
VP16E2 or CAV-1- CMV-VP16E2 cosmid and electroporated into BJ5183s 
electrocompetent E.coli cells. By this insertion the E l promoter region from base pair 
282-415 in the CAV-1 genome was removed from the cosmids. The homologous 
recombination is schematically illustrated in figure 3.2.6. Inserts were confirmed by 
restriction digestion with Hind III and Xho I, diagnostic PCR and sequencing. Due to 
the poor DNA quality obtained with the BJ5183s cells, constructs with correct inserts 
were retransformed into Stbl 2cells to be able to obtain larger quantities of better quality 
DNA. The resulting cosmids were named CAV-1-hTERT+El and CAV-1- CMV+E1 
and are illustrated schematically in figure 3.2.7. EcoR I restriction digestion of mutant 
virus and wild type virus cosmids as shown in figure 3.2.8 was conducted to assure 
DNA quality and correctly sized bands, indicating no unwanted recombination reaction 
had taken place. The bands on figure 3.2.8 were of predicted size indicating that no 
gross abnormalities of the mutant viruses were present.
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Figure 3.2.8
1 * 5 * ?
± t  T f T t
“  X  331 331 T S R T C M V
Figure: 3.2.8 Restriction digest of viral cosmid DNA
Figure showing restriction digest o f  wild type viral DNA in cosmid and mutant viruses 
in cosmids. 1 kilo base ladder and X  Hind III phage ladder shown on the left. 331 refers 
to the wild type virus. TERT and CM V refers to the CA V -1-hT ER T+El and CAV-1- 
CMV+E1 viruses respectively.
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3.2.3 Production of live virus.
To produce live virus, the cosmids containing the viral sequence were digested 
to separate the cosmid backbone and the virus DNA and was then transfected into 
canine cells.
3.2.3.1 Digestion and transfection of virus.
In order to separate the viral DNA sequence from the cosmid backbone, the CAV-1- 
hTERT+El and CAV-1- CMV+E1 cosmids were digested with Fse I. After the 
digestion the reaction was heat inactivated and cleaned by ethanol precipitation. The 
digested product was resuspended in a small volume of ddE^O. Approximately 5pg cut 
cosmid DNA was transfected into MDCK cells using the nucleofector L-Kit as 
described in materials and methods. Cells were incubated at 37°C in 5% CO and every 
3-4 days 2 ml fresh medium was added to the plates. 14 days after transfection the cell 
plates transfected with CAV-1-hTERT+El showed almost 100% cell death. Cell death 
was observed as cells curling up and detaching from the cell plate. No cell death was 
observed in the CAV-1-CMV+E1 transfected cells. In parallel a positive control wild 
type CAV-1, named 331, was digested and transfected in the same manner as the 
mutant viruses (this wild type virus was digested with I-Sce I instead of Fsp I). The wild 
type virus induced 100% cell death in the nucleofecter transfected cells 10 days after 
transfection. A summary of the cloning process and the generation of live virus is 
shown in figure 3.2.9.
Similar tranfections were repeated in two El complementary cell lines MDCK 
P-3.1 and MDCK Fspl .9 in order to test whether the lack of cell death observed with 
the CAV-1- CMV+E1 could be related to a fault in either the E l gene or the CMV 
promoter. Cell death was observed in both cell lines transfected with either wild type 
virus 331 or CAV-1-hTERT+El. In contrast no cell death was observed in El 
complementing cells transfected with CAV-1- CMV+E1, suggesting that this virus is 
defective in an area other than the E l gene.
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3.2.3.2 Harvest of virus and generation of virus stock.
At the presence of nearly 100% cell death the above mentioned cell plates 
transfected with wild type virus 331 and mutant virus CAV-1-hTERT+El were 
harvested as described in materials and methods. This harvested virus was regarded as 
primary virus stock. Larger volumes of secondary virus stock were made by inoculating 
a T-75 and T-175 cell flask with MDCK cells and 1ml primary virus stock from wild 
type virus 331 and mutant virus CAV-1-hTERT+El respectively. The wild type virus 
was left to replicate for 2 days and the mutant virus CAV-1-hTERT+El was left to 
replicate for 4 days before the virus was harvested, aliquoted and frozen at -80°C.
3.2.3.3 Determining virus concentration in telomerase positive canine cells.
To determine the concentration and infectivity of the secondary virus stocks TCID50
assays were carried out as described in materials and methods. 96-well plates were
infected with half log dilutions of wild type virus 331 or mutant virus CAV-1 -
hTERT+El with four replicates for each dilution. The lowest dilution tested was 10'1
11 ^and the highest dilution was 1 O' . Cells were examined daily and 8 days after infection 
the final level o f cell killing was observed and the TCID50 determined. In figure 3.2.10 
the results from the TCID50 assay are schematically illustrated. The TCID50 was 
determined using the formula:
Log TCIDso= D-A(S-0.5)
Plaque forming units pr ml was following calculated as:
Pfu = (1/10 L°sTCID») xl0x0.69.
The Log TCID50 and Pfu for the wild type virus 331 and mutant virus CAV-1 - 
hTERT+El were as follows:
Log TCID50 33i= -7 Pfii33i=6.89 xlO 8Pfu m l'1
Log TCID50 CAV-1-hTERT+El =-2.875 PfUCAV-1 -hTERT+El = 5.17xl03 Pfll ml 1
Based on these calculations MDCK cell plates were infected with 500 Pfu of 
either virus 331 or CAV-1-hTERT+El. The cells were observed on a daily basis.
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Sporadic cell killing was observed with the CAV-1-hTERT+El virus compared to the 
wild type 331 virus which showed cell killing in plaques as shown (figure 3.2.11). The 
more evident, rolled up cells on these pictures represent lysed cells.
The virus was harvested from the infected plates as tertiary virus stock 5 days after 
infection and a new TCID50 assay was set up, using the newly harvested viruses. Plates 
were checked daily and after 8  days a final determination of TCID50 was performed and 
the plates were stained with crystal violet. This stain is taken up by live cells and darker 
staining is seen in live cells while lighter or complete lack o f staining indicates cell 
death. The results from the crystal violet stain are shown in figure 3.2.12. The pattern 
seen is very similar to the pattern observed in figure 3.2.10. A schematic presentation of 
the generation of primary, secondary and tertiary virus stock is presented in figure 
3.2.13.
The TCID50 and Pfu for the tertiary virus were calculated as following.
LogTCID5033i = -6.65 Pfu 331 = 3.08xl07Pfu ml ' 1
LogTCIDso CAV-1-hTERT+El = “2.5 Pftl CAV-1-hTERT+El = 2.18xlQ3 Pftl ml 1
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Figure 3.2.10
a)
b)
c)
1 2 3 4 5 6 7 8 9 10 11 12
A -1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
B -1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
C -1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
D -1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
E - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2  5
F - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
G - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
H - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
1 2 3 4 5 6 7 8 9 10 11 12
A X X X X X - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
B X X X X - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
C X X X X - 3 - 3 . 5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
D X X X X - 3 - 3  5 - 4 - 4 . 5 - 5 - 5 . 5 - 6 - 6 . 5
E - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
F - 7 - 7 . 5 - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
G - 7 - 7  5 - 8 - 8  5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
H - 7 - 7  5 - 8 - 8  5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
1 2 3 4 5 6 7 8 9 10 11 12
A X X X X X X X X X X X X
B X X X X X X X X X X X X
C X X X X X X X X X X X X
D X X X X X X X X X X X X
E X X X - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
F X X - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2  5
G X X X - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1  5 - 1 2 - 1 2 . 5
H X X - 8 - 8 . 5 - 9 - 9 . 5 - 1 0 - 1 0 . 5 - 1 1 - 1 1 . 5 - 1 2 - 1 2 . 5
Figure 3.2.10: Model showing the wells with cell death in the TCID 50 assay on 
secondary virus stock.
a) Negative control plate, b) mutant virus CA V -1-hT ER T+El infected plate, c) 331 
wild type virus infected plate.
Red crosses indicate wells with cytopathic effect. Numbers indicate the log dilution.
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Figure 3.2.11
rti'r'
; ;  • •
Figure 3.2.11: MDCK cells infected with 500 Pfu per plate of secondary virus stock 
4 days post infection
a) Negative control uninfected cells, b) cells infected with wild type 331 virus 500 Pfu 
per plate based on calculations o f  T C ID 5 0 , c) cells infected with mutant virus C A V - 1 - 
hT E R T + E l 500 Pfu per plate based on calculations o f  T C ID 5 0 .
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Figure 3.2.12
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c)
Figure 3.2.12: Crystal violet stained TCID50 plates from tertiary virus
TCID 5 0  assay performed on tertiary virus. Plates stained 8  days after infection, a) mutant 
virus CA V-1-hTERT+El infected plate, b) 331 wild type virus infected plate c) 
Negative control plate.
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3.2.3.4 Eetecting virus DNA by PCR
To assure that no cross contamination had occurred between the wild type virus 
331 and he mutant virus CAV-1-hTERT+El, a diagnostic PCR was performed on the 
secondaiy virus stock. Two PCR reactions were performed using a 5’ primer which 
binds to he beginning of the CAV-1 DNA, and two different 3’ primers. The 3’ primer 
used for eaction 1 binds to the sequence upstream of the E l promoter. The 3’ primer 
used for -eaction 2 binds to the presumed E l promoter sequence. Because the mutant 
virus CAV-1-hTERT+El does not contain the El promoter sequence it was expected 
that only the PCR reaction 1 would result in a PCR product, unless contamination of 
wild type virus had occurred.
Peactions were set up using either 2pl wild type virus 331 or 2pl mutant virus 
CAV-1 -1TERT+E1 as template. 5 reactions were set up for each virus and each primer 
set. PCRreactions were allowed to proceed for 10, 15, 20, 25 or 30 cycles. This was to 
determine whether the clear difference in infectivity from the TCID50 assay would be 
reflectedin the amount of virus DNA present in each stock. As seen in figure 3.2.14, 
reaction I results in PCR products after only 15 cycles for the wild type virus whilst 
only after 20 cycles for the CAV-1-hTERT+El virus indicating that there is a difference 
in the coicentration of the virus, however this does not explain the 5 log difference in 
infectivity seen in the TCID 50 assay. In reaction 2 no PCR product is seen in the 
reactions using the CAV-1-hTERT+El as template indicating that no wild type virus is 
present in the stock. Clear PCR products are seen after 15 cycles in reaction 2 with the 
wild type virus as template.
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Figure 3.2.14
Reaction 1
Reaction 2
A : C A V -1-hT E R T +E l  
A  331
A A A A A A A A A A
10 15 20 25 30 PCR cycles
Figure: 3.2.14: PCR on wild type and m utant virus
PCR using the secondary virus stock o f  mutant virus CAV-1 -hTERT-V P16E2 and the 
wild type 331 virus as template. Reaction 1 was performed using primers with binding 
sites for both viruses. Reaction 2 was performed using primers with binding sites for the 
wild type virus only. Reactions were taken out after 10, 15, 20, 25 and 30 cycles as 
indicated.
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3.2.3.5 Determining cell death in telomerase negative cells
After observing the ability of the mutant virus CAV-1-hTERT+El to induce cell 
lysis in the telomerase positive canine MDCK cell line, the effect was studied in 
telomerase negative canine cells.
A TCID50 assay was set up in two canine telomerase negative cell lines. A 
primary fibrosarcoma cell line and a primary fibroblast cell line which both tested 
telomerase negative in the TRAP assay as described in chapter 3.1.5 were used. The 
TCID50 assay was carried out as for the MDCK cells. Due to the slower growth o f the 
cells, primary fibrosarcoma cells were left to grow for 2 0  days and the primary 
fibroblast cell line for 14 days before the TCID50 was determined and the plates were 
crystal violet stained. In figure 3.2.16 and 3.2.18 the stained cell plates are shown. It 
was apparent in both cell lines that significant cell lysis had occurred in the cells 
infected with virus 331 while cells infected with the CAV-1-hTERT+El virus showed 
no such effect. In figure 3.2.15 and figure 3.2.17 photographs of primary fibroblast and 
primary fibro sarcoma cells respectively from wells infected with the highest and the 
lowest concentration of virus illustrate cell death in the 331 virus infected cells whilst 
no such effect was seen in the CAV-1-hTERT+El infected cells. Log TCID50 and Pfu 
were calculated for the wild type virus 331 and the mutant virus CAV-1-hTERT+El. 
For both cell lines no cytopathic effect was observed with the CAV-1-hTERT+El virus 
and therefore no Log TCID50 and Pfu could be calculated. However as seen below, 
values were calculated for the wild type virus 331 and were higher than those calculated 
in MDCK cells.
Telomerase negative primary fibroblast
LogTCID5033i — 10.375 
LogTCIDso CAV-1-hTERT+El =  0
Pfu 33,=  1.63x10" Pfa ml' 1
P f t l  CAV-1-hTERT+El — 0
Telomerase negative fibro sarcoma cells
LogTCIDso 331= -10.625 
LogTCIDso CAV-1-hTERT+El =  0
Pfu 331 = 2 .90xl0n Pfu ml' 1
Pfu CAV-1 -hTERT+El =  0
2 0 1
Figure 3.2.15
e)
Figure 3.2.15: Pictures of cells from TCID 50 assay in prim ary fibroblasts 14 days 
after infection.
a) 10’ 1 dilution o f  331 virus, b) 10 ’ 1 2 5 dilution o f  331 virus, c) 10’ 1 dilution o f  CAV-1- 
hTER T+El virus, d) l O' 1  ^dilution o f  C A V -1-hTERT+El virus, e) uninfected control 
cells.
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Fgure 3.2.16
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Figure 3.2.16 Crystal violet stained prim ary fibroblast TCID50 plates.
a Plate infected with C A V -1-hTERT+El virus, b) Plate infected with 331 wild type 
v rus, c) negative control uninfected cells.
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Figure 3.2.17
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Figure 3.2.17: Pictures of cells from TCID 50 assay in prim ary fibrosarcom a cells 
2 0  days after infection.
a) 10’1 dilution o f  331 virus, b) lO"12'^  dilution o f  331 virus, c) 10"' dilution o fC A V -1 -  
hTER T+El virus, d) 10’l2 :i dilution o f  C A V -l-hT E R T + E l virus, e) uninfected control 
cells.
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Figire 3.2.18
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Figure 3.2.18: Crystal violet stained primary fibrosarcoma TCID50 plates.
a) Plate infected with CA V -1-hT ER T+El virus, b) Plate infected with 331 wild type 
\irus, c) negative control uninfected cells.
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3..2.4 Detection of viral protein
In order to test whether viral proteins were expressed during viral infection, 
W estern blots were carried using protein lysates from infected cells.
3.2.4.1 Detection of viral protein using polyclonal antibody against human Ad5
MDCK cells were infected with 500 and 1000 PFU of either wild type virus 331 
o r mutant virus CAV-1-hTERT+El. Secondary viral stocks described in chapter 3.2.3.2 
were used and dilutions were based on results from TCID50 assay 3.2.3.3. Cells were 
harvested 3 and 5 days after infection and lysates examined by Western blot. 3 days 
after infection sporadic cell lysis was observed in the CAV-1-hTERT+El infected cells 
while no obvious cell lysis was observed in the 331 infected cells. 5 days after infection 
an increase in cell lysis was observed in the CAV-1-hTERT+El infected cells and in the 
3 31 infected cells clear lytic plaques were observed. It was important to harvest o f cells 
at a time when many cells would be infected and expressing viral proteins but before the 
virus induced cell lysis.
To our knowledge there are no commercial antibodies against canine adenovirus type 1 
available for use in Western blots. The membrane was therefore probed with a 
polyclonal antibody against human adenovirus type 5. The results from the Western blot 
are shown in figure 3.2.19. Several bands appear to be specific for the virus infected 
cells and absent in the negative control lanes. No or low levels of virus specific bands 
were seen in the 331 infected cells harvested 3 days after infections correlating with the 
observed lack of cell lysis. Based on the amino acid sequence of the viral surface 
proteins estimates were made of the protein size, in order to identify the bands on the 
gel as seen in table 3.2.1 (Morrison et al. 1997). In figure 3.2.19 arrows with the name 
o f the putative viral proteins have been placed at bands thought to be specific for virus 
infected cells.
3.2.4.2 Detection of viral protein using canine serum as primary antibody.
Dogs are commonly vaccinated against CAV-1 using a vaccine based on 
attenuated CAV-2 since there is cross reactivity between these two serotypes as 
described in the introduction. It was therefore anticipated that canine serum could be 
used as primary antibody for detection of viral proteins in a Western blot. Canine serum 
samples from the diagnostic laboratory at University of Glasgow Faculty o f Veterinary
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Medcine were pooled and used for detection of canine adenovirus in conjunction with a 
secondary HRP conjugated antibody against canine IgG. MDCK cells were infected 
witl 100, 500 or 1000 Pfu of either wild type virus 331 or mutant virus CAV-1- 
hTIRT+El or left uninfected as a negative control. Secondary viral stocks described in 
charter 3.2.3.2 were used and dilutions were based on results from TCID50 assay 
3.23.3. Cells were harvested 3, 5 and 7 days after infection and lysates examined by 
W etem  blot. Prior to harvest pictures were taken of the culture plates to show the 
presnce of cell death. In figure 3.2.20 a, b and c pictures o f cell plates taken on day 3, 5 
and7 respectively are shown. On day 3, as seen in figure 3.2.20 a), sporadic cell death 
wasobserved in cells infected with CAV-l-hTERT+El at 500 and 1000 Pfu while little 
or id  cell death was observed in the remaining plates. On day 5, as seen in figure 3.2.20
b), ncreased sporadic cell death was observed on plates infected with CAV-1- 
hTIRT+El at 500 and 1000 Pfu. The remaining plates infected with either CAV-1- 
hTfRT+El or 331 showed clear cytopathic effect in the form of plaque formation. The 
nunber and size of plaques was larger in cells infected with a higher Pfu showing a 
corelation between the cytopathic effect and the infectious dose. On day 7 as seen on 
figire 3.2.20 c) sporadic cell death was observed on plates infected with either CAV-1- 
hTERT+El or 331 at 500 and 1000 Pfu. On plates infected with only 100 Pfu of either 
vins, cell death was still limited to localised plaques. In general at day 7 more cell 
deah was observed with the wild type virus 331 infected cells than the mutant virus. No 
celldeath was observed in the negative control cell plates.
The harvested cells were prepared for Western blotting and the membrane was 
incibated with a 1:50000 dilution of pooled canine serum in 5% marvel in PBS-Tween 
as primary antibody. Subsequently the membrane was incubated with the secondary 
HR1 conjugated antibody against canine IgG.
The results from the Western blot are shown in figure 3.2.21. Two bands on the 
blots are seen to be specific to virus infected samples and are absent in the negative 
conrol sample. These two bands are believed to be the viral hexon and penton proteins 
ruming on the gel as above 98kDa and above 62 kDa respectively. This size differs 
ffon the predicted size according to the calculated protein sizes in table 3.2.1 but 
corelates with the bands observed in figure 3.2.21. The results from the Western blot 
refltct the cell death observed in the pictures taken before harvesting the cells. The 
proein bands are stronger in the samples in which a higher level of cell death was 
observed and therefore bands increase in density in correlation with the number of days
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post transfection reflecting an increased number of infected cells and production of viral 
proteins.
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Table: 3.2.1
Protein Amino acid size Estimated kDa size
Hexon 905 99
Penton 477 52
Protein V 421 46
Protein VI 238 26
Protein VII 170 19
Table 3.2.1: Adenovirus surface protein sizes.
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Figure 3.2.19
98kD
62kD  
49kD
38kD  
28kD
17kD 
14kD
1 2 3 4 5 6 7 8 9  10
Figure 3.2.19: Detection of viral proteins using Ad5 antibody
W estern blot show ing the expression o f  the viral surface proteins in infected M DCK 
cells using antibody against hum an adenovirus type 5. Cell lysates were harvested 3 and 
5 days post infection and exam ined by W estern blot as described in m aterials and 
m ethods. The locations o f  the m olecular weight m arkers (kDa) are shown to the left of 
the blot. Location o f  viral proteins and putative proteins are indicated by arrows to the 
right o f  the blot.
1: U ninfected cells 3 days post treatm ent, 2: CAV-1 -hT E R T +E l lOOOPfu infected cells 
3 days post infection, 3: C A V -l-hT E R T + E l 500 Pfu 3 days post infection, 4: 331 1000 
Pfu infected cells 3 days post infection, 5: 331 500 Pfu infected cells 3 days post 
infection, 6: Non infected cells 5 days post treatm ent, 7: C A V -1-hT ER T+El lOOOPfu 
infected cells 5 days post infection. 8: C A V -1-hT ER T+El 500 Pfu 5 days post 
infection, 9: 331 1000 Pfu infected cells 5 days post infection, 10: 331 500 Pfu infected 
cells 5 days post infection.
- M M 331 331 - M M  3 3 1 3 3 1  (M = CAV-1 -h T E R T + E l)
Hexon  
Penton 
Protein V
Protein VI 
Protein VII
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Figure 3.2.20 a) 3days post infection
C A Y - 1-hTERT+El 100 Pfu Wild type virus 331 100 Pfu
C A V -1-hT E RT +E l 500 Pfu Wild type virus 331 500 Pfu
CAV -1-hTERT+El lOOOPfu Wild type virus 331 lOOOPfu
Uninfected  cells
211
Figure 3.2.20 b) 5days post infection.
K * •
v-..
* *  ;■ -  .
Wild type virus 331 100 Pfu
Wild type virus 331 500 Pfu
C A V -1-hT E R T +E l 100 Pfu
CA V -1-hT E R T +E l 500 Pfu
C AV -1-hT E RT +E l lOOOPfu Wild type virus 331 lOOOPfu
U ninfected  cells
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Figure 3.2.20 c) 7days post infection.
C A Y - 1 -hTERT+E 1 100 Pfu Wild type virus 331 100 Pfu
C A V -1 -hTERT+E 1 500 Pfu Wild type virus 331 500 Pfu
C A V -1 -hTERT+E 1 1000 Pfu Wild type virus 331 1000 Pfu
Uninfected cells
: i 3
Figure 3.2.20: Pictures of cells prior to harvest for western blot.
Pictures show cell plates after 3, 5 and 7 days after infection with either mutant or wild 
type virus. Cytopathic effect is seen as dead cells which appear as dense darker clusters 
on the photos.
a) Pictures taken 3 days after infection, b) pictures taken 5 days after infection, c) 
pictures taken 7 days after infection.
I) CAV -1 -hTERT+E1 100 Pfu, II) CAV-1-hTERT+El 500 Pfu, III) CAV-1-hTERT+El 
1000 Pfu, IV) Uninfected cells, V) Wild type virus 331 100 Pfu, VI) Wild type virus 
331 500 Pfu, VII) Wild type virus 331 1000 Pfu.
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Figure 3.2.21
a)
98 _
62
49
k D
3 days post infection. 
Virus specific bands
100 500 1000 100 500 1000 0 Pfu
' v '  v----------- v----------- '
Neg.CAV-1-hTERT+El 331 Wild type
b)
c)
188
98
62
49
k D
5 days post infection. 
Virus specific bands
500* 500* 100 1000 100 1000 0 Pfu
V y 1 V______________________^ V.____________)
331 CAV-1-hTERT+El 331 Wild type Neg.
98 —
62
49
k D
7 days post infection. 
Virus specific bands
100 500 1000 100 500 1000 0 Pfu
's v  J  K v  J
CAV-1-hTERT+El 331 Wild type virus Neg.
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Figure 3.2.21: Western blot detecting CAV-1 using canine serum antibodies.
Western blot showing the expression of CAV-1 proteins in infected MDCK cells using 
pooled canine serum as a primary antibody. Cell lysates were harvested 3, 5 and 7 days 
post infection and protocol carried out as for normal western blot as described in 
materials and methods. The location of the molecular weight marker (kDa) is shown to 
the left o f the blot. Location of viral proteins is indicated by arrows to the right o f the 
blot, a) 3 days post infection, b) 5 days post infection, note the discontinuity of the 
samples as noted by *, c) 7 days post infection.
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Chapter 4.
Discussion
4.1 Development of the two step amplification system for targeting cancer cells.
Many gene therapy trials, even though proven to be safe, have shown no 
treatment efficacy (Nathwani et al. 2004, Trent & Alexander 2004, Selkirk 2004) 
demonstrating that improvements in current systems are necessary. In order to increase 
cell specific transgene expression, various systems have been developed. The TSTA 
system used in conjunction with the Gal4VP16 fusion protein has shown great potential 
to increase specific transgene expression (Fang et al. 1998, Gu & Fang 2003). In this 
project an alternative to Gal4VP16, VP16E2 was used in a bid to improve the TSTA 
approach.
4.1.1 Comparison of the Gal4VP16 and the VP16E2
To improve transgene expression for gene therapy it was proposed that the 
VP16E2 transcriptional activator fusion protein, which has been shown to be a strong 
transcriptional activator in mammalian cells in previous work (Vance et al. 1999, Vance 
et al. 2001), could offer a potential improvement to the Gal4VP16 TSTA system due to 
the origin of the E2 DNA binding domain from a virus specialised in replicating in 
mammalian cells. This was tested by comparing the Gal4VP16 and the VP16E2 in a 
TSTA system under control of a CMV promoter followed by use o f the hTR and 
hTERT telomerase promoters. Figure 3.1.2 shows that in conjunction with the CMV 
promoter, the VP16E2 transcriptional activator may elicit a higher level o f reporter gene 
expression than Gal4VP16. Western blotting (figure 3.1.3) shows that VP16E2 is better 
expressed than Gal4VP16 and this may relate to differential transcriptional activity. 
Although both proteins are expressed from the CMV promoter, the VP16E2 protein 
may be more stable than Gal4VP16, explaining the difference observed.
The two step amplification system with incorporation of the hTR and hTERT 
promoters was tested in 3 different cell lines known to have telomerase activity (figure 
3.1.5-3.1.7). As expected the reporter gene expression was not as strong in conjunction 
with the two step amplification mechanism initiated by the two telomerase promoters
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compared to the CMV promoter due the relative low transcriptional activity of the 
telomerase promoters. These experiments demonstrated that the VP16E2 transcriptional 
activator induces a stronger level of reporter gene expression than the Gal4VP16 in all 
cell lines. The advantage of the VP16E2 over the Gal4VP16 transcriptional activator is 
particularly pronounced in the MCF-7 and the C33a cell lines. In these two cell lines the 
difference between the reporter gene expression between VP16E2 and Gal4VP16 is 10 
fold. In comparison the maximal difference observed in the 293-T cells is only 3 fold. 
The C33a cell line is a keratinocyte cell line and it is therefore possible that the 
pronounced effect from the VP16E2 transcriptional activator in this cell line could be 
associated with the epitheliotrophic origin o f the E2 DNA binding domain. This 
suggests that the VP16E2 transcriptional activator could be especially potent in treating 
cancers originating from epithelial cells.
The VP 16 sequences used in both the Gal4VP16 and the VP16E2 fusion 
proteins were the same, suggesting that the difference seen in transcriptional activation 
between these two fusion proteins could be related to the DNA binding domains and 
their abilities to bind to specific DNA sequences, their stability and their interaction 
with the VP 16 and cellular transcription factors. Both the Gal4 and the E2 bind to their 
specific DNA binding sites as a dimer (Walker et al. 1993, McBride & Myers 1996, 
Hedge 2002, Traven et al. 2006) and fused to the VP16 this binding recruits cellular 
transcription factors to the site. The full length Gal4 is a regulatory gene in yeast 
Saccharomyces cerevisiae and is important for inducing transcription of genes for 
galactose metabolism (Traven et al. 2006). It is however only the Gal4 DNA binding 
domain of the Gal4 regulatory domain that has been incorporated into the Gal4VP16 
construct. The E2 used in the VP16E2 construct consists of the C-terminal 161 amino 
acids of the E2 gene from the epitheliotrophic bovine papillomavirus type 1. The N- 
terminal part of the E2 gene encodes a transcriptional activation domain (Hegde 2002), 
however this sequence is not included in the VP16E2 construct. One hypothesis is that 
the derivation of the E2 from a mammalian virus renders this protein more potent than 
the Gal4 protein which functions in yeast cells. Even though there are many similarities 
in transcription between yeast and mammalian cells there are also differences (Levsky 
et al. 2007) which could account for the lower activation by Gal4VP16. Both the E2 and 
the Gal4 DNA binding domains and their interaction with DNA binding sites have been 
studied and the crystal structure determined (Lohr et al. 1995, Hedge 2002). Though 
there are differences in the way that the two DNA binding domains fold and bind to
218
their recognition sequence, it has not been established if this accounts for the difference 
in  transcriptional activation. The Western blots suggested that the VP16E2 was more 
stably expressed than the Gal4VP16 which is likely to be related to the nature of the E2 
domain.
A condition that should be addressed is the spatial placement o f the E2 binding 
sites versus the Gal4 binding sites in the reporter vector (figure 3.1.2 a)). It has been 
siiown that spatial separation of the DNA binding sites from the promoter can reduce 
the transcriptional activity (Ray et al. 2004). This could explain why the Gal4VP16 
shows a lover level of transcriptional activity than the VP16E2. This would however not 
explain the reduced protein expression seen in the Western blots (figure 3.1.3 and 3.1.8) 
and it is therefore believed that the spatial separation of the Gal4 DNA binding sites 
from the promoter in the reporter vector does not account for the difference in 
transcriptional activity induced by Gal4VP16 and VP16E2.
The potential increase in transcriptional activity by VP16E2 compared to 
Gal4VP16 in combination with the telomerase promoters provides an opportunity to 
improve current gene therapy protocols. The fact that transcriptional activity is observed 
with the VP16E2 at concentrations where no activity is seen with the Gal4VP16 allows 
for an increase in sensitivity of the TSTA system and potentially widening of the 
therapeutic window. As described in chapter 1.3, many disease and tissue specific 
promoters have been isolated and have potential to replace the hTERT promoter in the 
TSTA system. The survivin promoter, which is active in many cancer forms, would be 
suitable for an alternative approach targeting multiple cancer types (Zhu et al. 2004, 
Uchide et al. 2004). A more cancer type specific system could be developed by 
replacing the hTERT promoter with the prostate specific antigen promoter and enhancer 
and thereby restricting the use of the system to prostate cancer (Diamandis et al. 1998, 
Zhang et al. 2002).
4.1.2 Testing the specificity of the two step transcriptional amplification system in 
conjunction with hTR and hTERT.
A potential hazard of developing a very potent TSTA system is the risk of 
promiscuity of the system which could have detrimental effects to non target cells. 
Therefore the two step amplification system was tested in conjunction with the VP16E2 
and the hTR and hTERT promoters in telomerase negative cells to determine if the
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system would provide specificity for telomerase expressing cells (figure 3.1.10). The 
activity from the hTR and hTERT promoters from these experiments indicates that the 
hTR promoter is less specific for telomerase activity since it shows a high level of 
transcriptional activity in the GM-847 and MRC-5 cells in particular. This observation 
that hTR promoter activity is not reflective o f telomerase activity is consistent with 
previous studies (Weinrich et al. 1997, Bodnar et al. 1998, Yin et al 2004). It has been 
shown that telomerase activity can be induced in telomerase negative cell lines by 
transfecting these cell lines with a hTERT expressing plasmid (Bodnar et al. 1998, 
MacKenzie et al. 2000), indicating that the other elements of the telomerase complex 
including the RNA template may be continuously expressed.
Activity o f the hTERT promoter was observed in the MRC-5 cells. These cells 
are primary human fibroblasts that had been cultured for several passages at the time of 
use and a selection for telomerase expressing cells could have occurred. In the TRAP 
assay performed (figure 3.1.13), telomerase activity was detected in this cell line which 
could account for the transcriptional activity observed in conjunction with the hTERT 
promoter.
The results in the telomerase negative cells support the hypothesis that the 
hTERT promoter is suitable for specific targeting of telomerase expressing cells and 
also indicates the potential promiscuity of the hTR promoter. It is difficult to directly 
compare transcriptional activity seen between the different telomerase positive and 
negative cell lines, however if one examines the transcriptional activity relative to the 
pCG-VP16E2 transfected cells, there appears to be a therapeutic window at which low 
transcriptional activity is observed in the telomerase negative cells transfected with the 
hTERT-VP16E2 and a relatively high level of activity is seen in the telomerase positive 
cell lines.
4.1.3 Testing the system in canine cells.
To be able to use the canine population as a model for human gene therapy it is 
necessary that the promoters are transcriptionally active in canine cells and are still 
restricted to the same transcriptional specificity as in human cells. The two step 
amplification system was therefore tested in the canine telomerase positive MDCK cell 
line and in the canine primary chondrocyte cell line which was expected to be 
telomerase negative.
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The two step transcriptional amplification system in conjunction with the hTR 
and hTERT promoters was able to elicit a similar level o f reporter gene expression as 
the CMV promoter in the telomerase positive MDCK cell line (figure 3.1.11) 
demonstrating that the system can indeed be translated between the human and canine 
species without losing its potency. The activity of the hTERT, and in particular the hTR, 
promoter seen (figure 3.1.12) in the primary canine chondrocyte cell line was 
unexpected. Human primary chondrocytes cultured in vitro have however shown to 
exhibited telomerase activity reflected by expanded life span (Parsch et al. 2004). 
Indeed the primary canine chondrocytes used demonstrated telomerase activity in the 
TRAP assay (figure 3.1.13).
The activity of the TSTA system in conjunction with the human telomerase 
promoters in canine cells also confirms the work done by others showing the homology 
between the human and canine TERT promoter sequence and function (Long et al.
2005).
4.1.4 Testing the transfection efficiency
The TSTA results discussed so far depend upon co-transfection of two plasmids. 
It was therefore relevant to test that in cell lines which have a transfection efficiency of 
less than 100% that transfected cells would be transfected with both plasmids. Figures 
3.1.15-3.1.17 indicated that the transfection with two plasmids observed by the use of 
florescent GFP and RFP reporter plasmids overlapped. This effect is important for both 
in vivo and in vitro use of the two step amplification system as a two vector system, 
since transfection with either vector alone would have no therapeutic effect.
4.1.5 Evaluation of the one vector system.
The incorporation of the two step amplification system into a one vector system 
has been shown by others to increase the efficacy o f the system. This effect has been 
observed using adenovirus vectors (Zhang et al. 2002) and a plasmid vector system 
(Fukuzawa et al. 2004).
When comparing the forward and reverse construct of the 6xE2-3’BpTATA- 
hTERT-VP16E2 a slight difference in activity was seen between these in telomerase 
negative and positive cells. As illustrated (figure 3.1.19) the reverse construct showed a
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tendency towards greater activity. The increased activity of the 6xE2-3’BpTATA- 
hTERT-VP16E2 REV in the telomerase negative cells in particular makes the reverse 
construct less favourable to use.
The general transcriptional activity o f the one plasmid system in telomerase 
positive cells was reduced compared to the two plasmid system. This reduction in 
activity was most likely to be caused by two effects: Firstly the transcriptional activator 
is very potent and therefore the rate limiting effect for transcriptional activity is the 
concentration o f the second promoter transcribing the reporter gene. When testing the 
TSTA system as a two plasmid system the reporter plasmid was added at a dose o f 1000 
ng regardless of the concentration of the hTERT-VP16E2 plasmid. In the one plasmid 
system the concentration of the reporter vector follows the hTERT-VP16E2 
concentration, accounting for the lower transcriptional activation. To be able to directly 
compare the efficacy of the one vector versus two vector system one would need to 
titrate in dilutions of the reporter vector. Another reason for observing a reduced 
transcriptional activity with the one plasmid system is the potential interference that can 
occur between the primary and secondary promoters due to their close proximity in the 
plasmid which can have debilitating effects on the system. Others have managed this 
problem by using adenovirus vectors and inserting the primary and secondary promoters 
in distinct regions within the virus, allowing for good spatial separation (Sato et al. 
2008). It should be noted that the promoter driving the transcription in the reporter 
vector used with the two vector TSTA system in figure 3.1.5 is different from the 6xE2- 
3’BpTATA which was used in the one plasmid system. It is however not expected that 
this has any influence on the reduced transcriptional activity since the 6xE2-3’BpTATA 
is a very responsive promoter as seen when tested in the canine cells figure 3.1.11 and 
as others have described (Vance et al. 2001).
When comparing the 6xE2-3’BpTATA-hTERT-VP16E2 with the Gal46xE2- 
3’BpTATA-hTERT-Gal4VP16 the advantage of the VP16E2 transcriptional activator 
compared to the Gal4VP16 is conserved in the one vector system. In previous studies 
with the two plasmid system (figure 3.1.8), the VP16E2 protein in Western blots was 
detected as a double band significantly stronger than the Gal4VP16. In the one plasmid 
system the VP16E2 protein appears as a single band of similar intensity as the 
Gal4VP 16 indicating that the one plasmid system might have a compromising effect on 
VP16E2 expression (figure 3.1.23). The interaction between the papilloma virus E2 and 
the telomerase activity in papilloma virus infected cells has been investigated and a
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negative correlation was found between E2 expression and telomerase activity (Lee et 
al. 2002, Seo et al. 2004, Nishimura et al. 2006). It has been suggested that this is an 
indirect effect in relation to infection with papilloma virus and E2’s effect on the viral 
E6  and E7 expression (Seo et al. 2004, Nishimura et al. 2006). However, others have 
suggested that E2 binds directly to the hTERT promoter and down regulates 
transcription (Lee et al. 2002). This interaction of E2 with the hTERT promoter was 
studied using a full length E2 protein and it is therefore not known if the E2 region 
contained in the VP16E2 fusion protein has retained this ability. Since no repressive 
effect was seen by the E2 used in the two plasmid system and since there was a similar 
reduction in transcriptional activity in the one plasmid system with the Gal4VP16 
(which is not known to interact with hTERT) then it is not likely that the VP16E2 has a 
repressive effect on the hTERT activity but more likely that the reduction in activity is 
due to limiting concentrations o f the 6xE2-3’BpTATA promoter.
When looking at the transcriptional activity of the one plasmid system in 
telomerase positive and negative cells, it is seen that relative to the activity of the PCG- 
VP16E2 construct there is a potential therapeutic window in which a concentration 
would allow for transgene expression in telomerase positive cells whilst not in 
telomerase negative cells.
4.1.6 Killing of telomerase positive cells by incorporation of TRAIL into the TSTA 
system.
The TRAIL gene has been exploited for the use in cancer gene therapy due to its 
ability to induce apoptosis in cancer cells but not normal cells (Wiley et al. 1995, Lin et 
al. 2002). The canine TRAIL (cTRAIL) gene was isolated and cloned to determine if 
the canine gene shared functional homology with its human counterpart. The cTRAIL 
and hTRAIL share 87% sequence homology (figure 3.1.26) and the function of the 
TRAIL gene in inducing apoptosis is preserved in human and canine species as 
observed by detection of activation o f apoptosis related proteins in Western blots (figure 
3.1.27-3.1.29). Work has been published showing that canine cancer cells are sensitive 
to TRAIL induced apoptosis by treatment with soluble human TRAIL (Spee et al.
2006). The isolation of canine TRAIL and its ability to induce apoptosis in canine cells 
supports these findings.
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The results from the TUNEL assays (figure 3.1.31) demonstrated that the full 
length TRAIL in conjunction with the TSTA system could be used in telomerase 
targeted cancer gene therapy as it induces apoptosis in telomerase expressing cells only. 
The characteristics of the TRAIL gene to induce apoptosis in cancer cells whilst not in 
most untransformed cells is an extra security barrier in the system since unspecific 
TRAIL expression in normal cells would not necessarily be toxic (Wiley et al. 1995, 
Lin et al. 2002). There is a concern when using such a system to target telomerase 
expressing cancer cells that ALT dependent cells will be selected (Yan et al. 2002, 
Reddel 2003, Harley 2008, Nittis et al. 2008). Therefore it is important that the 
transgene used for cell killing shows a pronounced bystander effect allowing for 
apoptosis induction in cells that are not expressing the transgene. Full length TRAIL has 
been shown to carry out a marked bystander effect (Kagawa et al. 2001). Since TRAIL 
is a trans-membrane protein it is most likely that this bystander effect is induced by cell­
cell interactions rather than via diffusion or gap junctions (Kagawa et al. 2001).
Unlike the U20S cell line which has been shown to be TRAIL sensitive 
(Garnett et al. 2007), the 293-T cell line used for the TUNEL is commonly used for 
generating TRAIL expressing virus vectors (Ma et al. 2005, Kim et al. 2006) and is 
therefore considered partially TRAIL resistant. The Western blot (figure 3.1.27) and 
the TUNEL stain, however, show that 293-T cells were susceptible to TRAIL induced 
apoptosis as others also have reported (Ozoren et al. 2000). The full length TRAIL has 
been used in combination with our TSTA system although it is possible to use versions 
of the TRAIL gene encoding recombinant soluble TRAIL forms to allow for secretion 
of the TRAIL gene (Kim et al. 2004a), Ma et al. 2005, Kim et al. 2006). This effect 
would significantly increase the bystander effect of the treatment, however, it has been 
shown that some cancer cells are resistant to soluble TRAIL but are still sensitive to 
killing by full length TRAIL (Voelkel-Johnson et al. 2002, Seol et al. 2003). Therefore 
full length TRAIL was chosen for use in our system.
Many other genes, and in particular suicide genes, have shown a great potential 
for cancer gene therapy as described in chapter 1.1 and the TRAIL gene in our TSTA 
system could be replaced with any of these genes to alter the treatment. In combination 
with other promoters our TSTA system could also be applied to other types of gene 
therapy in which a tight regulation of transgene expression would be required.
Our TSTA system in conjunction with TRAIL shows telomerase specific cell 
killing, demonstrating this system has potential for cancer therapy. To apply a system
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like this to in vivo therapy one would have to consider how to deliver the DNA to cells. 
Most work using full length TRAIL for gene therapy has been done using adenoviruses 
as gene delivery vectors which has a synergistic effect since some adenoviral proteins 
sensitise cells to TRAIL induced apoptosis (Voelkel-Johnson et al. 2002). It is 
important however to remove the adenoviral E3 region since this region encodes 
proteins that down regulate TRAIL receptor expression and hence inhibit apoptosis 
(Howitz 2004). As described in chapter 1.2 there are now many ways of increasing 
cellular uptake of DNA and therefore the TSTA plasmid system could potentially be 
applied to in vivo using physical cellular delivery mechanisms to improve the uptake of 
the plasmid DNA.
4.1.7 Alterations to improve the TSTA system.
As described by others (Zhang et al. 2002) the TSTA system is a flexible system 
with many variables that can be altered to improve the efficacy. This includes altering 
the promoters and transcriptional activator elements but also spatial alterations that can 
alter the system (Zhang et al. 2002, Fukuzawa et al. 2004, Sato et al. 2008). As 
described in chapter 3.1.7, the spatial effect of incorporating the TSTA system into one 
vector was studied and did not show any obvious improvement to the system. In order 
to study the impact o f other elements in the telomerase responsive TSTA system in 
conjunction with the VP16E2, alterations of the telomerase promoter, the VP 16, the E2 
and the E2 binding sites were studied.
It was investigated whether a xenogeneic versus an allogeneic TERT promoter 
would increase the transcriptional activity as others have reported when using the 
mouse TERT promoter in human cells (Horikawa et al. 2005). We observed (figure 
3.1.36) a 2 fold increase in transcriptional activity with the 665 base pair dogTERT 
promoter compared to the human hTERT promoter when administered at a dose of 
lOOOng in human cells. This effect was not however replicated in the 2000ng dose and 
therefore it was concluded that no clear advantage was seen using a xenogeneic 
promoter in either canine nor human cells. The results from this study did however 
demonstrate that the hTERT and dogTERT promoters function to a similar extent in 
both species and that systems developed for treatment in either species can be translated 
into use in the other which could be useful when using canine patients as models for 
human cancer treatment.
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The impact of incorporating an extra VP 16 domain into the TSTA system was 
studied. Others have reported a 3 fold increase in transcriptional activity of the TSTA 
system when incorporating a tandem repeat of the VP 16 sequence compared to a single 
construct (Zhang et al. 2002). This effect was observed with the VP 16 sub-domain 
(amino acids 413-454) which have been shown to be sufficient for activating a promoter 
with multiple binding sites for the transcriptional activator fusion protein (Walker et al. 
1993, Flint & Shenk 1997). Our results (figure 3.1.39) demonstrated an increase in 
transcriptional activity with the incorporation of the VP 16 in tandem versus the single 
construct although the effect was not as pronounced as reported by others (Zhang et al. 
2002). The VP 16 sequence used to construct the VP 16 in tandem consisted of amino 
acids 410-487 of the VP 16 protein. Amino acids 455-487 are not necessary for 
activation of the 6xE2-3’BpTATA promoter since this promoter has several DNA 
binding sites for the transcriptional activator fusion protein and perhaps a more 
pronounced difference in effect with the tandem protein would be seen in conjunction 
with a shorter VP 16 fragment. Work we have done comparing the effect of a shorter 
VP 16 versus a longer VP 16 fragment in conjunction with the Gal4VP16 transcriptional 
activator did not reveal any significant difference in transcriptional activity and 
therefore the VP 16 fragment used in the VP16E2 fusion protein could be reduced to a 
shorter fragment by removing the terminal 454-487 amino acids (Walker et al. 1993, 
Flint & Shenk 1997).
Increasing the number o f transcriptional activator binding sites has been shown 
by others to improve the efficacy of the TSTA system. We studied this effect by using 
the TSTA system in conjunction with the BPV-4 PV2 promoter with 4, 8 or 12 
upstream E2 binding sites. No improvement in transcriptional activity was observed by 
increasing the number of E2 binding sites upstream of the PV2 promoter in 293-T cells 
(figure 3.1.41). In C33a cells (figure 3.1.42), a small increase in transcriptional activity 
was observed. Others reported a 60 fold increase in transcription when increasing the 
number of Gal4 binding sites from 2 to 5 in conjunction with the Gal4VP16 
transcriptional activator fusion protein and the TSTA system (Zhang et al. 2002). We do 
not observed such a of dramatic effect although the lowest number o f E2 binding sites 
used in this study was 4 and perhaps a saturation effect had already been reached, 
allowing for only small increases in effect. The PV2 promoter is derived from BPV 4 
and is a longer 127 base pair version of the 3’BpTATA promoter described by others 
(Vance et al. 2001). This promoter construct has retained an epitheliotropic predilection
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from the original BPV 4 promoter from which it is derived. This could explain the lack 
o f  any effect from increasing E2 sites when the system was tested in 293-T cells while 
an effect was observed in the C33a keratinocyte cell line. The increase in E2 binding 
siites could be studied in conjunction with the 3’BpTATA promoter to determine the 
direct effect on our TSTA system although our results with the PV2 promoter suggested 
that no effect will be seen and therefore the inclusion of 6  E2 binding sites appeared 
sufficient.
Modifying the E2 protein in order to increase stability was studied also. Others 
reported a 20 fold increase in viral BPV-1 replication when mutating the E2 serine 
residue 301 to an alanine, thereby eliminating a major phosphorylation site (Mcbride & 
Howley 1991). We carried out the same point mutation in our VP16E2 fusion protein 
and examined protein expression from this construct. This mutation increased 
expression of the VP16E2 fusion protein (figure 3.1.43), but the effect o f the mutated 
VP16E2 has not been studied in transcription assays however this should be done before 
incorporating it into the final TSTA system.
4.2 Evaluating the CAV-1 based CRAd
The CAV-1-hTERT+El virus is not suitable for use in human oncolytic therapy 
due to the species specific replication of CRAds renders them unsuitable for cell killing 
in species other than their original host species (Hemminki et al. 2003). Such species 
specificity is a problem for studying the effect and possible toxicity o f CRAds in animal 
models. The many similarities in pathogenesis and aetiology between human and canine 
cancers, as well as other diseases, makes the dog a suitable spontaneous animal model 
for studying cancer and cancer therapy (Hansen & Khanna 2004, Paoloni & Khanna 
2007, Paoloni & Khanna 2008). The dog has been used for a long time by the 
pharmaceutical industry for studying drug metabolism since the physiological 
similarities between humans and canines results in drugs being utilised in a similar 
fashion between these species. This has led to a recent interest in studying cancer in 
dogs as a comparative model for humans (Mack 2006). The development of the CAV-2 
based CRAd to specific target killing of osteosarcoma cells in canines is an attempt to 
develop a cancer treatment for dogs with the aim of developing a potential treatment for 
human cancer (Le et al. 2006). As in humans, dogs commonly have antibodies against 
canine adenoviruses making this a suitable comparative animal model system. The
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CAV-1-hTERT+El was developed in order to study the effect o f a CRAd in an animal 
model system. This system has in comparison to the osteosarcoma targeted canine 
CRAd a broader application since the telomerase promoter is active in a wide range of 
cancers, with up to 95% of canine cancers testing positive for telomerase activity 
(Yazawa et al. 1999). The incorporation of the TSTA system increases the sensitivity of 
the CRAd compared to conventional CRAds which do not contain an amplification 
system. The CAV-1 which was used to create the CAV-1-hTERT+El is a highly 
pathogenic virus which, unlike CAV-2 , can cause severe disease and can be found in 
many tissues following an infection (Decaro et al. 2007). This pathogenesis can be seen 
as a threat to the safety of the virus for cancer treatment. However, since most dogs are 
vaccinated against CAV-1, the potential for this virus or for the mutant CAV-1- 
hTERT+El to cause disease is limited. The ability of CAV-1 to replicate in multiple 
tissues and its pathogenic potential supports the use of this virus to induce cell lysis in 
different cancer types originating from various cell types. The use of the CAV-1 fiber 
protein to generate hybrid human gene therapy vectors with an increased tropism 
illustrates the value of this virus in targeting many tissue types (Zheng et al. 2007). The 
presence of neutralising antibodies against CAV-1 is not seen as a direct disadvantage 
of the system but rather as a safety precaution assuring that the virus will not induce 
disease and perhaps lead to an increase in treatment efficacy by immunological support 
as seen with immunity against oncolytic herpes viruses in mice models (Zhu et al.
2007). There are several routes by which oncolytic virus treatment can be administered. 
The CAV-1-hTERT+El is developed with the intention of being used for local cancer 
therapy by intratumoural injection. This mode of delivery circumvents the problem 
regarding neutralisation by circulating antibodies but still maintains the benefit of 
immunological support to eradicate the tumour cells. In clinical trials in humans, 
antitumoural effects have been observed with all oncolytic viruses delivered 
intratumourally (Liu et al. 2007). On the other hand, systemic delivery has not shown to 
result in a similar clinical effect (DeWeese et al. 2001, Small et al. 2006, Alton et al. 
2007). The reduced response observed following systemic delivery could be the result 
of too low viral concentrations at the tumour site. Ideally an oncolytic virus should be 
administered systemically for the virus to be able to target distant metastases, however 
this application remains a challenge. Anti-tumoural responses in metastases after 
intratumoural oncolytic injection of the primary tumour have been observed, suggesting
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that the immune response plays a supporting role in the anti-tumour activity of the virus 
treatment (Liu et al. 2007).
4.2.1 CAV-1-hTERT+El
The CAV-1-hTERT+El virus was able to induce cell lysis in telomerase 
positive cells while no cytopathic effect was observed in telomerase negative cells as 
reflected in the TCID50 assays (chapter 3.2.3). In comparison, the wild type virus 331 
killed both telomerase positive and negative cells, with higher levels o f cell killing 
observed in telomerase negative cells. The observation that no cell toxicity at all was 
observed in the telomerase negative cells infected with the CAV-1-hTERT+El implies 
that no toxic effect occured in the absence o f viral replication. The specific replication 
of the CAV-1-hTERT+El in telomerase positive cells and the ability to kill such cells 
suggests that this virus can be used to selectively kill telomerase expressing cancer cells 
without harming normal cells. The incorporation of the TSTA system into a replication 
competent virus is a novel approach which has not been reported previously and 
therefore our work has taken the TSTA system forward into a replication competent 
viral system with promising results.
4.2.2 Consideration about the CAV-1-hTERT+El design.
The viral titres o f the CAV-1-hTERT+El and the wild type 331 virus secondary 
virus stock varied markedly, as did the tertiary virus stock. The reason for this great 
difference has not been determined but there are many possible explanations.
The CAV-1-hTERT+El virus depends on telomerase expression in cells in 
order to replicate. Low activity of the telomerase promoter could therefore limit virus 
production despite the amplification from the TSTA system in cells which are not 
sufficiently telomerase positive.
The TSTA is, as the name implies, a two step system and the viral replication 
with this system will potentially be delayed compared to wild type virus since the 
transcription and expression of the VP 16E2 transcriptional activator is required to 
activate the transcription of the virus E l gene and initiation o f viral replication. This 
temporal delay could allow for cellular defence mechanisms to be activated and perhaps 
premature cell death, before viral particles had matured.
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Another factor that could result in lower production o f mutant virus is the 
removal of the El promoter region in the CAV-1-hTERT+El. This region is located in 
the proximity of the viral packaging signals. Comparison o f the CAV-1 sequence with 
other adenovirus sequences suggest that the viral packaging signal was not affected by 
the removal of the proposed E l promoter region. Studies in the CAV-2 virus show that 
alterations in certain sequences between the inverted terminal repeat sequence and the 
transcription start site for the E l can significantly alter the viral packaging efficiency 
(Soudais et al. 2001). In this context it was shown that deletion o f the CAV-2 sequence 
base pairs 302-356, 248-259 and a double deletion from 201-218 and 248-259 reduced 
the viral packaging efficiency 50, 200 and 500 fold respectively as determined by 
replication competition assays (Soudais et al. 2001). The sequences o f interest in this 
study were the 5’- TTTA- 3’ and 5’-TTTG- 3’ motifs located in the CAV-2 virus 
between base pairs 200-400 in the viral genome. The E l promoter deletion in CAV-1- 
hTERT+El is from base pairs 282 to 415 in the CAV-1 genome. In this sequence there 
is both a 5’-TTTG -3’ and a 5’-TTTA- 3’ motif and it is therefore possible that the 
removal of the E l promoter region in the CAV-1-hTERT+El has compromised the 
viral packaging efficiency. This problem could be addressed by studying viral 
replication and cytopathic effect of different viral mutants containing different El 
promoter deletions.
Wild type human adenoviruses should be able to carry up to 4 kbp foreign DNA 
without compromising the viral replication (Cao et al. 2004). In the CAV-1-hTERT+El 
1591 base pairs of foreign DNA in total was inserted in the AE1 promoter region and 
the AE3 region. The AE1 promoter region and the AE3 region that were excluded from 
the virus contained 979 base pairs, hence 621 base pairs of extra DNA were inserted 
into the virus. It is not known if  these additional base pairs could affect the packaging or 
stability o f the virus, however, when the relatively small size of this fragment is 
compared to the whole viral genome and the capacity of the human adenoviruses to 
carry additional DNA is considered, then this is most unlikely. It has been reported as 
well that the CAV-1 can package between 106 to 109% of wild type virus genome size 
(Morrison et al. 2002)
Another possible reason to account for the low viral production is the viral 
sequence which could have a cis acting influence on the inserted hTERT promoter. A 
polyAAA sequence was inserted upstream of the 6xE2-3’BpTATA promoter to
230
eliminate any up or down regulation of promoter activity by cis acting viral sequences 
on this promoter. It has been shown that poly AAA sequences are able to terminate any 
upstream transcriptional activity (Hoffmann et al. 2005, Nag et al. 2006). The hTERT 
promoter was inserted into the virus without an upstream poly AAA signal. Others have 
experienced that cis acting virus sequence can compromise the activity of exogenous 
promoters when inserted into a human adenoviral delivery system (Blackwood &
Argyle 2004). It is therefore possible that the low viral replication is a result of a 
compromised hTERT promoter resulting in low initiation of the TSTA system and 
hence low viral replication. This could be addressed by inserting a polyAAA or another 
insulator sequence upstream of the hTERT promoter in the virus.
A further aspect to be considered with regard to the low virus titer is the 
exclusion of the viral E3 gene in the CAV-1-hTERT+El virus. It is known that the viral 
E3 gene is not essential for adenovirus replication in vitro however the region does have 
other functions which are important for infection (Linne 1992). In human adenoviruses 
the viral E3 gene region encodes proteins important for down regulation o f MHC I 
expression, down regulation of tumour necrosis factor induced apoptosis and down 
regulation of FAS and TRAIL receptors. The proteins important for these functions are 
all expressed as early genes during viral replication (Horwitz 2004). In addition the E3 
region encodes a pro-apototic protein named adenovirus death protein (ADP) which has 
been shown, unlike the other E3 proteins, to be expressed by a major late promoter 
(Horwitz 2004). The complete CAV-1 E3 region has been deleted in the CAV-1- 
hTERT+El virus. This deletion could have impacted upon the ability of the virus to 
induce cell lysis and could explain the low virus titer of the CAV-1-hTERT+El virus 
stocks. The CAV-1 E3 gene region is significantly different both from the human 
adenovirus E3 region and from the CAV-2 E3 region (Linne 1992, Morrison et al.
1997). A comparison between the CAV-1 and CAV-2 E3 regions has shown that they 
share conserved N and C terminal regions however that there is a significant difference 
in the majority of the E3 region and the open reading frames. The CAV-2 virus E3 
region contains 5 open reading frames whilst the CAV-1 E3 contains only 2 (Linne 
1992). It is not known exactly what the effect of this difference is, but it is hypothesised 
that the difference could account for the difference in pathogenesis between the CAV-1 
and CAV-2 viruses (Linne 1992). The exact function of the CAV-1 E3 region is not 
known and it is therefore not known if it encodes a protein with a similar function as the 
ADP found in human adenoviruses. It is therefore uncertain if the low titer of the CAV-
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1-hTERT+El could be caused by compromised viral cell lysis due to the lack of the E3 
coding region. The great differences between the CAV-1 and other adenoviruses in the 
E3 region suggest that this region might be dispensable for cell lysis in CAV-1. The 
importance o f the E3 region for viral induced lysis could be studied by infecting cells 
with CAV-1 virus with and without a deletion of the E3 coding region. Subsequently 
this, a simple comparison of the cytopathic effect on the cells infected with virus with 
and without E3 should demonstrate the effect of the E3 deletion.
4.2.3 Detection of virus DNA and proteins
PCR analysis (figure 3.2.14) confirmed that there was no contamination between 
the wild type and mutant viruses in the virus stocks and provided an indirect 
measurement of the amount o f virus template present in the stocks. The presence of a 
PCR product from the 331 virus after only 15 PCR cycles in comparison to the CAV-1- 
hTERT+El which only produced a product after 20 cycles suggested that the 331 virus 
was more concentrated than the CAV-1-hTERT+El. This result could reflect the 
difference observed in the virus titre between these two viruses. The result from the 
PCR could therefore indicate that either defective virus particles are produced with the 
CAV-1-hTERT+El infections or that viral particles are not released efficiently. This is 
supported by the fact that PCR was performed on viral stocks which were generated by 
lysing infected cells allowing for intracellular virus particles to be released.
In figure 3.2.19 a Western blot is shown from cells infected with various 
amounts of CAV-1-hTERT+El and 331 virus. Two interesting points emerged from 
this experiment. Firstly the antibody used to detect the CAV-1 virus in this experiment 
was a polyclonal antibody raised in rabbit against Ad-5. It is evident from the Western 
blot that cross reactivity exists between antibodies against Ad-5 and CAV-1. One of the 
arguments for developing canine adenoviruses as human gene delivery vectors has been 
that this provided a means to circumvent the problem with humans having pre-existing 
anybodies against the human adenoviruses (Kremer et al. 2000). If human adenovirus 
anybodies cross react with canine adenoviruses, then using a canine adenovirus as a 
geie therapy vector will not change the neutralising effect of circulating antibodies. The 
second thing that was interesting about the Western blot was that in agreement with the 
cy.opathic effect that was observed on visual inspection of the infected cells, virus 
proteins from the CAV-1-hTERT+El virus were detected at 3 days post infection while
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wild tyje vims proteins are only detected at 5 days after infection. This observation 
does suggest that the concentration of the secondary CAV-1-hTERT+El viral stock was 
higher tian suggested from the TCID50 assays.
n the Western blots stained with canine serum antibodies (figure 3.2.21) 
supported by pictures (figure3.2.20) the same effect was observed with virus proteins 
being oserved at an earlier time point for the CAV-1-hTERT+El than the 331 vims. 
Anothe; interesting thing about this western blot is the pattern of cell killing which was 
observed on the supporting pictures. For the CAV-1-hTERT+El sporadic cytopathic 
effect vas seen at concentrations of 500 and 1000 PFU per plate after only 3 days and 
more ponounced at 5 days. In comparison the wild type vims showed cytopathic effect 
localised to plaques but only after 5 days o f infection. This observation does suggest 
that theactual concentration of the CAV-1-hTERT+El stock is higher than determined 
by the ICIDso assay but that the vims may not replicate as efficiently as the wild type 
vims ormay not be released. At day 7 after infection the cytopathic effect was more 
pronouiced in the 331 infected plates, than the CAV-1-hTERT+El infected plates 
indicatiig that although the wild type vims was slow initially to generate a cytopathic 
effect itthen replicated faster than the CAV-1-hTERT+El vims.
The Western blots were not quantitative for viral replication but did provide 
evidence of viral replication as seen by the increase in viral protein between early and 
late harvested plates. This, supported by the cell killing observed in the pictures, 
provided evidence that viral replication and cytopathic effect are correlated.
Putting all these observations together the data suggest that the CAV-1 - 
hTERT-El vims is compromised in replication, cytopathic effect or packaging 
compand to the wild type vims and possible modifications could be carried out to 
improve the viral replication and cytopathic effect. The good telomerase specificity 
observed with the CAV-1-hTERT+El vims is however an important strength for the 
vims ard alterations to be made should not compromise this.
4.2.4 Bystander effect of the virus.
\ s  with the TRAIL telomerase targeted gene therapy, there is a risk that a 
positive selection pressure will be put on ALT dependent cells when using the 
telomerase controlled CRAd to kill cancer cells (Yan et al. 2002, Reddel 2003, Harley 
et al. 2C08, Nittis et al. 2008). There is no direct bystander effect from the vims on 
surrounding cells although the immune response may play an important role since viral
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replicaton can induce an immune response against cancer associated antigens and can 
therebyincrease the anti-tumoural efficacy of the virus (Rein et al. 2006, Liu et al.
2007). Armed oncolytic viruses carrying a cytotoxic or a suicide gene provides means 
o f incoporating a bystander effect to the oncolytic viral system (Ye et al. 2005). In this 
system,expression of the transgene will enable targeting surrounding cells which might 
not support viral replication. In this context our CRAd could be reinforced with a 
TRAILgene. The adenovirus E3 region which is known to down regulate expression of 
TRAIL receptors (Horwitz 2004) is removed in our CRAd and therefore TRAIL could 
be verypotent in inducing cellular apoptosis in our system. Due to the strength of the 
VP16EI transcriptional activator, an incorporated TRAIL gene could be under the 
transcriptional control of a second 6xE2-3’BpTATA promoter as illustrated in figure 
4.1, since the VP16E2 would be able to activate two 6xE2-3’BpTATA promoters as 
demonSrated when testing low levels of VP16E2 in conjunction with high levels of 
reporter vector.
3ncolytic viruses are often used in combination with chemotherapy (Liu et al.
2006). Some of the stem cell cancer models suggest that stem cells are highly resistant 
to most conventional therapies such as chemotherapy however that they possess strong 
telomense activity and use of a combination of telomerase targeted therapy and 
chemotherapy may eradicate both cancer and cancer stem cells (Shay & Keith 2008).
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4.3 Conclusion
The major obstacles in gene therapy are specific targeting of transgene 
expression, adequate levels of transgene expression and efficient in vivo transgene 
delivery. The achieving work in this thesis has been carried out in order to address each 
o f these areas.
A novel TSTA system in conjunction with the VP16E2 transcriptional activator 
fusion protein, the 6xE2-3’BpTATA promoter and the hTERT promoter allows for a 
strong level of specific transgene expression in telomerase expressing cells, at a higher 
level than the commonly used Gal4VP16 system. The system in combination with the 
full length TRAIL as a transgene allows for specific apoptosis induction in telomerase 
expressing cells without exerting toxicity to non telomerase expressing cells.
The development of the CAV-1-hTERT+El under replicative control of the 
hTERT promoter and with incorporation of the TSTA system allows for specific killing 
of telomerase expressing cells and addresses the difficulty o f in vivo delivery. This 
CAV-1-hTERT+El is a valuable tool for investigating telomerase targeted oncolytic 
cancer treatment in an immune competent spontaneous canine cancer model system. 
Further development of this virus will have application for gene therapy in canines and 
humans.
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4.4 Future work
The plasticity of the TSTA system and the many possible applications in gene 
therapy leaves this project with a broad range of possible study aspects to be carried 
forward. As seen in figure 4.2 both the hTERT promoter and the transgene can be 
exchanged for other units to target the system towards other diseases. This opens the 
possibility for studying the use of the TSTA system for targeting other cell types and 
other diseases.
The transcriptional activator fusion protein can also be altered to optimise the 
system further such as by altering the length and the number of VP 16 coding sequences. 
Other approaches to improve the TSTA system further could be incorporation of control 
elements such as tetracycline activation or repressor elements upstream of the hTERT 
promoter allowing for a possible in vivo control of transgene expression.
A positive feed back reinforcement o f the TSTA system could easily be 
incorporated by placing E2 binding sites upstream of the hTERT promoter. In this form 
the transcription of the VP16E2 would act as a positive feedback on further VP16E2 
transcription by activation of the hTERT promoter as seen in figure 4.3. It is important 
to ensure that modifications which offer increased efficacy of the TSTA system do not 
compromise the specificity of the system.
There are several aspects of the CAV-1 based CRAd that should be improved in 
future work. The viral stock of the CAV-1-hTERT+El generated to date is relatively 
dilute and therefore a more concentrated viral stock should be produced. This can be 
achieved by using more cells in larger volumes of media which when harvested are 
subject to ultracentrifugation in order to concentrate viral particles in a small volume. 
The current viral stocks originated from one cosmid clone after the second step of 
homologous recombination. Other clones have been isolated during the process and 
these could be studied to see if they would generate a more potent CRAd in case any 
compromising mutations may be present in the CAV-1-hTERT+Elgenome. A negative 
control virus based on the CRAd but without the El insert should be generated since 
this would act as a good negative control to ensure that non replicating virus particles do 
not exert a deleterious effect on their own. This virus could be generated in an El 
complementary cell line. It would also be interesting to look at the effect of virus 
replication and cell lysis in viruses with and without deletion of the viral E3 region. A 
more simplistic CRAd with the hTERT driving the transcription o f the E l gene without
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the TSTA system could also be interesting to study to see if  the advantage o f the TSTA 
system seen in the plasmid system is retained in the viral system. Examining different 
E l deletion sequences could be useful to determine if an alteration could improve viral 
packaging.
Real time PCR with a probe and primer set directed against viral DNA 
sequences should be carried out to evaluate the replication of viral particles in culture. 
In this aspect it would be interesting to monitor the amount of viral DNA present in 
infected cells and media at different time points after infection. Comparing the intra and 
extra cellular viral DNA level could give valuable information regarding the replication 
and release of the virus as has been studied by others (Morrison et al. 2001). It would 
however not differentiate either defective viral particles or virus DNA which is not 
packaged from functioning infectious viral particles.
A future perspective of this work is to apply the CAV-1 based CRAd CAV-1 - 
hTERT+El to a clinical setting. Injecting of the CRAd into viable resected tumour 
tissue and following fixation and staining of the tissue could give useful information on 
short term cellular uptake of viral particles and immediate distribution of the virus. In 
order to look at viral replication and actual spread of the virus the CRAd could be 
applied to terminally ill canine cancer patients prior to euthanasia. This would require 
generation of large quantities of purified virus which would be generated in a 
commercial lab. Virus could be applied to terminally ill canine cancer patients prior to 
euthanasia at a time point which would allow for viral replication to occur before 
euthanasia. It could also be applied in a similar fashion locally to tumour tissues prior to 
surgical removal. Post mortem or surgically resected tissues could then be evaluated to 
determine viral spread and replication. Blood samples could be evaluated alongside to 
determine whether local viral injection would give rise to acute systemic adverse 
effects. Despite the argument that the CAV-1 based CRAd circumvents the use of 
rodent animal models it is still essential for safety purposes that rodent studies are 
performed to examine in vivo toxicity and potential carcinogenicity of the virus. Once 
treatments have been considered safe and effective in these model systems, the goal 
would be to take this forward to phase I, II and III clinical trials for canine cancer 
patients, most likely as a combination therapy in conjunction with surgery and 
chemotherapy.
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Figure 4.2
E 2 1 E 2 1 E2 [ E21'E2 ] E2 1 3 ’BpTATA i— I t r a il  i-hTERT j VP16E2
VP16E2
Figure 4.2 Prom oters and transgenes can be exchanged in the TSTA system.
The plasticity o f  the TSTA system  allow s for prom oters and transgenes to be exchanged 
to target specific diseases and treatm ents.
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Figure 4.3
E2 E2 E2 E2 E2 E2 3’BpTATA 1 TRANS GENEhTERT VP16E2
Figure 4.3 Positive feedback activation of the hTERT prom oter
Illustration o f  insertion o f  E2 binding sites upstream  o f  the hTERT prom oter to act as a 
reinforcing positive feedback m echanism  on prom oter activity.
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